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Pharmaceutical companies and FDA (Federal Drug Administration) rules rely 
heavily on crystalline active pharmaceutical ingredients delivered as tablets and 
powders in the form of neutral compounds, salts and solvates of neutral 
compounds and salts. About half of all drugs sold in the market are in the form 
of salts which are held together by ionic bonds along with some other forces. 
Recently, Ionic liquids (ILs) an interesting class of chemical compounds have 
offered potential opportunity for exploration as novel drug ionic liquid salts, 
particularly in the field of transdermal/topical drug delivery. Due to the 
multifunctional nature of these salts they could allow generation of new pathway 
to manipulate the transport and deposition behaviour of the drug molecule. It is 
this modular approach of IL that forms the basis of the research presented here, 
in which pharmaceutically acceptable compounds are combined with selected 
drugs with known problems.  
IL salts were generated by combining at least one drug molecule with FDA 
approved compounds and were assessed for physicochemical properties, skin 
deposition and permeation studies. Skin deposition data suggested that these 
systems exhibit high skin retention, which was found to correlate with the 
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molecular weight. On the other hand, permeation data displayed an inverse 
relationship between flux values and molecular weight of the permeant. Similar 
work was extended with ILs with mixed anions containing two drugs. The 
benzalkonium-sulfacetamide ILs were investigated for synergism and the 
biological studies data display no synergistic effect. It was also illustrated that 
in-situ IL based ibuprofen hydrogels systems could be manipulated via IL 
approach for topical application. These findings suggest the potential 
applicability of IL based formulations for topical delivery of drugs.  
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Chapter 1 Introduction 
 
Solid materials exist as single or multicomponent crystals or amorphous forms. 
Crystal engineering involves tailoring of properties of the solid materials to 
achieve desired product properties. The pharmaceutical industry relies on 
crystalline active pharmaceutical ingredients (APIs), which can be found in 
several forms including salts, hydrates, solvates, crystalline and amorphous 
materials and co-crystals. The solid APIs (BCS Class II) suffer from several 
problems such as low solubility, low bioavailability and polymorphism. However 
apart from the issues mentioned above there are number of other factors such 
as morphology, particle size and bulk properties which could have significant 
effect on the pharmacokinetics of the solid APIs. The main challenge of the   
pharmaceutical industry in drug development is to improve the bioavailability 
and low solubility of new and currently marketed drugs which still remains the 
same (Shamshina and Rogers 2014). Co-crystals are emerging as an attractive 
alternative to these solid APIs. Co-crystals can enhance the physicochemical 
property of the solid APIs such as hygroscopicity, solubility and compaction 
behaviour without affecting the pharmacological behaviour of APIs (Weyna et 
al. 2009; Khan et al. 2010). However co-crystals also suffer with the same  
problems which are associated with solid crystalline active pharmaceutical 
ingredients comprising polymorphism (Karpinski 2006).  
Recently Ionic liquids (ILs) have been growing in interest within various 
pharmaceutical fields including the formulation of active pharmaceutical 
ingredient ILs (API-ILs). Ionic liquids are defined as organic salts that are liquid 
below 100 °C. The generation of ILs involves the reduction of melting point of 
the APIs leading to an increase in solubility and dissolution rate (Hough et al. 
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2007a; Stoimenovski et al. 2010a). More importantly, ILs can be generated with 
tailored properties for any specific application. The physicochemical properties 
such as viscosity, hydrophobicity, solubility and density can be fine-tuned by 
simply choosing combinations of cations and anions. The molar ratio of 
counterions and degree of ionocity are vital properties for pharmaceutical 
companies as these factors are responsible for governing bioavailability of 
active pharmaceutical ingredients including solubility, absorption, distribution, 
metabolism and finally excretion (Kelley et al. 2013). ILs have been reported as 
carrier for drug delivery (Moniruzzaman et al. 2010b) and as drug ionic liquid 
salt for  topical/transdermal drug delivery (Park and Prausnitz 2015). ILs have 
been used as additives in several topical formulations  (Kamal et al. 2006; 
Kamal et al. 2007; Moniruzzaman et al. 2010b; Bica et al. 2011; Dobler et al. 
2013; Goindi et al. 2014). 
Nowadays, the topical drug delivery pathways (transdermal, buccal, nasal, 
vaginal, rectal, dermal, ocular etc.) have an increasing part in pharmaceutics. 
The vital reason for the importance of topical application of drugs is not only the 
elimination of first-pass metabolism leading to enhanced bioavailability but also 
a reduction in side effects caused by the decline of the drug concentration after 
orally administered drugs. Apart from this many beneficial advantages are 
offered by topical delivery of drugs, such as patient-tailored delivery, extended 
duration of activity and avoidance of several dosing schedules (Cevc 1997).  
Topical and transdermal drug delivery is associated with three basic target sites 
which are (a) skin surface (b) the skin itself (epidermis and dermis)   (c) 
systematic circulation. The skin surface is the prime target when considering 
cosmetics, insect repellent and disinfectants. Topical drug delivery is basically 
targeting various layers of skin where the disease state is present within the 
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organ itself, for instance in inflammatory disorders and microbial infections of 
the skin. On the other hand, systemic circulation is the target site for 
transdermal drug delivery (Morrow et al. 2007). The prime issue associated with 
topical drug delivery is that only a limited number of APIs have the ability to 
overcome the biological barrier in the body. Skin is the well-known biological 
barrier to humans, the topical and transdermal delivery of APIs becomes very 
difficult and in some cases impossible because of the very highly ordered 
structure and diffusional resistance properties of the outermost layer of the skin 
which is called as stratum corneum (SC) (Schäfer-Korting et al. 2007). 
Development of drug delivery through skin is an innovative and important 
research area in modern therapy. The drug molecule should possess enough 
solubility; it should not only display adequate lipophilic nature to penetrate via 
the SC domain but should also possess sufficient hydrophilic property to 
distribute in the tissues of the epidermis (Benson 2005). 
Some conventional non-steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen and diclofenac have been reported to increase cardiovascular risk 
(Komatsu and Sakurada 2012).  When administered orally, ibuprofen is largely 
metabolized in the liver resulting into a short biological half-life. That is why 
ibuprofen administration frequently causes extensive gastric ulceration when it 
is used for long duration especially in the case of treatment of arthritis. 
Ibuprofen is widely used for the treatment of osteoarthritis, rheumatoid arthritis, 
ankylosing spondylitis and is been rated as the safest traditional 
NSAIDs(Bushra and Aslam 2010). The oral administration of diclofenac is also 
associated with severe gastrointestinal, cardiovascular and renal side effects. 
The mechanism of action of diclofenac is via inhibition of prostaglandin 
synthesis (Altman et al. 2015). Diclofenac is a poorly water soluble drug 
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because of its high melting point and intrinsic hydrophobicity(Cordero et al. 
1997).  
When seeking alternatives to oral administration, properties of other materials 
relevant to topical administration should be considered. Salicylic acid is found to 
possess a broad range properties such as anti-inflammatory, analgesic, 
antiseptic and preservative, and a key ingredients of many skin care products 
(Wu 2007). Sulfacetamide is a sulfonamide antibiotic drug which is prescribed in 
the form of sodium salt and finds its applications in ophthalmic (Sridhar et al. 
2001) and skin (Margolis et al. 2005). Sulfonamide drugs destroy bacteria by 
blocking the synthesis of folic acid in bacteria (Maren 1976).  Topical application 
of ibuprofen, diclofenac, salicylic acid and sulfacetamide in the form of an IL 
drug salt not only allows elimination of the solid state problems but also helps to 
achieve higher local concentration of the drug at the site of inflammation and 
pain (Tegeder et al. 1999; Reddy et al. 2011). 
It is a challenging task for pharmaceutical scientists to develop efficient topical 
drug delivery systems with enhanced penetration effects for API absorption. 
Due to recent advances in the field of ILs including pharmaceutical applications, 
the fact that ibuprofen, diclofenac and salicylic acid are considered as one of 
the most preferred NSAIDs for the treatment of arthritis and various 
inflammatory conditions and sulfacetamide is a common and useful antibiotic 
drug, this study aimed to investigate such ionic liquid drug salts for topical drug 
delivery systems. 
1.1 Aim of the study 
To synthesise pharmaceutically acceptable ILs based on ibuprofen, diclofenac 
salicylic acid, sulfacetamide and investigate these neat API-ILs as topical 
delivery systems. 
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1.2 Specific objectives 
1. To examine effect of counterions on physicochemical properties and 
biopharmaceutical performance of benzalkonium based NSAIDs ILs. 
2. To investigate synergism and the effect of cationic counterion 
benzalkonium on penetration behaviour of benzalkonium-sulfacetamide 
via Ionic liquid (IL) approach 
3. To understand the effect of ionic/hydrogen bonding interaction: insights 
into the physicochemical properties and transport behaviour of 
benzalkonium based mixed anion ILs. 
4. To consider the potential of In-situ formation of ibuprofen – IL in topical 
ibuprofen gel formulation. 
1.3 Scope of thesis 
On the basis of the physical, chemical and biological properties drug molecules 
can exist as neutral or salt forms (Stahl and Wermuth 2002).  Approximately 
half of all the therapeutic drugs are used as solid salts. As already discussed, 
ILs have been studied as carriers for topical/transdermal drug delivery. In order 
to understand the drug ILs as topical drug delivery systems, this thesis will 
discuss the formation of ILs from pharmaceutically acceptable drug molecules 
and how the structure of cations and anions, and the interaction between them 
will affect the physicochemical properties and pharmaceutical performance of 
drug molecule.   
Chapter 2 provides background information and a comprehensive literature 
review of papers relevant to this study. Chapter 3 describes the materials, 
general methods and the experimental techniques used to determine the 
physicochemical properties and characterisation of the synthesized ILs.  
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Results of the experimental work are then presented in Chapter 4 which 
explains the formation of ILs with benzalkonium cation with anions (ibuprofen, 
diclofenac) which have been already used but the pharmaceutical performance, 
specifically in regard to topical application, has not been reported. The effect of 
counterions on the physicochemical properties, skin deposition and permeation 
profiles was evaluated.  
Chapter 5 illustrates the investigation into any synergistic effect of combining 
benzalkonium cation and the antibiotic sulfacetamide in anionic form. The effect 
of cationic counterion benzalkonium on the skin deposition and permeation 
profile of sulfacetamide along with the physicochemical properties wasalso 
studied. 
The data obtained from Chapter 4 provides important information regarding the 
effect of counterions on the physical and chemical properties of the ILs. 
However, the ILs studied in Chapter 4 were for two component systems 
consisting of only one drug molecule therefore research regarding three 
component systems (ILs with mixed anion) containing two drug molecules was 
the prime focus of Chapter 6. The same benzalkonium cation used in the work 
described in the Chapter 4 was coupled with ibuprofen and salicylic acid to 
generate IL with mixed anion which was characterised by NMR spectroscopy. 
The combination of two drug molecule will not only provide dual functionality to 
the IL but also allows lowering of melting point. Thus, this chapter provides the 
insights of the physicochemical properties of ILs with mixed anions and the 
effect of ionic and hydrogen bonding interaction on the permeation rates of the 
drug molecules.  
Chapter 7 is more focused on the understanding of the interactions between the 
ingredients during formulation development. The attention of this chapter is on 
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demonstration of in-situ formation of ibuprofen IL during formulation and 
penetration of ibuprofen via artificial membrane.  
Finally, Chapter 8provides conclusions obtained from the study described in this 
thesis and delivers suggestions for future work. 
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Chapter 2 Background and Literature 
2.1  Background 
2.1.1 Introduction of ionic liquid 
Ionic liquids (ILs) are defined generally as liquids composed entirely of ions with 
melting points or glass temperature below 100 ºC(Hough et al. 2007b). Those 
ILs which are liquid at room temperature are considered as room temperature 
ionic liquids (RTILs) (Ferraz et al. 2011) (Figure 2.1). ILs can be distinguished 
from molten/fused salts as ILs are generally composed of an organic cation 
instead of an inorganic cation. This avoids the disadvantages of molten/fused 
salts, such as their high working temperatures and their corrosive and viscous 
nature. The incorporation of asymmetric and bulky organic moiety leads to a 
decrease in melting temperature. Melting point of the derived ILs generally 
depends on the size and complexity of the ions. For example the melting point 
of sodium chloride is 803ºC, even though the melting point of the eutectic 
mixture of LiCl-KCl is 355 ºC whereas the imidazolium chloride displays 77-79 
ºC (Wasserscheid and Welton 2008) 
                             
Figure 2.1 Representation of ionic liquid (Shamshina et al. 2015) 
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2.1.2 History of Ionic Liquid Research 
The history of ILs can be traced back to the mid-19th century, when a chemist 
reported ‘red oil’ produced from a side product of a Friedel- Craft reaction. Later 
on a group of chemists in Japan suggested that the red oil was a mixture of 
alkylated aromatic ring cation and chloroaluminate anion and gave this the 
name ionic liquid (Dean et al. 2010a). 
The very first known room temperature ionic liquid was synthesized by Walden 
in 1914,has a melting point of 12 ◦C and is known as ethyl ammonium nitrate 
(Plechkova and Seddon 2008) (Figure 2.2).  
                                           
Figure 2.2 Ethyl ammonium nitrate 
 
Soon after this work, ionic liquids gained enormous interest as a research field 
and this interest continued growing throughout and after the nineteenth century.  
Extensive research in ILs was carried out in 1960s and 1970s with the 
discovery of chloroaluminate salts for the use of thermal batteries which was 
discovered by US Air force Academy in collaboration with research groups at 
University of Colorado State. A number of ILs investigated during this time 
period were found to have low melting points but suffered with hydrolysis 
issues; this led to the search of more stable ILs (Koch et al. 1976)(Gale et al. 
1978). 
Investigation of Imidazolium cation based ILs with ions such as acetate, 
sulphate, tetrafluoroborate, hexafluorophosphate found them to be water stable 
at room temperature. The discovery of water and air stable ILs gained 
enormous interest in various fields (Wilkes and Zaworotko 1992). The alkylated 
10 
 
substituted imidazolium and pyridinium cations with halide anions are applied as 
electrolytes. There has been an enormous increase in research publications on 
ionic liquids as catalyst, electrolytes, solvent /co-solvents over the past two 
decades(Wilkes 2002). 
2.1.3 Properties of Ionic Liquids 
Ionic liquids have significant and interesting physicochemical properties. 
Research on their physical, biological and chemical properties is very limited 
when compared with traditional organic solvents. Recently this field has been of 
great interest due to the fact that the physical, chemical and biological 
properties of ionic liquids could be altered with specific requirements for various 
applications. This tunability of their physicochemical properties opens a new 
challenge in this research area. Quaternary ammonium salts have been 
available commercially for a long time and some are best known for their 
application as phase transfer catalysts. The most useful property of ionic liquids 
is the independent ‘tunability’ of the cations and anions, and this is the key 
feature of ionic liquids which gives them a wide range of properties. For 
example, miscibility and immiscibility with water, acidic, basic and neutral nature 
of ionic liquids and toxicity and nontoxicity. Over 200 known ionic liquids have 
been synthesized but for most of the ionic liquids, the data relating to their 
physicochemical properties is not available or is incomplete.  
Generally they have negligible vapour pressure, high liquidus range, high 
thermal stability, low combustibility, high ionic conductivity, a large 
electrochemical window and the ability to solvate compounds of varying 
polarities. ILs are used as solvent to facilitate many important chemical 
reactions such as Diels Alder reaction and Friedal Crafts alkylation and 
acylation reaction (Brennecke and Maginn 2001). They can be used as acids, 
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bases, ligands and an important precursor to prepare stable carbenes. The 
solubility of different species in ILs depends on the basis of polarity and 
hydrogen bond. 
2.1.3.1 Melting points 
Ionic liquids are commonly defined as salts with a melting point below 100 ◦C. 
The components of ILs have a significant impact on the physicochemical 
properties. Both cations and anions, along with the charge distribution 
contribute to the melting point of the ILs (Wasserscheid and Welton 2008). The 
melting point of ionic liquid depends on the size of the cation: generally melting 
point decreases with increase in the size of the cation. For example 
phosphonium and tetraalkylammonium salts with alkyl shielded charge provide 
depressions in the melting point (Wasserscheid and Keim 2000). Symmetry of 
the cation also plays an important role, as ions with higher symmetry have 
higher melting points which are due to more efficient ion packing in the crystal 
unit cell. On the other hand unsymmetrical cations lead to delocalisation of 
charges in the crystal unit cell, which reduces lattice energy and finally leads to 
decrease in melting point (Gordon and Rao 1978).The melting temperature of 
the system could be decreased or increased by varying aromatic stacking, ion 
packing and methyl-pi interactions (Wasserscheid and Welton 2008). The 
melting temperature of 1-alkyl-3-methylimidazolium tetrafluoroborate system 
was studied as the function of alkyl chain length and the melting point of the 
system was found to decrease with increase in chain length due to disruption of 
the lattice unit cell. The increase in melting point was observed for the alkyl 
chain length greater than 10 carbon atoms because of the increase in Van der 
Waals interaction between alkyl chains which leads to formation of liquid 
crystalline phases (Holbrey and Seddon 1999). The melting point of the ILs with 
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higher degree of alkyl branching was found to be higher, which could be 
attributed to the efficient ion packing due to the decrease in the free rotation 
volume (Ngo et al. 2000). 
The size and structure of the anion also plays a significant role in the melting 
point of ILs. Increase in the size of anion leads to decrease in melting point of 
ILs because of the disruption in the columbic interactions causing decrease in 
lattice energy (Wasserscheid and Keim 2000). Hydrogen bonding in the lattice 
is a major factor in increasing melting point. ILs with strongly coordinating 
anions such as halides exhibits higher melting point because of their ability to 
form hydrogen bonding. On the other hand ILs with highly fluorinated anions 
have lower melting point due to delocalisation of charge (Gordon et al. 1998; 
Hardacre et al. 2002). 
2.1.3.2 Polarity 
Polarity is an important property used to describe solvation capability of a 
solvent, when considering a solvent for a particular application. Several ILs 
based on 1-alkyl-3-methylimidazolium were tested for polarity using 
solvatochromic Nile Red. The visible absorption maximum wavelength was 
found to move towards longer wavelength when Nile Red was dissolved in the 
increasingly polar solvents. This study illustrates that the value of visible 
absorption maximum wavelength obtained from ILs was found to be similar to 
short chain alcohols (Carmichael and Seddon 2000). 
Solvation in ILs occurs through a number of interactions such as pi-pi 
interactions, Van der Waal interactions, ionic interactions, dipole-dipole and 
hydrogen bonding. Hence it could be suggested that ILs exhibits greater 
solvating power when compared to traditional organic solvents (Freemantle 
2010). However, the magnitude of the various interactions depends on the 
13 
 
components of ILs (cation and anion), substituted alkyl chain length and on the 
solute(Freemantle 2010).Dielectric constant or relative permittivity is used to 
determine the polarity of solvent. ILs are composed of ions therefore they are 
supposed to conduct electricity. However, indirect methods such as microwave 
dielectric spectroscopy could be used to measure the polarity of ionic liquids 
(Wakai et al. 2005).  
2.1.3.3 Liquid range and thermal decomposition 
Liquid range is also known as liquidus range, which is defined as the 
temperature between melting point or glass temperature and boiling point or 
thermal decomposition temperature. ILs has far higher liquid range than 
molecular solvents. The liquidus range of organic solvents is typically in the 
range of 100 to 200 k whereas ILs liquidus range falls in the region of 300 to 
500 K.  The higher liquidus range of ILs offers an opportunity to work at much 
higher temperature ranges which could not be achieved by using traditional 
organic solvents (Freemantle 2010). 
Generally ILs are considered to be non-volatile therefore the higher limit of 
liquid range of ILs is governed by thermal decomposition temperature 
(Wasserscheid and Welton 2008). Research has shown that the degradation 
pathway of imidazolium based ILs was found to be the reverse of the reaction 
pathway used to generate ILs (Chan et al. 1977). The authors have investigated 
the thermal stability of imidazolium based ILs with different anions such as Cl,I, 
BF4, DBS (para-dodecylbenzenesulfonate), PF6, NTf2. The stability of ILs was 
found to be inversely proportional to the stability of the alkyl-anion species 
formed through the decomposition process (Maton et al. 2013).  
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2.1.3.4 Conductivity 
A large ionic conductivity was originally expected for ionic liquids, considering 
they are primarily comprised of ionic species. However this is not the case and 
the conductivity of ILs was found to be relatively low at room temperature (Noda 
and Watanabe 2000). The number of the charge carriers and their mobility is 
the primary factor responsible for the conductivity of any solution. The 
conductivity of ILs is far less than concentrated aqueous electrolytes because of 
the reduction of free charge carrying species due to the ion-pairing and the 
presence of large constituent ions which reduce ion mobility (Wasserscheid and 
Welton 2008). 
ILs based on imidazolium cation exhibit higher conductivities (10 mS/cm) than 
ionic liquids based on dialkylpyrrolidinium, tetraalkylammonium, piperidinium 
and pyridinium which is in the range of 0.1 mS/cm to 5 mS/cm (Galiński et al. 
2006).IL conductivity decreases with decrease in planarity of the cation, the flat 
imidazolium cation has a higher conductivity than the tetrahedral 
tetraalkylammonium cation while the pyrrolidinium based Ils have an 
intermediate conductivity (MacFarlane et al. 1999). 
Temperature, viscosity and conductivity are strongly interrelated with each 
other. The conductivity increase with decrease in viscosity while increases with 
increase in temperature. For example the conductivity of 1-ethyl-3-
methylimidazolium bis[(trifluoro-methyl)-sulfonyl] amide and 1-ethyl-3-
methylimidazolium tetrafluoro borate with respect to temperature is shown in 
Figure 2.3 . 
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                                                 Temperature (°C) 
Figure 2.3 Variation of conductivity with temperature for EMITFSI and 
EMIBF4 (Garcia et al. 2004) 
 
2.1.3.5 Vapour pressure 
Generally ILs are reported to have negligible vapour pressure but this does not 
mean that all ILs have no vapour pressure. Negligible vapour pressure is one of 
the most celebrated properties of ILs as they do not evaporate in reaction 
vessels and cannot contribute to related health concerns or to air pollution. The 
strong coulombic interaction between the components of ILs is the significant 
factor responsible for the lack of vapour pressure at temperatures up to their 
thermal decomposition temperature. Using density and experimental surface 
tension dataa group of scientists reported that ILs could be designed to undergo 
distillation. Imidazolium cations containing long alkyl chain lengths with [NTf2]
- 
anions such as [C10mim] [NTf2]  and [C12mim] [NTf2] could undergo distillation at 
temperatures between their estimated  boiling and decomposition temperatures 
(Earle et al. 2006). 
In general, the vapour pressure of ionic liquids, especially for the widely used 
imidazolium ionic liquids with short alkyl chains are negligible at room 
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temperatures and pressures. Consequently most of the ILs display very little or 
no evidence of distillation below their decomposition temperatures.  
2.1.3.6 Solubility in ILs 
ILs are generally considered to be polar solvents having polarities equivalent to 
alcohols and aprotic solvents such as: dimethylformamide and 
dimethylsulfoxide. ILs are also called as designer solvents, as they can be 
designed to be alternatives to organic solvents for variety of applications 
including synthesis, electrochemical processes and liquid/liquid separations 
(Carmichael and Seddon 2000)(Aki et al. 2001).  
The polarity and co-ordinating ability of an IL is significantly affected by the 
components of the IL system and can be tailored for specific purposes. The 
lipophilicity of the system can be varied through cation substitution and the 
solubility of IL in water can be tuned from slightly miscible to complete miscible 
by changing the anion of the system from Cl- to [PF6]
-. The solvent property of 
the IL depends on the H-bond accepting, H-bond donating abilities of the 
components of the IL system (Wasserscheid and Welton 2008). 
Authors have also investigated the interactions of ILs with organic solutes and 
suggested that ILs containing long alkyl chain can act as low polarity phases, 
which strongly interact with non-polar solutes. Polar solutes having proton donor 
functional groups interact strongly with ILs, while the solutes such as esters, 
ketones and aromatics with proton donor/acceptor functional groups interact 
through Van der Waals and ion-dipole interactions (Armstrong et al. 1999). 
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2.1.4 Classification of Ionic liquids 
A. Classification on the basis of degree of ionization 
Ionic liquids are organic salts which are entirely composed of ionized species 
with melting point below 100 ◦C. On the basis of degree of ionization ILs are 
classified into the following species.  
 
Figure 2.4 Classification of ionic liquids (Balk et al. 2015a) 
 
Stoichiometric ratios of completely ionized anions and cations with melting 
points below 100 ◦C are called Ionic liquids. Liquid co-crystal, low melting 
eutectic mixture and deep eutectic mixture are the liquid equivalents of co-
crystals, for example the liquid complex of lidocaine and fatty acids (Kelley et al. 
2013),(Bica et al. 2011)and the complex of lidocaine and ibuprofen (Wang et al. 
2014) (Figure 2.4). The hydrogen bonded complex formed between the acid 
and base with strong ion pairing was reported for the above case. There is no 
transference of proton between acid and base. 
Oligomeric ionic liquids are the complexes of ionized and unionized form, which 
shared a delocalised proton, prepared when a salt is combined with an excess 
of acid or base. For example lidocainium with the counter ion being a complex 
of salicylic acid and salicylate (Bica and Rogers 2010)as well as salicylate when 
combined with lidocaine and lidocainium (Johansson et al. 2008). 
 
 
    Ionized                                                                                     Neutral 
 
        Liquid 
   (MP < 100 °C) 
                                                                                            Liquid co-crystal 
 Ionic liquid                        Oligomer  ILs                    Hydrogen bonded complex 
                                                                                  Low melting eutectic mixture 
                                                                                        Deep eutectic mixture 
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B. Classification on the basis of properties 
On the basis of the properties, Ionic liquid are classified into three generations 
(Figure 2.5). 
 
 
 
 
         
Figure 2.5 Classification of ionic liquid on basis of properties 
 
The so-called first generation ILs were basically interesting as solvents with 
desirable physical and chemical properties, which includes enhanced thermal 
and chemical stability, non-flammable properties, negligible vapour pressure 
and wide liquid range as compared to molecular solvents (Freemantle 2010). 
The second generation of ILs are also called task specific ILs, with desired 
chemical properties combined with specific physical properties. The physico-
chemical properties such as reactivity, energy density, oxygen balance and 
many others can be tailored for specific purpose. The IL concept provides a 
unique architectural platform where the characteristics of both cation and anion 
can be modified to generate novel functional materials. For example by 
First  
Generation ILs 
• Melting point 
• Density 
• Viscosity 
• Thermal stability 
• Conductivity 
• Refractive index 
• Hydrophobicity 
Second 
Generation ILs 
• Chemical reactivity 
• Solvation 
• High energy density 
• Chiral induction 
• Electrochemical   
window 
Third  
Generation ILs 
• Anti-inflammatory    
drug 
• Antibiotic 
• Anti-acne 
• Vitamin 
• Antibacterial 
• Antifungal 
• Local anesthetic 
Ionic 
liquid 
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combining low melting point with high thermal stability and non-volatility with 
desired energetic features allows an improvement in the safety concerns 
associated with the generation of energetic materials (Smiglak et al. 2007). 
The third generation of ILs consists of those ILs which are mostly used for 
pharmaceutical and medical purposes such as drug delivery and drug 
production, formulation concept for active pharmaceutical ingredients and 
expanding into pharmaceutical application (Hough et al. 2007b). ILs could be 
designed to serve as solvents for APIs and to convert the APIs into appropriate 
IL salt (API-ILs). Ionic liquids were also applied as solvents for poorly water 
soluble drugs (Jaitely et al. 2008; Mizuuchi et al. 2008), as excipients for the 
preparation of microemulsions (Mizuuchi et al. 2008; Marrucho et al. 2014)and 
as solvents for the dissolution of APIs (Eastoe et al. 2005; Moniruzzaman et al. 
2010a; Moniruzzaman et al. 2010c). 
2.1.5  Toxicity, biodegradability, environment and safety of ILs 
In order to utilise the potential of IL technology especially in medical and 
pharmaceutical applications, ILs should be devoid of toxicity and possess good 
biodegradability. Therefore it is significantly important to understand the toxicity 
of ILs along with their biodegradation, ecotoxicity, and environmental fate 
(Haerens et al. 2009; Busetti et al. 2010; Zhao et al. 2011). 
2.1.5.1 Toxicity of ILs 
The first and second generation ionic liquids have been extensively investigated 
in terms of their toxicity and cytotoxicity level. Ionic liquids are also called 
designer solvents meaning that ILs with desired properties could be easily 
prepared by selecting appropriate cation/anion combinations or only by 
changing the alkyl chain length attached to the cation. This idea led to the 
search of biocompatible ILs which could be generated by picking nontoxic and 
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biocompatible organic cations and inorganic anions (Gouveia et al. 2014).A 
related study based on the cytotoxicity of imidazolium, pyridinium, quinolinium 
and morpholinium cations illustrates that the morpholinium head group was 
found to be least toxic as compared with the other studied head groups (Pernak 
et al. 2011). ILs should be designed very carefully for medical and 
pharmaceutical applications as the toxicity of ILs basically depends on the 
cation and alkyl chain length attached to the cation. The introduction of the polar 
functional groups such as ether, nitrile and hydroxyl into the cation is another 
way to generate nontoxic ILs (Stolte et al. 2007a; Stolte et al. 2007b; Morrissey 
et al. 2009). Another study reported that the hydrophobic and most fluorinated 
anions like hexaflourophosphate and tetrafluoroborate are not appropriate for 
designing nontoxic and biocompatible ILs (Garcia et al. 2005). Kathrine et al 
reported the cytotoxicity and biocompatibility data of choline based phosphate 
ionic liquid. Five phosphate based anions were analysed for cytotoxicity namely: 
dihydrogen phosphate (DHP), dibutyl phosphate (DBP), bis(2-ethylhexyl) 
phosphate (BEH), bis(2,4,4-trimethylpentyl) phosphinate (TMP) and o,o’-diethyl 
dithiophosphate (DEP) using a J774 murine macrophage cell line. The EC50 is 
the concentration of the drug that gives half maximal response. The EC50 
values of choline DHP, choline DBP and choline DEP were found to be lower 
than simple salts and choline chloride. On the other hand much lower values 
are found in case of choline TMP and choline BEH. The EC50 values of the 
tested ionic liquid were linked with the anion mass and the presence of 
moderately branched and/or long alkyl chains counterions (Weaver et al. 2010).  
In vitro cytotoxicity investigation was carried out using MCF7 human breast 
cancer cells for imidazolium, pyridinium, pyrrolidinium, piperidinium cations 
containing different alkyl chain lengths. IC50 is the concentration of an inhibitor 
21 
 
where the response is reduced to half. The IC50 values for these ILs were 
found to be in the range of 8µM to 44 mM. The data suggests that the presence 
of both the cation and anion plays a significant role in the toxicity of ILs, 
especially the cation with long alkyl chain length (Kumar et al. 2009). 
Increased research into the biocompatibility and cytotoxicity of ILs led to the 
evaluation of third generation ionic liquids, which finally expanded their 
pharmaceutical applications. However, recent approaches for the generation of 
ionic liquids were attempted with those counterions which are FDA approved or 
are generally regarded as safe (GRAS) for example choline, artificial 
sweeteners such as acesulfame K, cyclamate and saccharin, 
quaternaryammonium counterions and p-toluenesulfate (Hough et al. 2007a; 
Dean et al. 2008; Dean et al. 2010b).  Another very common and simple 
example is docusate which is combined with ranitidine, propntheline and 
licdocaine to give ranitidine docusate, propantheline docusate and lidocaine 
docusate room temperature ionic liquid (Hough et al. 2007a; Prakash 2011). 
Naturally occurring aminoacids and fatty acids are the other harmless option to 
generate room temperature ionic liquid (McCrary et al. 2013). 
Hence the counterions which are generally regarded as safe or the naturally 
occurring molecules could be utilised to generate nontoxic, biocompatible ionic 
liquids. However, proper toxicological investigation should be carried out for 
new counterions. 
2.1.5.2 Biodegradability of ILs 
Currently, a number of studies have been reported which paid much more 
attention towards the synthesis of biodegradable ILs. The ILs with short alkyl 
side chain attached to the cation exhibit poor biodegradability and less toxic as 
compared to the same cation with long alkyl chain length (C > 6).  It should be 
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noted that the biodegradable data of ILs shows conflict with the data reported 
for biocompatible ILs. ILs based on pyridinium cation were found to exhibit good 
biodegration potential as compared to the imidazolium based ILs which shows 
reduced biodegrability (Gathergood et al. 2004). Newmann et al. investigated 
the biodegradability of pyridinium based ILs on the basis of the presence of 
alkyl chain length attached to cation and functional groups (ester groups at 1-
and 3- positions), suggested that the ILs with ester group shows good 
biodegradability under aerobic conditions. On the other hand ILs with long alkyl 
chains attached to cation were found to be poor biodegradable (Neumann et al. 
2014). 
Biodegradability of ILs is also affected by the presence of the anions. A related 
study has been reported that anions such as ethanoate and propanoate bearing 
shorter alkyl chain length were found to be not readily biodegradable. On the 
other hand the anions which contain longer side chain (C >3) such as 
butanoate, pentanoate, hexanoate and octanoate were found to be completely 
biodegradable (Harjani et al. 2009). In another study, the effect of anions 
including sulphate acetate and phosphate groups on biodegradation was 
investigated. These anions were found to be readily biodegradable. Extreme  
care must be taken while working with fluorinated anions such as 
hexafluorophosphate and tetrafluorophosphate because these anions are 
unstable in nature and can undergo hydrolytic degradation which results in the 
liberation of toxic and corrosive HF into the environment (Sowmiah et al. 2009). 
The ILs based on imidazolium, phosphonium, pyidinium and ammonium cations 
which shows good toxicity levels against microorganisms are found to be readily 
biodegradable (Wells and Coombe 2006). 
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2.1.5.3 Environment and safety 
The depletion of environmental toxicity arising from chemical compounds which 
are used in product formulations and industrial process is one of the vital ideas 
of green chemistry. Sonia et al. investigated the influence of aromaticity on the 
toxicity of dissimilar ILs such as imidazolium, piperidinium, pyridinium, 
pyrolidinium containing the same anion (hexaflurophosphate). They have also 
worked out the impact of the position of alkyl chain length on the toxicity of IL 
against vibrio fischeri, daphnia magna, pseudokirchneriella subcapitata. The 
results of this study suggest that the toxicity of ILs increases with increase in the 
lipophilicity while the aromatic and non-aromatic ILs displays different  
dependencies of ionic liquid toxicity with respect to water solubility (Ventura et 
al. 2013). Due to negligible vapour pressure, ILs eliminates the possible risk of 
air pollution. A number of studies illustrate the toxic behaviour of ILs therefore 
the water miscibility of ionic liquid is quite necessary in order to understand the 
effect of ionic liquids on the environment. Mutual solubility data between 
imidazolium series (C2-C8) ionic liquid and water in the temperature range of 
288.15 to 318.15 was reported. It was found that Ionic liquid solubility in water 
was entropically driven and the hydrophobic character of ILs increases with 
increase in the alkyl chain length attached to the cation (Freire et al. 2008).  
Although ILs are considered as green solvents, the safety aspects of ILs must 
be considered, especially in the synthesis of chemicals. Compatibility of ILs with 
reaction components need to checked before performing any chemical 
synthesis (Chowdhury et al. 2007).  A related study suggests that the ILs with 
fluorinated anions such as hexaflurophosphate and tetrafluoroborate would lead 
to generation of hydrogen fluoride gas in the presence of water. Therefore care 
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should be taken while working with such types of materials and all degradation 
products need to be assessed (Huddleston et al. 2001).  
2.1.6 Potential application of ionic liquids in pharmaceutical 
applications 
2.1.6.1 Ionic liquids as crystallisation media and pharmaceutical solvents 
The tailored properties of ILs could be explored to generate interesting 
discoveries. Manish Kumar et al. reported a new crystal form of nicotinamide-
oxalic acid salt (2:1) by utilising the potential of ILs in crystal engineering. The 
phosphonium based ILs namely trihexyl(tetradecyl)phosphonium 
bis(oxalate)borate [P6,6,6,14][BOB], trihexyl(tetradecyl)phosphonium 
bis(mandelato)borate [P6,6,6,14][BMB], trihexyl(tetradecyl)phosphonium 
bis(2,4,4-(trimethylpentyl))phosphinate [P6,6,6,14][B(TMP)P], 
trihexyl(tetradecyl)phosphonium dicynamide [P6,6,6,14][DCA], 1-ethyl-3-
methylimidazolium bis(mendelato)borate [EMIM] [DCA], 
tributyl(octyl)phosphonium bis(oxalate)borate [P4,4,4,8][BOB] are used to 
investigate the formation of crystal structure of nicotinamide-oxalic acid salt 
system (Figure 2.6). Single crystal XRD was used to analyse the structure of 
the synthesised salt. The nicotinamide-oxalic salt 1:1 was found to have 
perpendicular “tape like” structure while the other one salt with 2:1 ratio 
revealed two dimensional layered structure. It was also illlustrated that 2:1 salt 
form could only crystallised from the ILs possessing hydrogen bond acceptor 
functionality (Shimpi et al. 2017). 
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Figure 2.6 ILs Structures used in study (An and Kim 2012) 
 
Another related study reported the antisolvent crystallisation technique to 
analyse the polymorphic design of adefovir dipivoxil. A new form of adefovir 
dipivoxil was generated at a temperature below 50 ºC by using 1-allyl-3-
ethylimidazolium tetrafluoroborate as solvent and 1-butyl-
2,3dimethylimidazolium tetrafluoroborate as antisolvent. The unique 
intermolecular interactions between adefovir dipivoxi and ILs allow generation of 
new polymorph which could not be attained by any conventional solvents.  DSC 
and XRD tools were used to analyse the crystal (An and Kim 2012).  The shape 
of the components of ILs used for crystallisation also plays a significant role. 
Generally, ILs consists of unsymmetrical and bulky ions which lead to low lattice 
energies due to poor packing of ions resulting in the low melting point of these 
designer solvents. A very distinctive environment could be generated for the 
crystallisation of solutes by appropriate selection of ions, where the ions can 
provide specific intermolecular or interionic interactions. The very first step for 
utilising the potential of ILs in crystallisation is the accurate selection of IL 
components (hydrophobic, hydrophilic coordinating/non-coordinating, hydrogen 
[P6,6,6,14][DCN] 
[P6,6,6,14][BOB] 
[P4,4,4,8][DCN] [P6,6,6,14][B(TMP)P] 
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bond donor/acceptor, which is found to be a critical (Reichert et al. 2006). 
Imidazolium based ILs such as 1-butyl-3-methylimidazolium 
hexafluorophosphate and 1-hexyl-3-methylimidazolium hexafluorophosphate 
were investigated for crystallisation studies. The solubility data was reported for 
ibuprofen and paracetamol in these ILs at a temperature range of 298.15 K – 
338.15 K. It was suggested that both ILs could be utilised as solvents for 
pharmaceutical application (Smith et al. 2011). Studies have also been reported 
which aim to look towards the alternative solvents for pharmaceutical 
applications. Reliable solubility data was generated for isoniazid (tuberculosis 
antibiotic drug) using a series of imidazolium based ILs coupled with 
bis(trifluromethylsulfonyl)amide and trifluromethanesulfonate as anion. The 
study illustrated that the studied ILs (solvents) would be a good choice for 
manufacturing of drugs and appropriate for pharmaceutical processes. The long 
alkyl chain containing imidazolium IL (1-decyl-3-methylimidazolium 
trifluoromethanesulfonate) was considered to be the best solvent for drug 
among all of the ILs studied (Forte et al. 2012). A very similar study (Melo et al. 
2013) was conducted with the same drug isoniazid and pyrazinecarboxamide 
using ammonium based ionic liquids. Isoniazid drug displays higher solubility in 
the studied ILs as compared to pyrazinecarboxamide drug. The ILs and drugs 
were analysed for their morphological properties such as phase transition 
temperatures, melting point, and enthalpy of fusion. Didecyldimethylammonium 
nitrate was considered to be the best solvent for the drugs solubility among the 
studies ILs. Studies have been reported which show that crystallisation can be 
induced due to slight exposure to water. For example procainium acetate is an 
ionic liquid at room temperature but extreme care should be taken while 
isolating it. However the presence of water gives crystalline procainium acetate 
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dihydrate which could not be dehydrated without decomposition. This leads to 
alternation of solubility and bioavailability of the active pharmaceutical 
ingredients. Therefore extreme care should be taken while studying 
crystallisation behaviour of active pharmaceutical ingredients ionic liquids 
(Cojocaru et al. 2013). 
Studies have reported on the potential application of ionic liquids when 
designing polymorphs of the API (adefovir dipivoxil) in drowning-out 
crystallization. Due to the influence of 1-allyl-3-ethylimidazolium 
tetrafluoroborate on the formation of intermolecular interaction of adefovir 
dipivoxil in the solution, new anhydrous (N-II) and hemihydrates (N-I) 
polymorphic crystals of adefovir dipivoxil were reported when varying the ionic 
liquid fraction and crystallization temperature. The ionic liquid solvent was found 
to be responsible for formation of the polymorphic crystals of adefovir dipivoxil. 
Optimisation of ionic liquid proportion and crystallization temperature can be 
achieved. It is seen that there is significant enhancement in the thermal stability 
of adefovir dipivoxil molecules in the 1-allyl-3-ethylimidazolium 
tetrafluoroborate–water mixtures, due to lack of hydrolysis of adefovir dipivoxil 
molecules up to a temperature of 90◦C. Differential scanning calorimetry studies 
suggest that N-I and N-II crystals were transformed into other crystal phases in 
the solid state (An et al. 2010).  Ethambutol dihydrochloride salt exists in three 
polymorphic forms. Ethambutoldibenzoate salt was obtained by screening S, S-
ethambutol free base with organic acids such as benzoic acid. Three different 
polymorphic forms are generated via crystallisation of ethambutol dibenzoate 
salt via different conditions, which are characterised by various techniques such 
as DSC, PXRD,IR and Raman and solid state 15N NMR. Ethambutol dibenzoate 
salt form 2 is the least stable compared with form 1 and form 3 was observed to 
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be the most stable at 90°C. On the other hand at 25 °C form 1was the most 
stable followed by form 3 and form 2 was found to be most stable (Cherukuvada 
and Nangia 2012). 
A polymorph can be defined as a solid crystalline phase of given compound 
which arises due to at least two different internal arrangements of the molecules 
of that compound in solid state. Different crystalline polymorphs and solvates 
possess different molecular conformation and/or crystal packing, as well as 
different crystal lattice energy and entropy which lead to differences in their 
physicochemical properties such as solubility, dissolution rate, melting point, 
density, tabletability, enthalpy, stability and bioavailability. One of the most 
significant benefits of room temperature ionic liquids (RT-ILs) is the ability to 
convert solid active pharmaceutical ingredients (API) in liquid state; the use of 
the liquid form of drug would eliminate the problem of polymorphism associated 
with solids (Song and Sohn 2011; Marrucho et al. 2014). Ranitidine 
hydrochloride is H2 receptor antagonist which exists in at least two different 
forms. Attempts to solve the polymorphism in ranitidine hydrochloride yielded to 
form [ranitidine] [docusate] as room temperature ionic liquid formed by using the 
counterion docusate (Agatonovic-Kustrin et al. 2001). A similar approach to 
addressing the problem of polymorphism was also attempted for propantheline 
bromide which is a muscarine acetylcholine receptor antagonist. This active 
pharmaceutical ingredient (API) was converted into room temperature ionic 
liquid (RTILs) by using the counterions p-toluene sulfonate and acesulfamate 
(Dean et al. 2008; Stoimenovski et al. 2010a). Free naproxen acid was also 
transferred into stable tetrabutylphosphonium based ionic liquids (TBP-ILs) with 
lower melting points and glass temperatures as well as enhanced solubility’s 
and dissolution rates than the corresponding free acid (Bica et al. 2012; Balk et 
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al. 2015b). Other efforts have also been made to eliminate the problem of 
polymorphism associated with ibuprofen sodium by converting it into 
imidazolium based ionic liquid (Tourné-Péteilh et al. 2011).  
The solubility’s of drugs like paracetamol and ibuprofen were reported in 1-
butyl-3-methylimidazolium hexafluorophosphate [BMIM][PF6] and 1-hexyl-3-
methylimidazoliumhexafluorophosphate [HMIM][PF6] at temperatures of 298.15 
K, 308.15 K, 318.15 K, 328.15 K, and 338.15 K (Smith et al. 2011). In addition, 
solubility data for paracetamol and ibuprofen in water was reported at the same 
temperatures extending the data commonly reported in pharmaceutical 
reference texts. Solubility increment can be observed with increase in 
temperature. It is reported that a solvent is sufficient for pharmaceutical 
processing when the solubility exceeds 1 mg/ml. 
The solvency of alkyl imidazolium salts (PF6, Br, Cl) for poorly water soluble 
model drugs, albendazole and danazol, indicating their potential application as 
pharmaceutical solvents/cosolvents has been reported by Mizuuchi et al. The 
solubility of albendazole was found to increase by more than 10,000 times in 1-
butyl-3-methylimidazolium hexaflourophosphate [BMIM][PF6] (Mizuuchi et al. 
2008). The aqueous miscibility of a poorly water soluble RTIL such as 
[BMIM][PF6] can be improved by inclusion of a second more miscible RTIL  
(e.g. 1-hexyl-3-methylimidazolium bromide [HMIM][Br]. Furthermore the extent 
of improvement in water miscibility was found to correlate with the hydrophilicity 
of the second RTIL.  This ability to modulate the water solubility of RTILs 
increases their usefulness as pharmaceutical solvents. In addition, studies 
suggest negligible toxicity of [BMIM][PF6] and [HMIM][PF6] towards caco-2 cells, 
though a slightly higher toxicity is observed in the same test system with the 
[OMIM][PF6]  salt, which is surface active (Figure 2.7). 
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Figure 2.7 Structures of [BMIM][PF6], [HMIM][PF6], [OMIM][PF6] 
 
2.1.6.2 IL as carrier for drug delivery 
The successful application of novel IL-assisted non-aqueous microemulsion 
stabilized by a blend of two nontoxic surfactants, polyoxyethylene sorbitan 
monooleate and sorbitan laurate for transdermal delivery of acyclovir, which is 
insoluble or sparingly soluble in water and most common organic liquids was 
demonstrated (Moniruzzaman et al. 2010b). 
The influence of ILs on emulsion properties was studied by incorporating ILs 
into the emulsion structure, resulting in stable formulations. The conventional 
oil-in-water (O/W) and water in oil (W/O) emulsions containing ionic liquids such 
as the hydrophilic IL [HMIM][Cl]  and hydrophobic IL [BMIM][PF6] were prepared 
resulting in stable formulations. The antimicrobial activity of ILs in the 
formulations was analysed and their application as preservatives was confirmed 
by performing preservative efficacy tests. Evaluation of the in vitro cytotoxicity of 
the emulsions containing hydrophilic or hydrophobic ILs showed the low 
cytotoxicity of the carriers. Finally penetration enhancement of a fluorescent dye 
(Fluorescein sodium) as a model drug in the presence of ionic liquids was 
shown (Dobler et al. 2013). 
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The influence of imidazolium ionic liquids on bio-chemical parameters that 
influenced the in vivo behaviour of nimesulide was studied. In this context, the 
binding of nimesulide to human serum albumin (HSA), in IL media, was studied. 
In addition to that the evaluation of the interaction of drug-IL systems, with 
micelles of hexadecylphosphocholine (HDPC), enabled the calculation of 
partition coefficients (kp).  Both assays were performed in buffered media in the 
absence and in the presence of [EMIM][BF4], [EMIM] [Ms] and [EMIM] [TfMs]. 
Even though there was an increase of the dissociation constant (kd) in IL media, 
nimesulide still binds to HSA by means of strong interactions. The 
thermodynamic analysis indicated that the interaction was spontaneous for all 
the tested systems. Moreover, the studied systems exhibited properties that 
were favourable to the interaction of the drug with biological membranes, with 
(kp) values 2.5-3.5 higher than in aqueous environment.  The studied 
nimesulide-IL systems presented promising characteristics regarding the 
absorption and distribution of the drug in vivo, so that studied solvents seem to 
be good options for drug delivery (Azevedo et al. 2013). 
Studies have been carried out on a novel ionic liquid-in–oil microemulsion 
capable of dissolving drugs which are poorly water soluble or insoluble in water 
and most of the pharmaceutically accepted organic liquids. This work comprised 
the formation of nanometer-sized ionic liquid droplets in isopropyl myristate with 
a blend of nonionic surfactants like polyoxyethylene sorbitan monooleate and 
sorbitan laurate. Results showed that the ionic liquids containing strong 
hydrogen bond acceptor coordinating anions played a significant part in the 
formation of microemulsion droplets, when a set of ionic liquids was tested as 
dispersed phase. The shape, size and size distribution of the aggregates in the 
characterized microemulsions illustrates the formation of spherical micelles in 
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the range of 8-34nm. The study was extended to the solubility of some insoluble 
or sparingly soluble drugs such as acyclovir, methotrexate, and 1-[(5-(p-
nitrophenyl) furfurylidene) amino] hydantoin sodium) and a high degree of 
solubilization in the IL microemulsions observed. Thus the unique physical, 
chemical and biological properties of microemulsions formed with ILs offer novel 
opportunities to develop a potential drug delivery carrier for poorly soluble drug 
molecules (Moniruzzaman et al. 2010a). 
 Hydrophobic RTILs can be useful as versatile solvents and matrices for 
designing of controlled release drug delivery systems. Some relevant properties 
of [BMIM][PF6], [HMIM][PF6], [OMIM][PF6] were studied and explored, indicating 
that this set of ionic liquids exhibited low aqueous solubility with increasing alkyl 
chain length and could be easily understood by the given data as : 0.035 mol/l,  
(bmim),  0.032 mol/l, (hmim) and 0.09 mol/ l (omim). The release of sucrose and 
dexametasone from water immisible RTILs deposited into water was prolonged 
over 48 hours. The saturated solution of these RTILs demonstrated little toxicity 
towards caco-2 cells, although the (omim) derivative, which is more surface 
active, has a small effect on cell viability. Water immiscible ionic liquids are 
interesting reservoirs for electrically controlled release of insoluble or sparingly 
soluble drug molecule. An enhancement in the drug release profile of some 
solutes in water is observed on passage of electric current through these ionic 
liquids (Jaitely et al. 2008). 
The influence of the 1-butyl-3-methylimidazolium tetrafluoroborate on drug-
surfactant association as binder has also been explored. The association 
between the drug curcumin and anionic surfactant sodium dodecyl sulfate was 
found to be increased in presence of IL. On addition of the IL, the positive 
charged head groups of the imidazolium cation help to stabilize the negative 
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charges of the sulfate ion of anionic surfactant sodium dodecyl sulfate and the 
deprotonated curcumin. On the other hand, repulsion was observed between 
the deprotonated form of curcumin and negative head groups of sulfate ion. The 
presence of the IL dramatically increased the association of curcumin and 
neutral Triton X-100 (TX100), this could be attributed to the hydrogen bonding 
and the dipole-dipole force of attraction between the positive charge of the head 
group of the Il and TX-100. This leads to strong interactions and associations of 
curcumin with the neutral surfactant solutions (Patra and Barakat 2011) (Behera 
et al. 2007). 
Another similar study investigates the binding ability of ionic liquid (1-tetradecyl-
3-methylimidazolium bromide) for the acetylcholine chloride and dopamine 
hydrochloride. The results for the binding ability of the IL was compared to the 
conventional cationic surfactant tetradecyltrimethylammonium bromide 
[TTA][Br]. The IL (1-tetradecyl-3-methylimidazolium bromide) was found to 
possess good binding ability and an efficient drug carrier for both drugs. Both 
surfactant molecules act as good binder for dopamine hydrochloride as 
compared to acetylcholine chloride due to cation-π interactions between the 
positive charge of the surfactant molecules and aromatic region of the 
dopamine hydrochloride. Among both surfactant molecules the IL was found to 
have good binding ability to the dopamine hydrochloride due to π-π interactions 
between the aromatic region of the dopamine hydrochloride and the 
imidazolium ring of the IL (1-tetradecyl-3-methylimidazolium bromide). The polar 
head groups repulsion in the ionic liquid (1-tetradecyl-3-methylimidazolium 
bromide) was found to be greater than [TTA][Br] as the positive charge in the 
imidazolium ring is delocalized, which leads to create steric hindrance and 
finally helping to form aggregates (Figure 2.8). The polar head group of the IL 
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allows having lower critical micelle concentration (CMC) as compared to 
[TTA][Br] (Mahajan et al. 2012).  
 
              
 
Figure 2.8 Possible interaction between drug and IL (Mahajan et al. 2012) 
 
Williams and colleagues have exploited the potential of ionic liquid in oral drug 
delivery systems by using a poorly water soluble drug danazol. In this study 
self-emulsifying drug delivery systems (formulations) were made by 
incorporating ILs. Then danazol was loaded into these formulations and has 
been evaluated for its dissolution profile in simulated gastric and intestinal fluids 
after dispersion. IL based formulation containing danazol was found to give 4.3 
fold higher exposure than crystalline drug and lipid formulation. In-vivo results 
shows that IL based SEDDS were found to be highly effective in keeping 
danazol in a solubilised state. IL-based SEDDS formulations allow high drug 
loading ability, facile dispersion in GI fluids and insensitivity to GI digestive 
systems (Williams et al. 2014). 
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2.1.6.3 Drug ionic liquid 
The significant aspect of drug development is the design and synthesis of 
pharmaceutically acceptable salts. Almost more than half of all drugs used are 
administered as salts. The important pre-formulation task is the salt formation of 
the desired drug molecule as it improves the water solubility, industrial 
processing, safety aspects and sometimes biological properties. The 
replacement of the counter-ion of the active moiety can enhance these 
characteristics. Collating all these gives an idea of utilizing ionic liquids in the 
pharmaceutical industry that is fascinating and inspiring. A number of ionic 
liquid formulations with known therapeutics have been reported. Any 
combination of two or more drugs that have appropriate and opposite ionic 
forms are possible as long as both active ingredients form a stable cation and 
anion. In this way the newly formed drug comprises an IL containing an API 
moiety which may be either cation or anion and a counter-ion component which 
is selected from the generally regarded as safe (GRAS) list is potentially a non-
toxic, pharmaceutically acceptable compound. The formation of drug ionic 
liquids offers novel and unique properties which may not be expressed by the 
standard crystalline salt forms of the API currently available in the market. 
Newly formed drug ionic liquids render enhancement in the dissolution profile of 
the drug molecule which can be utilized through different administration by 
selection of a counter-ion that is appropriate for tailoring the physical and 
chemical properties to a chosen administration route (Ressmann et al. 2011) . 
Currently, half of all the API molecules used are administered in the form of 
salts; the preparation and formulation of suitable salt as drug candidate are 
considered as vital steps in the preclinical phase of modern drug discovery. A 
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number of reports could be found in the literature suggesting the formation of 
salt just by pairing active pharmaceutical ingredients (API) in the cation or anion 
form with biocompatible or inert counterions (Sekhon 2011). 
Ranitidine hydrochloride exists in two different crystalline forms.  Room 
temperature ionic liquid (RTIL), [ranitidine][docusate] was made to overcome 
the problem of polymorphism by combining ranitidine and the counterion 
docusate (Hough et al. 2007a). Liquid aspirin is synthesised by ion-exchange 
reaction between acetyl salicylate and pharmaceutically acceptable ammonium 
salt. The author’s report significant enhancement of the pharmacological 
properties such as bitter taste, poor solubility, and large tablet required for the 
dosage of the prepared salt over solid aspirin (Bica et al. 2010). Another similar 
study was reported in which salicylic acid (SA) was used as a model drug, 
combined with imidazolium cation with varying alkyl side chains to generate a 
room temperature ionic liquid. Three different types of API-ILs were prepared: IL 
bearing SA as anion, IL bearing SA as cation or anion, IL bearing SA as cation. 
The cytotoxicity studies were carried against human colon cancer cell line and 
were found to be significantly higher than the pure SA and that of conventional 
imidazolium based ILs. The synthesised API-ILs showed higher water solubility 
when compared to SA (Egorova et al. 2015). 
Cole et al, synthesised the antibiotic ampicillin based ILs by employing 
metathesis reaction between cationic pyridinium, imidazolium and sodium salt 
of ampicillin. The objective of this study is to conquer antibiotic resistance, 
particularly in β-lactam drugs. The antibacterial activity of the synthesised 
ampicillin based ILs and their parent materials were studied and the results 
suggest that the synthesised ILs exhibited enhanced antibacterial activity 
compared to their parent materials. Thus this study illustrates the feasible 
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alternative as antibacterial agents (Cole et al. 2011b). Another similar study 
used a different method for synthesising ampicillin based ILs. The author first 
made basic ammonia solution of ampicillin which was then neutralised with the 
different organic cation hydroxides namely: [EMIM], [EOHMIM], [Chol], [TEA] 
and [P6,6,6,14]. The salts prepared by this method exhibited greater thermal 
stability and water solubility compared to parent starting material (Ferraz et al. 
2012).  Later in a subsequent study, ampicillin based IL was explored for their 
bacterial and growth inhibition properties against a number of sensitive bacteria, 
most specifically Gram-negative resistant bacteria. The ampicillin mechanism of 
action was significantly influenced by ion-pair combination, hence the authors 
selected hydrophobic ampicillin moiety for this study. Among all ILs studied, 
[C16Pyr][Amp] displays highest inhibition. Although the rest of the ILs also gain 
better results compared to the control [Na][Amp] and starting chloride and 
bromide salts (Ferraz et al. 2014b). The pharmacological properties such as 
partition coefficient (octanol-water), water solubility, and critical micelle 
concentration of ampicillin based ILs were also studied. Among all the studied 
ILs, [Chol] [amp] was the IL found to exhibit enhanced water solubility and 
octanol-water partition coefficient compared to starting materials (Florindo et al. 
2013).  
Another study (Pinto et al. 2013) was conducted, where salicylate based IL 
such as [cetylpyridinium][salicylate], [benzalkonium][salicylate] and 
[EMIM][salicylate] were explored for their pharmacological properties such as 
partition coefficient,  critical micelle formation and protein binding ability. The 
results suggest that all the studied ILs displays the ability to form micelles and 
bind strongly to human serum albumin. The partition coefficient values were 
found to be 6 times greater than that of starting materials. Interestingly, the IL 
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salts display more affinity for the lipid phase compared with the starting 
materials.  
Ionic liquids prepared with cholinium cation are biocompatible, which is 
essential nutrient for the normal growth of cells and its deficiency in diet caused 
fatty liver and some other abnormalities in humans and adult animals. Keeping 
this in mind, a study of novel cholinium based API-IL was accomplished from 
nalidixic acid, niflumic acid, 4-amino-salicylic acid, pyrazinoic acid and picolinic 
acid. The API-IL was prepared by a simple, two step anion exchange reaction. 
The parent materials along with the synthesised API-ILs were subjected for their 
solubility studies to both water and buffer solutions at 25 °C and 37 °C. The 
biopharmaceutical properties especially water solubility, melting point, 
bioavailability and membrane permeating ability were found to be enhanced 
compared with the parent active pharmaceutical ingredients. In-vitro cytotoxicity 
studies have been conducted to explore the cytotoxicity level through two 
different human cell lines, Caco-2 colon carcinoma cells and HepG2 
hepatocellular carcinoma cells for both the synthesised cholinium based API-ILs 
and the starting materials. The most interesting results were obtained for 
[chol][nalidixate] and [chol][niflumate], whose starting APIs were nearly water 
insoluble( solubility < 0.1 mg ml-1 ) (Araújo et al. 2014). 
Another similar study reports the potential of transforming poorly soluble acidic 
active pharmaceutical ingredients into tetrabutylphosphonium salts. Metathesis 
reaction was carried out to generate tetrabutylphosphonoium based API-ILs 
from the sodium salts of the poorly water soluble acidic APIs (Diclofenac, 
Ibuprofen, ketoprofen, naproxen, Sulfadiazine, Sulfamethoxazole, Tolbutamide). 
The melting point and glass transition temperature of tetrabutylphosphonium 
salts were found to be lower compared with the starting material and the 
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solubility profiles of the synthesised salts were enhanced to be 1000 times 
greater than the parent APIs (See Fig. 2.9). The increase in the dissolution 
profiles of the tetrabutylphosphonium salts was expected due to the increase in 
hygroscopicity. Solubility issues associated with the poorly water soluble APIs 
could be addressed via API-IL concept (Balk et al. 2015). 
 
                  
Figure 2.9 The glass transition temperatures and melting points of APIs, 
sodium salts and tetrabutylphosphonium salts (Balk et al. 2015) 
 
Alves et al. reported that the model drug tetracycline when combined with the 
biocompatible anion docusate allows tuning of hydrophilicity of salts. Some of 
the important properties for antibiotics such as hydrophilic-hydrophobic balance 
and water solubility were studied. The API-IL tetracycline docusate, was studied 
and characterised in terms of water solubility, thermal stability and UV-vis 
spectrophotometry was utilised to study octanol-water and liposome-water 
partition coefficient as tetracycline display absorbance around 270nm. The 
interactions of newly synthesised API-IL (tetracycline docusate) and tetracycline 
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hydrochloride with liposomes were analysed by determination of partition 
coefficient using derivative spectroscopy. Egg yolk phosphatidylcholine 
liposomes were utilised as model for cell membrane. The octanol-water and 
liposomes-water partition coefficient data suggest favourable partition towards 
lipophilic phase. The water solubility of tetracycline-docusate was decreased to 
half when compared to parent drug tetracycline hydrochloride (Alves et al. 
2013). 
Recently the API-IL strategy was applied to form ketoconazole citric acid and 
ketoconazole tartaric acid ionic liquids. Ketoconazole is synthetic antifungal 
drug containing imidazole ring which is insoluble in water, while citric acid and 
tartaric acid are pharmaceutical acceptable counter-ions. Solvent evaporation 
technique was employed to synthesise ketoconazole citric acid and 
ketoconazole tartaric acid ionic liquids using different molar ratios. The results 
of this study suggest that the solubility of the synthesised ILs increase with 
increase in the molar ratio of the citric acid and tartaric acid. Only slight 
difference of solubility was observed between the physical mixture and non-
processed ketoconazole. The findings of this study offer number of attractive 
advantages such as increased in solubility, overcome polymorphism issue and 
disadvantages of ketoconazole (Keramatnia et al. 2016).  
The use of silica-supported IL phase (SILP) to immobilise API-ILs on 
mesoporous silica has been demonstrated by using stability, sorption and 
release properties of two ILs namely, tetrabutylphosphonium ibuprofenate [P 
4444][Ibu] and lidocainium ibuprofenate [Lid][Ibu]. This is a simple technology 
used to handle and dose liquid formulations. One of the attractive features of 
silica supported ionic liquid (SILP) delivery systems is the ability to fine tune and 
to control the adsorbed IL release by altering the design of ionic liquids. This 
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technology could also act as a device for drug delivery with complete and rapid 
release of the drug from the silica carrier when place in aqueous environment 
(Bica et al. 2012).The degree of ionicity has been evaluated for 28 PILs using 
NMR spectroscopy.  It is well known (Moreira et al. 2015) that the ionic drugs do 
not permeate easily through biological membrane. The aim of the study was to 
understand the effect of ionic state in the API combinations and their solutions 
in DMSO. A series of acids such as salicylic acid, flurbiprofen, flufenamic acid, 
diclofenac, two artificial sweeteners (saccharin and acesulfame K, docusate (a 
laxative) with three bases: lidocaine, prilocaine, bupivacaine and an antibiotic 
drug metformin combines to generate the desired protic ionic liquids. This study 
provides an easy and accessible procedure to analyse the degree of ionicity of 
protic ionic liquids based on NMR spectroscopy (Moreira et al. 2015). 
Similar study was reported which focused on the issue of proton transfer and 
salt formation in the family of pharmaceutically active acids and bases. The 
objective of the study was to understand the factors responsible to control H-
bonding, melting point and proton transfer and accordingly the authors selected 
a set of acids (benzoic acid, salicylic acid, gentistic acid) and bases 
(Amantadine, tuaminoheptane, 2-Pyrrolidinoethanol)with minor change in 
structure and in physicochemical properties. The properties of the salts are 
governed by the degree of ionocity (protonic character). The proton transfer and 
the extent of ion association in these salts were studied by FTIR-ATR and 
transport properties (Waldon plot). The results show that strong ionic 
interactions were observed in primary amine due to the formation of extended 
hydrogen bonded clusters in salts which is the primary dominating factor for 
membrane transport properties of these compounds in vivo studies 
(Stoimenovski et al. 2012).  Studies have been reported to overcome the 
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problem of hygroscopicity of antitubercular drug ethambutol. A number of protic 
acids (adipic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, 
methanesulfonic acid) were used to obtain salt form of the drug. These salts 
were characterised by ATR-IR, NMR, TGA, DSC and XRD. The results showed 
that the new products were also found to be hygroscopic (Cherukuvada and 
Nangia 2013).  
Tourn -  teilh et al. (2 1   have been reported to understand the interactions 
between imidazolium cation and ibuprofenate anion in a set of imidazolium 
based ionic liquids varying alkyl chain length (n = 4, 6, 8). The authors also 
interestingly studied the structure and composition of the aggregates which form 
on self-assembling in water. The techniques used to understand the interactions 
between the counterions are dynamic light scattering, cryogenic transmission 
electron,1H NMR spectroscopy, and atom-scale molecular dynamics 
simulations. Surface tension and conductivity measurements were used to 
determine the CACs (critical aggregates concentrations) of the imidazolium 
based ibuprofenate ionic liquids and were found to be lower for ILs compared to 
parent materials. Mixed micelles were produced at high concentration and the 
composition basically depends upon the alkyl chain length of the imidazolium 
cation. Stoichiometric composition aggregates were formed upon increase in 
the number of alkyl chain length and composition became enriched in 
imidazolium cations. Micelles were mainly composed of ibuprofenate anion with 
some of the imidazolium cation, when the chain length is very short. The 
change in the chemical composition and the dilution effect are commonly 
responsible for the transitions from micelles to vesicles or ribbons. Thus it can 
be concluded that the ibuprofenate imidazolium cation association could be 
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considered as an ion-pair amphiphile displaying very low interfacial activities 
(Figure 2.10) (Tourn -  teilh et al. 2 1  . 
 
                    
Figure 2.10 Chemical structure of investigated imidazolium based 
ibuprofenate ILs 
 
The red and green circles indicate the tail groups of the anion and cation 
(Tourn -  teilh et al. 2 1  . The IL concepts of combining the biological 
property of quaternary ammonium compounds (QACs) with the biological 
activity of non-nutritive sweeteners such as saccharinate and acesulfame have 
been explored for pharmaceutical applications. Eight ILs namely: 
didecyldimethylammonium saccharinate, didecyldimethylammonium 
acesulfame, benzalkonium saccharinate, benzalkonium acesulfame, 
hexadecylpyridinium saccharinate, hexadecylpyridinium acesulfame, 3-hydroxy-
1-octyloxymethylpyridinium saccharinate and hydroxy-1-
octyloxymethylpyridinium acesulfame have been synthesised and 
characterised. The anti-microbial study of the six ILs have been studied, which 
shows no trend some of the ILs displays decreased anti-microbial activity while 
few exhibited significant increase in anti-microbial activity. Oral toxicity, 
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deterrent activity and skin irritation of didecyldimethylammonium saccharinate, 
didecyldimethylammonium acesulfame have been conducted and the results 
shows both of the ILs achieved category 4 (harmful) for oral toxicity and skin 
irritation, while the deterrent activity of both ILs was found to be good or very 
good against various types of insects (Hough-Troutman et al. 2009). 
(Balk et al. 2015a) reported to prodrug notion to compare with IL approach, a 
poorly soluble drug α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) antagonist was converted into IL in order to look for faster and higher 
oral availability compared to prodrug. The structural confirmations data was 
collected via NMR, DSC, IR, liquid state NMR and ESI-MS. The impact of 
counterion on solubility profiles, dissolution and precipitation kinetics were 
evaluated. Cytotoxicity studies were carried out in three cell lines of hepatic and 
renal origin in macrophages. Results shows that the IL strategy has profound 
influence on the physicochemical properties of API properties without any 
structural changes in the actual drug, which is required in prodrug approach. 
The dissolution profile of IL was found to be 700 fold faster than free acid, 
transepithelial transport was three times faster for IL compared to prodrug and 
the counterion was found to be nontoxic with IC50 (Balk et al. 2015a). 
Some of the challenges faced by the pharmaceutical industry can be resolved 
by the use of ionic liquids as RTILs offers advanced and original solutions in 
new treatment and drug delivery systems. For example researchers can 
synthesize an API in liquid form as liquid salt, which will not be receptive to 
polymorphism. This can be achieved by pairing an API of known characteristics 
with a counter-ion of notable tendencies resulting in an ionic liquid having a low 
melting point. It also seems that negative side effects of given active drug 
moiety can be prevented by delivering it as ionic liquid where the oppositely 
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charged active compounds nullify the side effects. Dual treatment therapies can 
be achieved by combining two active ions. For example, the local anaesthetic 
lidocaine was proved to have enhanced and prolonged effect on rats when 
applied as an ionic liquid in the form of lidocainium docusate when compared to 
the commonly used solid hydrochloride salt (Rodríguez et al. 2009). 
Bica et al.  (2010) prepared novel ionic liquids by using simple ion exchange 
reactions between salts of the active component of aspirin, or chemically similar 
salicylic acid and pharmaceutically active ammonium salts. Later on the 
counterion could be used to add a second function to the ionic liquid drug such 
as antibacterial or antimicrobial behaviour. The data suggest that the limited 
stability of acetylsalicylate ILs prevents pharmaceutical application(Bica et al. 
2010). Many potential drugs fail to perform a successful action as they do not 
fulfil their potential due to poor solubility. Such hurdles can be nullified by 
utilizing ionic liquids in drug formulations. 
 A recent study has been published which focuses on IL-based oral drug 
delivery. The objective of this work is to increase oral exposure by enhancing 
solubility in lipid based formulations and integration into lipid solubilisation 
pathways. Poorly water soluble drugs such as itraconazole, halofantrine and 
cinnazarine are converted into lipophilic ionic liquids by metathesis reaction. 
The reaction has been carried between hydrochloride salts of the drugs and the 
range of lipophilic counterions such as sodium oleate, sodium dodecyl sulfate, 
sodium docusate, sodium stearate, ammonium decylsulfate and ammonium 
octadecylsulfate. The API-ILs synthesised are either completely soluble or 
showed enhanced solubility in lipid formulations or formulations based on 
SEDDS. Itraconazole docusate and cinnazarine decylsulfate were completely 
dissolved at high concentration in SEDDS formulations to achieve high 
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exposure. Enhanced drug absorption was observed for itraconazole up to 20 
fold and for cinnazarine up to 2-fold compared to controlled suspension 
formulations. This study suggests that the synthesised lipophilic ionic liquids 
provides an alternative pathway to enhance drug solubility profile in SEDDS 
formulations and therefore overcoming the challenge associated with oral drug 
delivery systems (Sahbaz et al. 2015). 
2.1.7Skin as biological barrier 
Skin is the largest organ of the body which acts as a promising gateway for 
systematic or local action (Figure 2.11). The main function of skin is to act as 
barrier between the outer environment and the body. Human skin is composed 
of four main regions: the stratum corneum, epidermis, dermis and hypodermis. 
Stratum corneum is made up of phospholipids, cholesterol sulfate, protein (75-
85%), lipids (5-15%) and forms the outermost layer of the skin which acts as the 
actual barrier to the most of the substances. Epidermis is found between the 
stratum corneum and dermis having thickness range from 50-100 µm. The 
water content found in epidermis is about 90%. Dermis lies beneath the 
epidermis and having thickness range between 2000-3000 µm. It is composed 
of fibrous protein (Singla et al. 2012). 
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Figure 2.11 Cross section of human skin (Singla et al. 2012) 
 
2.1.8 Drug administration to the skin 
Topical and transdermal drug delivery has been attracting a huge interest 
throughout the globe as it offers many potential benefits over other routes such 
as avoiding local gastrointestinal irritation and hepatic first-pass effect  and 
providing improved patient compliance (Ranade 1991). The topical application 
of drug can be used to treat diseases of the outer part of the skin or can allow 
reach to the deeper tissues without any at all potential side effects. The active 
ingredient used to treat certain local muscuskeletal inflammations and 
osteoarthritis requires penetration as deep as underlying muscles. The 
therapeutic drug levels to treat acne should reach deeper into epidermal layers 
in order to target pilosebaceous structures in psoriasis disease. The domain of 
deep tissue penetration after topical application of drug gained limited attention 
(Guy and Maibach 1983). The topical delivery of local anaesthetics to deeper 
layers of skin would be the most beneficial in case of paediatric patients and for 
those patients who are uncomfortable with hypodermic needles.    
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2.1.9 Drug penetration routes 
The strictly ordered structure of stratum corneum makes the transdermal 
permeation of active pharmaceutical ingredients difficult or often impossible. 
The permeation of the drug molecules via skin basically includes diffusion 
through intact epidermis and through skin appendages such as sweat glands, 
hair follicle via shunt pathways through intact epidermis. However the surface 
area of these skin appendages are very low (0.1 %) of the total human skin and 
drug delivery via this route is considered to be very small. The drug delivery 
pathway is basically influenced by the formulation used and the 
physicochemical properties of the compound. The transcellular pathway is more 
favoured when penetration enhancer is used as it increases the permeability of 
the corneocytes by changing the keratin structure. The molecule passes 
through the cells in the transcellular route. The transcellular pathway is not 
considered under normal conditions due to very low permeability via 
corneocytes and due to problematic partitioning several times from hydrophilic 
corneocytes into lipid intercellular layers of stratum corneum and vice versa 
(Figure 2.12) (Kolesnikova et al. 2013).  
In intercellular pathway, the molecule passes through the spaces found 
between the cells, although it is the longest pathway but also one of the most 
prominent route compared to other pathways. Intercellular route allows 
hydrophilic substances to pass through via hydrophilic route and lipophilic 
substance via lipophilic route as this route provides both regions (hydrophilic 
and lipophilic) (Ehrhardt and Kim 2007).   
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Figure 2.12 Different penetration routes via SC (Williams and Barry 2012) 
 
The drug molecule must first dissolve in the vehicle in order to diffuse from 
stratum corneum/vehicle interface. Then the drug particles partitions into 
stratum corneum and diffuse through it and then partitions into the viable 
epidermis.  The partitioning of lipophilic drug through viable epidermis is not 
favourable because of the hydrophilic nature of the epidermis which results in 
the deposition of lipophilic drug into stratum corneum. The drug moves into 
blood for systemic removal after passing into the dermis. The skin can be 
considered as a trilaminate structure comprising the outermost dense 
keratinized layer called stratum corneum, followed by viable epidermis and then 
the dermis. 
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2.1.10 Formulation and drug modification for topical/transdermal drug      
delivery 
This section will provide brief insights into alternative chemical strategies which 
can be used to modify topical and transdermal drug delivery. 
2.1.10.1 Ion pairing 
Charged species do not readily permeate via the human skin membrane. This 
drawback could be overcome by formation of an ion pair which is formed by 
combining an oppositely charged species with the charged permeant; in theory, 
a complex in which the charges are neutralised allowing the permeant to 
penetrate through membrane where it may dissociate to eliminate the charged 
species. Scott et al.(2001) suggested that propranolol formed a 1:1 addition 
complex with many fatty acids during investigating the permeation of β-blocker 
via human skin, for instance lauric acid and β-blocker when applied concurrently 
they permeate at a rate of 1:1 mole ratio through human skin membranes (Stott 
et al. 2001). Studies have been reported where salicylates was paired with 
quaternary ammonium ions and amines (MEGWA et al. 2000).  Smith and Irwin 
reported that ion pairing was not only responsible for increase in flux through 
human skin membrane by penetration enhancers (Smith and Irwin 2000). 
2.1.10.2 Eutectic systems 
In addition to the properties such as partition coefficient and molecular weight, 
the melting point of the permeant has significant impact on transdermal 
permeation. The lower the melting point of the drug molecule the greater its 
solubility in skin lipids including in a given solvent. Eutectic formation is one of 
the methods by which the melting point of the drug delivery system can be 
lowered. Eutectic binary mixtures are formed by combining two components 
that do not interact with each other and form a new chemical entity which at a 
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certain ratio inhibits crystallisation process of one other resulting into the 
formation of eutectic composition. EMLA cream was the first commercially 
successful eutectic formulation formed by mixture of lidocaine and prilocaine 
(mixture of local anaesthetics) (Nyqvist‐Mayer et al. 1986).  
The use of eutectic mixtures was gaining interest in the field of topical drug 
delivery. The mixture of ibuprofen with a series of terpene penetration 
enhancers was reported to form eutectic mixture for improving transdermal drug 
delivery. Among the mixtures studied terpene penetration enhancer thymol was 
found to form at eutectic mixture which melts at 32 °C (Stott et al. 1998). 
2.1.10.3 Prodrugs 
Prodrug formation was one of the earliest and most successful strategies 
employed for both systemic and local delivery of topically applied drugs.  
Generally, the prodrug formation was designed for lipophilic drug molecule 
because the increase in lipophilicity will help in partitioning of the molecule into 
stratum corneum. Some polyoxyethylene ester prodrugs of ketoprofen, 
naproxen and diclofenac were reported and were found to increase 
percutaneous absorption in vitro, and also provided with sustained vivo effect 
(Bonina et al. 2001).  
2.1.10.4 Supersaturation 
The thermodynamic activity of any formulation can be increased beyond unity 
by using supersaturated systems. Supersaturation in any topical formulation 
can be achieved by evaporation of a solvent or co-solvent. Supersaturation of 
the drug molecule in the donor phase results in the uncontrolled and 
unpredictable evaporation of the vehicle from the skin surface. Many topically 
applied formulations are thought to operate probably by this mechanism 
(Coldman et al. 1969). These systems can also be formed by cooling a warm  
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saturated solution back down to skin temperature resulting in increasing 
thermodynamic activity of the molecule (HENMI et al. 1994). 
2.1.11 Summary of background 
This section sheds light on the definition, history, physicochemical properties 
and potential pharmaceutical applications of ILs.  The structure of skin, different 
drug penetration routes via skin, formulation and drug modification required for 
efficient topical and transdermal drug delivery was briefly described in 
background section. 
2.2Literature review 
As illustrated in the introduction part that this study was focussed on topical 
application of ILs, therefore this section gives detailed review of IL on topical 
and transdermal application. 
2.2.1 Significance of IL in topical drug delivery systems 
Different drug delivery systems have been developed with varied targeted 
delivery routes including topical, transdermal, oral, injection and nasal during 
the last two decades. The transdermal and topical drug delivery method seems 
to be ideal among the different routes as it is considered as a safest route for 
drug administration. Topical and transdermal application of drug offers several 
advantages over the conventional mode of drug delivery systems, as it 
surpasses first pass metabolism, increased patient compliance and depletion of 
few side effects. This method also helps to reduce the loss caused by 
metabolism in the oral cavity, gastrointestinal tract, liver and also offers the 
advantage of increase bioavailability (Herkenne et al. 2008).    
A number of active pharmaceutical ingredient-ionic liquids (API-ILs) have been 
reported, which are the liquid form of active pharmaceutical ingredients. API-IL  
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approach offers several attractive advantages over crystalline pharmaceuticals 
such as removal of polymorphism and enhanced bioavailability (Hough and 
Rogers 2007). API-IL approach helps to enhance the pharmacodynamics and 
pharmacokinetics property of the active pharmaceutical ingredients via 
administration of dual drug instead of two individual salts. The degree of ionicity 
and the molar proportion ratio of the counterion and the API are the critical 
characteristics which are directly related to the pharmaceutical industry as these 
properties have significant influence on the bioavailability, solubility, absorption, 
distribution, metabolism and excretion (Kelley et al. 2013). 
MacFarlane et al. reported that the ionic liquid permeation through membrane 
depends on the nature of the components. It is well known fact that the salts are 
less likely to permeate through the membrane from solution. The transport 
property of pharmaceutically active protic salts namely tuammoniumheptane 
salicylate and butylammoniumacetate was evaluated via a silicone membrane 
by applying either propylene glycol solution of IL or by applying neat IL. Two 
types of protic IL were studied one which is fully dissociated or complete proton 
transferred while the other protic IL is formed by partial transfer of proton 
resulting in formation of hydrogen bond (Figure 2.13).  
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Figure 2.13 Protic ILs (a) proton transferred and fully dissociated 
(b) proton transferred but form hydrogen bonded clusters 
(Stoimenovski and MacFarlane 2011) 
 
The hydrogen bonded complexes behave more likely to neutral compounds and 
function as ion-pair complexes. The protic IL are able to cross the membrane as 
fast as unionised neutral molecules because they are more associated and fail 
to exist in solution. On the other hand the starting materials which are simple 
salts fail to cross the membrane which could be attributed to the general rule 
that salts do not permeate through the membrane as rapidly as neutral 
molecules. However the protic ILs which are formed by the complete 
transference of acidic hydrogen are more likely to be dissociated in the solution 
or possess very low ability to form associated species also pass through the 
membrane but not as fast as associated protic ILs (Stoimenovski and 
MacFarlane 2011). 
Liquid co-crystals or deep eutectics are the equimolar ratio of two components 
which have different properties from those of individual components. A very 
strong, partially ionized hydrogen bond is responsible for the liquefaction of the 
crystalline pharmaceuticals. Liquid co-crystals are the unique complexes with 
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very strong hydrogen bond in which the acidic proton is thought to be localised 
between the acidic and basic components. A unique example of liquid co-crystal 
is the combination of lidocaine with fatty acids such as oleic acid or decanoic 
acid. The formation of such type of complexes results in a partially, not 
completely, proton transferred (ionized) state of each acid and base (Figure 
2.14). Thus specific type of interactions could allow the delivery of active 
pharmaceutical ingredient transdermally (acidic and basic drug moieties). The 
strong interaction through acidic proton not only helps to prevent crystallisation 
of neutral components of the liquid co-crystal but also simultaneous delivery of 
acidic and basic moieties (Bica et al. 2011).  
 
                   
Figure 2.14 Hydrogen bonded complexes 
 
The mechanism of action of ionic liquid is dramatically influenced by the 
interactions found between the components. This could be explained by taking 
a very simple example of lidocaine ibuprofen ionic liquid, which is formed by 
mixing the two components. Lidocaine ibuprofen has been reported as 
completely ionized API-IL in some of the publications (Park and Prausnitz 
2015), but extensive characterisation of lidocaine ibuprofen illustrates that the 
combination of these components results in the generation of deep eutectic 
liquid co-crystals through partially ionized interactions between two components 
or via strong hydrogen bond (Figure 2.15).  
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Figure 2.15 Interactions between lidocaine and ibuprofen 
(Berton et al. 2017) 
 
These interactions of the API-IL are responsible for different biological nature. 
The bioavailability of the ionized compounds was found to lower because the 
permeation through membrane of such type of compounds is limited, which is 
not the case of hydrogen bonded complex’s (Lidocaine-ibuprofen) (Berton et al. 
2017). These studies suggest that the proper choice of API in its liquid form and 
comprehensive characterisation of ionic liquids (allows overcoming the 
misunderstanding of interactions between components of ionic liquids) could 
have significant influence on the membrane transport properties, an important 
factor in bioavailability. 
2.2.2IL-mediated topical/ transdermal drug delivery 
2.2.2.1 IL as carrier for topical/transdermal drug delivery 
Studies have been reported which suggest that ILs could be useful for the 
solubilisation of poorly soluble drugs such as acyclovir, methotrexate and 
dantrolene sodium. They have reported IL-in-oil microemulsion in which the 
drug molecules were loaded in the IL droplets and these IL droplets are 
stabilised by a surfactant and co-surfactant in a continuous phase. A blend of 
nontoxic surfactant such as polyoxyethylene sorbitan monooleate (Tween 80) 
and sorbitan laurate (Span-20) were used to prepare IL-in-oil microemulsion. 
Isopropyl myrisate was used as continuous oil phase. It was observed that the 
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IL with strong coordinating anions which are strong hydrogen bond accepter 
can form IL droplets in the oil phase among the studied set of ILs (Figure 2.16). 
The authors suggested that the interactions between the polar groups of the 
drug molecule and the IL anion via hydrogen bonding are the key factor 
responsible for dissolution of sparingly soluble drug molecules. The in vitro 
analysis of skin permeation using full-thickness skin pieces from Yucatan micro 
pigs showed that the developed IL-in-oil microemulsion displays enhanced 
release of the drug acyclovir. The increase in the permeability of acyclovir by 
using IL-in-oil microemulsion was attributed to the high solubilisation of drug 
molecule in IL droplets and the effect of lipophilic components (Moniruzzaman 
et al. 2010a). 
 
                                
Figure 2.16 Ionic Liquid-in-oil microemulsion (Moniruzzaman et al. 2010a) 
 
A similar study has been reported which illustrates the potential of IL-in-oil 
microemulsion as an efficient transdermal drug delivery of sparingly soluble 
drugs. The developed formulation based on microemulsion was shown to 
increase the administration of MTX which was used as model drug. DMSO, a 
well-known chemical enhancer used for transdermal or topical drug delivery is 
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safe only when it is used in very low concentration (up to 10%). Cytotoxicity of 
the system was remarkably increased in the presence of highly concentrated 
DMSO. The same pattern was followed by the authors where they developed 
the IL-in-oil microemulsion having low concentration of ILs and they observed 
an increase in cell viability (> 80%) of a cancerous cell when compared with the 
controls (Dulbecco’s phosphate-buffered saline,  water-in-oil microemulsion and 
IPM ) (Yoshiura et al. 2013) .  
Another study suggests the subsequent development of a novel IL-in-oil 
microemulsion system for the dermal delivery of water soluble (poorly 
permeating) BCS class III drug 5-fluorouracil.  An imidazole based ionic liquid 1-
butyl-3-methyimidazolium bromide (BMIM Br) was used for development of 
microemulsion. The authors observed remarkable enhancement in the solubility 
of 5-flurouracil in IL-in-oil microemulsion as compared to water-in-oil 
microemulsion. IL-in-oil microemulsion was developed by using IPM, Tween 80, 
Span 20 and [BMIM] [Br]. Ex-vivo skin permeation studies were also conducted 
through mouse skin and the results indicates that the developed IL-in-oil 
microemulsion induced the significant permeation of 5-flurouracil. For example, 
when compared with the aqueous solution, hydrophilic ointment and water-in-oil 
microemulsion shows 4-fold, 2.3-fold and 1.6-fold respectively enhancement in 
the percent drug permeation. In addition to that the developed IL-in-oil 
microemulsion formulation could be effectively used to treat skin cancer. The 
analysis of in-vivo studies against dimethylbenz(a)anthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced mice skin carcinogenesis 
illustrates that IL-in-oil microemulsion could treat skin cancer effectively.  
Importantly erythema and irritation (common side effects) which were 
associated with the conventional drug formulations were not observed. 
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Interestingly, the histopathological studies suggest that the utilisation of the IL-
in-oil microemulsion did not cause any pathological and anatomical changes in 
the skin structure of the mice (Goindi et al. 2014). 
Later, in a similar study, the influence of hydrophilic [HMIM] [Cl] and 
hydrophobic [BMIM] [PF6] imidazolium based ionic liquids on the properties and 
stability of emulsion was investigated. In this study the water phase was 
replaced by [HMIM] [Cl] and the oil phase replaced by [BMIM] [PF6]. Both ionic 
liquids were successfully incorporated into the emulsion structure, resulting in 
stable formulations. Both of the ILs could be used as preservatives in the 
emulsion as they show antimicrobial activity. The droplet size and viscosity of 
the IL-based formulation was remarkably decreased and also maintained long 
term stability as compared with emulsion without IL. In-vitro cytotoxicity 
evaluation of the formulation containing hydrophilic and hydrophobic ILs 
suggests low cytotoxicity of the carriers. In addition to that skin penetration 
enhancement of the fluorescent dyes as a model drug was achieved in 
presence of ILs(Dobler et al. 2013).   
Goindi et al. (2015), reported the potential application of IL-in-water 
microemulsion formulation which is able to solubilize a poorly water soluble anti-
inflammatory drug etodolac (ETO). The microemulsion formulation is made up 
of IL [BMIM] [PF6], while tween 80 and ethanol was used as surfactant and co-
surfactant.  The ex-vivo drug permeation evaluation shows that IL-in-water 
microemulsion was effective in enhancing the drug solubility and shows better 
skin permeation when compared with other studied formulations. The in-vivo 
anti-arthritic and anti-inflammatory activities also suggested that ETO loaded IL-
in-water microemulsion was found to be more effective in controlling 
inflammation compared with commercial formulation of ETO and the oily 
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formulation, o/w microemulsion. The histopathological studies illustrate no 
anatomical and pathological changes in skin (Goindi et al. 2015). 
Araki et al. (2015) reported the potential application of ionic liquid as penetration 
enhancer in the drug delivery systems. In this study the ionic liquid 
[C12MIM][NTf2] was incorporated in as penetration enhancer in the studied 
vaccine formulations, resulting in significant enhanced skin-permeating ability of 
ovalbumin (OVA), a model antigen. The study illustrates that IL-mediated 
transcutaneous administration of high molecular weight protein and drug 
molecules was effective using solid-in-oil nanodispersions (Figure 2.17) (Araki 
et al. 2015).  
 
                             
Figure 2.17 Transcutaneous protein delivery using solid-in-oil 
nanodispersions (Araki et al. 2015) 
 
Koji Kubota et al. (2016) reported the formation of molecular assembly by 
combination of highly biocompatible and safe carboxylic acid and aliphatic 
amines, which was studied for an effective and safe penetration enhancer for 
transdermal drug permeation. Hydrophilic phenol red and hydrophobic 
tulobuterol was used to understand the mechanism of skin permeation 
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enhancement using the ionic liquids. FTIR was used to characterise the IL 
mixture which suggest that the carboxylic acid/amine mixture coexists at all 
states of mixture. ILs interact with the carboxylic acid via hydrogen bonds when 
acid is in excess state, thus the skin permeation enhancement effect was not 
only due to presence of ionic liquid (Kubota et al. 2016). 
2.2.2.2 Drug-IL for topical/transdermal drug delivery 
Lidocainium docusate was the very first API-IL made by Rogers and Houh et al. 
(2007). The author’s studied the topical treatment of analgesia in the two 
different models of mouse anti-nociception and observed remarkable 
enhancement compared with the parent API, lidocaine hydrochloride. They also 
observed the significant increase in the physical properties such as thermal 
stability and solubility of the synthesised salt [lidocainium] [docusate] (Hough et 
al. 2007a).  
Zakrewsky et al studied a set of neat ILs for the enhancement of the antibiotic 
delivery across skin layers. Choline geranate [Chol] [Geranate] was found be 
effective among all the studied neat ILs. This IL shows minimal toxicity against 
several human cancer cell lines. Choline geranate effectively enhanced the skin 
permeation for the delivery of the antibiotic cefadroxil by a factor of > 16 without 
causing skin irritation.  Importantly, in-vivo evaluation suggests outstanding 
antimicrobial activity against the biofilm protected microbes pseudomonas 
aeruginosa and salmonella enterica, greater than 95% bacterial death was 
observed after 2 hour treatment in a biofilm-infected wound model (Zakrewsky 
et al. 2014).  
                        Wang et al. (2014) have shown that acidic and basic active pharmaceutical 
ingredients (API) can be held strongly in deep eutectic form (liquid co-crystal) 
through hydrogen bonds or partially ionized interactions even in solution form. 
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In order to demonstrate this, researchers use permeation via a model 
membrane in a Franz diffusion cell and illustrate that acidic and basic APIs 
transports at much higher rate than the solutions of the individual material. By 
just mixing the solvent and corresponding API solutions, hydrogen bonded 
complexes are formed which are responsible to form deep eutectic of active 
pharmaceutical ingredients in situ. Therefore it is not necessary to premade 
deep eutectic of active pharmaceutical ingredients. In order to understand the 
nature of interactions between acidic and basic API, a number of 
nonstoichiometric mixtures of lidocaine and ibuprofen has been studied via 
spectroscopically and membrane transport (Wang et al. 2014).  
The potential application of pharmaceutically active IL has been demonstrated 
by all- in-one concept for drug delivery systems. An ionic liquid has been 
synthesised by combining the cationic drug amitriptyline hydrochloride (AH) and 
anionic surfactant molecule sodium dodecyl sulphate (SDS) and characterised 
by 1H NMR and DSC. The newly formed ionic liquid salt could work in both 
ways it can act as carrier and as well as the active drug molecule and in 
aqueous solution can undergo self-assemble to form vesicles (Figure 2.18). 
Controlled release of the drug molecule was observed from the carrier. The 
ionic liquid strategy of synthesising such type of pharmaceutically active IL 
vesicles offers many attractive advantages over conventional liposomal or 
polymer based drug delivery systems. For instance, fixed or high drug loading 
could be achieved up to 57.7%, depending on the equivalent mole number of 
SDS- and AH+. The method of preparation of pharmaceutical IL vesicles is quite 
simple, easy and the pharmaceutical IL is more stable. The newly prepared 
ionic liquid displays enhanced permeability compared to the drug component in 
the ionic liquid (Zhang et al. 2013). 
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Figure 2.18 Displaying self-assembling of API-IL (Zhang et al. 2013) 
 
Cholinium sulfasalazine (IL) was evaluated for its pharmacological performance 
as it has very low membrane permeability activity and limited water solubility 
(0.6 µg ml-1). Due to the poor exposure of the drug, a frequent oral dose of 1-3 g 
per day is required by the arthritis patents. The synthesised ionic liquid salt 
(cholinium sulfasalazine) was found to exhibit enhanced solubility profile 
compared to parent drug. In-vivo studied were conducted using rats which were 
exposed to intravenous (I.V.) administration. Interestingly, the synthesised salt 
was found to be administered in much higher I.V. doses compared to the low 
solution dose achieved by the physical mixture (Sulfa : choline) (Shadid et al. 
2015).  
Park and Prausnitz (2015) reported lidocaine (a local anaesthetic) in the ionic 
liquid form, which allows enhanced lidocaine absorption into the skin and 
reduce the time to achieve local anaesthesia.  The idea behind this study was 
that the injection process to administer the local anaesthesia lidocaine was 
painful and not comfortable. In addition to that the eutectic mixture of local 
anaesthesia, which is  equal quantities of lidocaine and prilocaine and is 
marketed as a 5% oil-in-water emulsion incorporated in a cream need to apply 
before 1 hour in order to achieve local anaesthesia. To overcome these 
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shortcomings authors performed a number of screenings with different 
counterions. Interestingly,   they manage to get ionic liquid form of lidocaine 
which is synthesised using ibuprofen. This study reports the potential of 
lidocaine-ibuprofen ionic liquid as improved and rapid method of topical drug 
delivery and results indicate enhanced lidocaine absorption into skin (Park and 
Prausnitz 2015). 
The development of ionogels as drug delivery system has been explored by 
Lydie et al. Ionogels are prepared in two steps, first step is to made 1-methyl-3-
butylimidazolium ibuprofenate (IL) by ion exchange reaction carried between 
sodium salt of ibuprofen and 1-methyl-3-butylimidazolium chloride. Then the IL 
synthesised in first step is used in sol-gel synthesis using pure 
tetramethoxysilane (TMOS) or tetramethoxysilane/ methyltrimethoxysilane 
(MTMOS) precursor mixtures. Ionogels were characterised by FTIR and XRD. 
Results of this study illustrates that the kinetics of the drug releasing system 
was controlled by the nature of the silica wall (Viau et al. 2010). 
In a recent study, a poorly soluble drug, etodolac has been converted into ionic 
liquid by mixing it with lidocaine in stoichiometric proportions in order to 
enhance its hydrophilicity, hydrophobicity and skin permeability. Differential 
scanning calorimetry, FTIR, and saturation measurement were used to 
characterise the synthesised ionic liquid and the parent drug molecule. The 
newly formed ionic liquid exhibit lower melting point compared to corresponding 
individual drug molecule alone which confirms the enhancement in 
lipophilicity/hydrophilicity of etodolac. In-vitro assessment has been carried out 
through patch (Etoreat) containing ionic liquid and the results show significantly 
enhancement in skin permeation of etodolac (9.3 fold) compared to etodolac 
patch alone. However no significant change was observed for lidocaine skin 
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permeation. This study illustrates that lidocaine substantially expand the 
formulation and helps to improve skin permeation of etodolac (Miwa et al. 
2016). 
Berton et al. (2017) evaluated the bioavailability of lidocaine on the basis of the 
interaction found in the formulation. The study begins with the incorporation of 
lidocaine to produce ionic liquid salt lidocainium docusate and lidocaine-
ibuprofen (deep eutectic). The transdermal absorption of lidocainium docusate 
and lidocaine-ibuprofen (deep eutectic) was compared with crystalline salt 
lidocainium chloride. Topical creams of crystalline salt lidocainium chloride and 
the salt and deep eutectic were prepared by mixing each compound to the 
vehicle cream to meet the concentrations of 3.5 and 5.0 wt % of lidocaine to 
mimic commercially available formulations. Then these topical creams were 
applied to Sprague-Dowley rats. The plasma concentration of lidocaine was 
monitored over time. Interestingly, the concentration of lidocaine in plasma was 
found to higher and faster in hydrogen bonded deep eutectic lidocaine ibuprofen 
compared to lidocainium chloride and lidocainium docusate (Figure 2.19) 
(Berton et al. 2017). 
 
 
 
 
 
 
 
 
 
66 
 
 
 
                      
Figure 2.19 Concentration of lidocaine in blood plasma over time after the 
application of creams (Berton et al. 2017) 
 
2.2.3 Summary of literature review 
The literature review covers the detailed studies relevant to the potential 
application of ILs in the field of topical and transdermal drug delivery. So the 
next section provides detailed information regarding materials used for 
synthesis, methods and different analytical techniques used for the study. 
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Chapter 3 Materials, methods and general experimental procedures 
3.1   Introduction 
This chapter describes the materials and methods used for synthesis of 
benzalkonium based NSAIDs ILs, benzalkonium-sulfacatmide ILs, 
benzalkonium based mixed anion ILs and ibuprofen IL hydrogels. This section 
also provides detailed information regarding experimental procedures and 
analytical tools such as NMR and IR used for characterisation. 
3.2 Materials 
3.2.1Chemicals used for the synthesis of benzalkonium based NSAIDs ILs 
Benzyltriethylammonium chloride, benzyldimethylhexadecylammonium chloride, 
sodium ibuprofen, chloroform, methanol, acetic acid, acetonitrile, 1-octanol were 
purchased from Sigma –Aldrich. Sodium diclofenac was purchased from VWR 
UK. 
3.2.2 Chemicals used for the synthesis of benzalkonium-sulfacetamide ILs 
Benzyltriethylammonium chloride, benzyldimethylhexadecylammonium chloride, 
sodium sulfacetamide, chloroform, methanol, acetic acid, acetonitrile, 1-octanol 
were purchased from Sigma –Aldrich.  
3.2.3 Chemicals used for the Synthesis of benzalkonium based mixed 
anion ILs 
Benzyltriethylammonium chloride, benzyldimethylhexadecylammonium chloride, 
salicylic acid, sodium salicylate, sodium ibuprofen, ibuprofen, chloroform, 
methanol, acetic acid, acetonitrile, 1-octanol were purchased from Sigma –
Aldrich. 
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3.2.4 Chemical used for synthesis of diisopropanolamine-ibuprofen (IL) 
and for formulation containing IL hydrogels 
Carbopol 974 was purchased from Lubrizol, diisopropanolamine, dialysis tubing 
cellulose membrane size 33mm × 21 mm were purchased from Sigma Aldrich. 
Distilled deionized water was used for making gels. Dura pore membrane filters, 
and Filter type: 0.45 µm HVHP were purchased from Sigma –Aldrich. 
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Table 3.1 Physicochemical properties of used materials 
 
 
 
 
Name 
 
 
Structure 
 
Molecular         
weight 
 
Melting 
point (°C) 
 
Source 
 
Purity 
(%) 
 
BTEA-Cl 
 
 
 
 
 
227.77 
 
190-192 
 
Sigma 
 
99 
 
BDMA-Cl 
 
 
 
 
 
396.09 
 
55-56 
 
Sigma 
 
99 
 
Ibuprofen 
sodium 
 
 
 
 
 
228.26 
 
129-131 
 
Sigma 
 
98 
 
Diclofenac 
sodium 
 
 
 
 
 
 
318.13 
 
- 
 
VWR 
 
98 
 
Sulfacetamide     
sodium 
 
 
 
 
 
 
254.24 
 
- 
 
Sigma 
 
99 
 
Salicylic 
sodium 
 
 
 
 
 
160.10 
 
200-202 
 
Sigma 
 
98 
 
Ibuprofen 
 
 
 
 
 
206.28 
 
76-78 
 
Sigma 
 
98 
 
Salicylic acid 
 
 
 
 
 
138.12 
 
158-161 
 
Sigma 
 
99 
 
Diisopropanola
-mine 
 
 
 
 
 
 
133.19 
 
42-45 
 
Sigma 
 
95 
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3.3 Methods used for synthesis 
3.3.1 Synthesis of benzalkonium based NSAIDs ILs 
Ionic liquids were synthesised according to previously reported methods 
(Hough-Troutman et al. 2009; Rogers et al. 2014). Four benzalkonium based 
NSAIDs ILs have been synthesised using a common synthesis (Figure 3.1): 
benzyltriethylammonium-ibuprofenate,  
benzyltriethylammonium-diclofenac,  
benzyldimethylhexadecylammonium-ibuprofenate, 
benzyldimethylhexadecylammonium -diclofenac.  
A common procedure was followed to synthesize the above listed API-ILs in the 
purest form using commercially available starting materials (Figure 3.1). Each of 
the cations was combined with ibuprofen and diclofenac anions by a 
stoichiometric metathesis reaction in aqueous solution using the sodium salt of 
each drug. The nature of the salts allowed them to be easily extracted from the 
aqueous phase into chloroform, which was then washed with water to remove 
the inorganic salt (monitored by silver nitrate test). Finally the solvent was 
removed by a rotary evaporator and it was dried under vacuum.   
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Figure 3.1 Scheme for the preparation of benzalkonium based NSAIDs ILs 
 
3.3.2 Synthesis of benzalkonium sulfacetamide ILs 
Benzyltriethylammonium sulfacetamide and 
Benzyldimethylhexadecylammonium sulfacetamide were synthesised using 
common synthesis process (Figure 3.2), which is explained in 3.3.1 section. 
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Figure 3.2 Scheme for the preparation of benzalkonium-sulfacetamide ILs 
 
3.3.3 Synthesis of benzalkonium based mixed anion ILs 
Four benzalkonium based mixed anion ILs have been synthesized: 
benzyltriethylammonium-ibuprofenate salicylic acid,  
benzyltriethylammonium-salicylate ibuprofen, 
benzyldimethylhexadecylammonium-ibuprofenate salicylic  acid, 
benzyldimethylhexadecylammonium –salicylate ibuprofen.  
A two-step common procedure was followed to synthesize the above listed ILs 
with mixed anions using commercially available starting materials (Figure 3.4).  
1. Four benzalkonium based NSAIDs ILs namely  
benzyltriethylammonium-ibuprofenate, benzyltriethylammonium-salicylate, 
benzyldimethylhexadecylammonium-ibuprofenate and 
benzyldimethylhexadecylammonium-salicylate were synthesised using common 
synthesis process, which is explained in Section 3.3.1. 
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2. The benzalkonium based NSAIDs ILs synthesized in step first was mixed 
with ibuprofen/salicylic acid to give ILs with mixed anions using conventional 
and solvent free approach: 
(A)    Conventional method: 
Benzyltriethylammonium ibuprofenate and solid salicylic acid in equimolar ratio 
were dissolved in 20 ml methanol and stirred for 30 minutes at room 
temperature. The solvent was evaporated to obtain benzyltriethylammonium-
ibuprofenate salicylic acid as a clear viscous liquid. The purity was confirmed by 
1H NMR, 13C NMR, DSC and TGA.  
 (B) Solvent free synthesis:   
Benzyltriethylammonium ibuprofenate and salicylic acid in equimolar ratio were 
ground for 25 minutes in a mortar at room temperature.   A viscous liquid was 
obtained.  Theremainingbenzalkonium ILs with anions were synthesised using 
the common synthesis method and were confirmed by 1H and 13C NMR, TGA 
and DSC. All the remaining ILs with mixed anions have been synthesised by 
common synthesis (Table3.1).  
 
                                    
Figure 3.3 Photograph showing benzalkonium based mixed anion ILs 
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Table 3.1 Benzalkonium based mixed anion ILs 
Sample          
ID 
 
Benzalkonium based NSAIDs ILs 
 
Acid 
API-IL: 
Acid 
(Ratio) 
 
Benzalkonium based mixed anion ILs 
M1 
Benzyltriethylammonium ibuprofenate  
[BTEA-Ibu] 
Salicylic 
acid 
1:1 
Benzyltriethylammonium ibuprofenate-
salicylic acid 
M2 
Benzyltriethylammonium Salicylate 
[BTEA-Sal] 
Ibuprofen 1:1 
Benzyltriethylammonium salicylate-
Ibuprofen 
M3 
Benzyldimethylhexadecylammonium 
Ibuprofenate  [BDMA-Ibu] 
Salicylic 
acid 
1:1.5 
Benzyldimethylhexadecylammonium 
ibuprofenate-salicylic acid 
M4 
Benzyldimethylhexadecylammonium 
Salicylate  [BDMA-Sal] 
Ibuprofen 1:1.5 
Benzyldimethylhexadecylammonium 
Salicylate- Ibuprofen 
       ⃰API-IL:  Active pharmaceutical ingredients-ionic liquid 
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Figure 3.4 Representing structural formulae of benzalkonium based mixed 
anion ILs 
 
3.3.4 Synthesis of synthesis of diisopropanolamine-ibuprofen (IL) and 
formulation containing IL hydrogels 
3.3.4.1 Synthesis of synthesis of diisopropanolamine-ibuprofen (IL) 
Appropriate amounts of Ibuprofen and diisopropanolamine were charged in a 50 
ml beaker and heated to a temperature in the range of 80-90ºC for 30-40 
minutes to form a homogeneous colourless liquid which was characterised by 
1H NMR, 13C NMR, and FTIR (Figure 3.5). The compositions of the ILs are 
shown in Table 3.2 
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Figure 3.5 Scheme for synthesis of diisopropanolamine-ibuprofen (1:1) 
 
 
Table 3.2 The various compositions of diisopropanolamine-ibuprofen IL 
    DIPA-Ibu* (IL): Diisopropanolamine-Ibuprofen ionic liquid  
    DI*: Diisopropanolamine-Ibuprofen  
 
 
 
 
Sample. Ratio  DIPA-Ibu* (IL) Amount of DIPA (g) Amount of Ibuprofen (g) Physical observation 
 DI*  0.2 0.2:1 0.128 1  Slightly   hazy,liquid 
DI  0.4 0.4:1 0.257 1 Colourless, uniform liquid 
DI   0.5 0.5:1 0.322 1 Colourless, uniform liquid 
DI   0.6 0.6:1 0.386 1 Colourless, uniform liquid 
DI   0.8 0.8:1 0.515 1 Colourless, uniform liquid 
    DI 1 1:1 0.644 1 Colourless, uniform liquid 
DI   1.2 1.2:1 0.778 1 Colourless, uniform liquid 
DI  1.4 1.4:1 0.902 1 Colourless, uniform liquid 
DI   1.5 1.5:1 1.018 1 Colourless, uniform liquid 
DI   1.6 1.6:1 1.031 1 Colourless, uniform liquid 
DI   1.8 1.8:1 1.160 1 Colourless, uniform liquid 
DI   2 2:1 1.289 1 Colourless, uniform liquid 
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3.3.4.2 Formulation of IL based ibuprofen hydrogels 
IL based ibuprofen hydrogels were prepared by incorporating 1% aqueous 
carbopol dispersion into synthesized diisopropanolamine-ibuprofen (IL) 
according to the following steps: 
a) 1 g of Carbopol 974 powder was dispersed in a final volume of 100 ml 
deionized water and left overnight to form 1% aqueous carbopol 
homogeneous dispersion. 
b) This 1% aqueous carbopol dispersion was subsequently added to the 
various synthesized IL compositions. 
c) The mixtures obtained in step (b) were stirred gently with the help of a 
spatula until a homogeneous hydrogel was formed. The pH of the IL 
based ibuprofen hydrogels was measured by Mettler Toledo pH meter. 
d) The IL based ibuprofen hydrogels obtained in step (c) were allowed to 
equilibrate for at least 2 days at room temperature and were then 
characterised by FTIR. The compositions of the IL based ibuprofen 
hydrogel formulation are shown in Table 3.3. 
 
 
 
 
 
 
 
 
Figure 3.6 Diagrammatic depiction of the method of preparation of IL 
based ibuprofen hydrogels 
Designing of Guest IL 
(Diisopropanolamine-ibuprofen) 
Designing of host support                                                                                                      
(Carbopol 974) 
     IL Loading                         
 
1 % aqueous 
carbopol  
ddispersioncarbopol
carbopoCarbopol 
IL based Ibuprofen     
hydrogel 
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Table 3.3 Compositions of IL based ibuprofen hydrogels 
*- DIPA-Diisopropanolamine 
 
 
                                
 
Figure 3.7 Photograph of the prepared IL based ibuprofen hydrogels (right 
to left) [S2], [S3], [S4], [S5], [S6] 
 
 
Sample 
Amount of 
Un-
neutralised 
1% carbopol 
dispersion 
pH of 
Un-
neutralised 
1% carbopol 
dispersion 
Ratio 
DIPA*:Ibuprofen 
(IL) 
Amount of 
DIPA*:Ibuprofen 
(IL) (g) 
pH of 
gel 
Strength 
of gel 
Physical observation 
S1 25 g 3.02 1:1 1.644 7.45 4 % Cloudy, uniform gel 
S2 25 g 3.02 1.2:1 1.778 7.48 4 % Cloudy, uniform gel 
S3 25 g 3.02 1.4:1 1.902 7.54 4  % Cloudy, uniform gel 
S4 25 g 3.02 1.5:1 2.018 7.70 4  % Colourless, uniform gel 
S5 25 g 3.02 1.6:1 2.031 7.75 4  % Colourless, uniform gel 
S6 25 g 3.02 1.8:1 2.160 7.88 4  % Colourless, uniform gel 
S7 25 g 3.02 2:1 2.289 8.7 4  % Colourless, uniform gel 
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3.4 General experimental procedures and analytical techniques 
3.4.1      1H and 13C NMR Spectroscopy 
NMR spectra of samples were obtained using a Bruker Avance III 400 
spectrometer operating at 400 MHz, in CDCl3. Tetramethylsilane was used as 
internal standard. The 1H NMR spectra were recorded in the range of 0-20 ppm 
at ambient probe temperature (273 K) at 16 scans. Coupling constants are 
quoted in Hertz (Hz). In general the sample size used was 10-20 mg and 0.7 ml 
deuterated chloroform 
13C NMR spectra were recorded in the range of 0-250 ppm at 128 scans.  
3.4.2      FTIR Spectroscopy 
Fourier Transform Infrared Spectroscopy (FTIR): Infrared spectra were 
recorded using neat samples on a Perkin-Elmer Nicolet FTIR spectrometer. 
Spectra were obtained in the range of 400-4000 cm-1 
3.4.3      Differential Scanning Calorimeter 
Thermal transitions (melting point and glass transitions) of the neat samples 
were determined on a TA Instruments DSC 2000 differential scanning 
calorimeter. Approximately 5-10 mg of the sample was placed in a standard 
aluminium pan with a pin-hole in the lid. The instrument was calibrated with 
indium and zinc standards. The samples were subject to heat-cool-heat cycle. 
The samples were first equilibrated at 10 ◦C, then heated to 80 ◦C (heating rate 
10 °C/min) and then held for 5 minutes at 80 ◦C. After this, samples were cooled 
to -70 ◦C (cooling rate 10 °C/min) and held for 5 minutes and then again heated 
to 80 ◦C.   
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3.4.4      Thermogravimetric analysis 
Thermogravimetric analysis was performed to determine the range of thermal 
decomposition temperatures for each of the synthesized ionic liquids. The study 
was performed using TA Instruments Q5000 series thermal gravimetric 
analyzer. The sample (5-10 mg) was loaded in a platinum pan and heated from 
25 ◦C to 350 ◦C at a heating rate of 10 ◦C min-1 under inert nitrogen environment. 
The obtained data was analyzed using TA Universal analysis software V4.5A. 
3.4.5      Electrical conductivity measurement 
The conductivity measurements were carried out on YSI Professional plus 
portable multiparameter water quality meter. The instrument was calibrated 
before and after use by using 1M KCl solution. The instrument conductivity 
ranges from 0 to 50 mS/cm.  All the measurements were carried out at room 
temperature were repeated three times, and the averages of the values were 
taken. 
3.4.6      Determination of octanol-water partition coefficient 
The octanol-water partition coefficient of ionic liquids was determined using a 
procedure mentioned by Zakrewsky et al. (2014). Firstly, octanol was saturated 
with water.  250 mL of n-octanol was mixed and shaken with 100 mL of distilled 
water and left overnight. The saturated octanol was used for the preparation of 
0.01 M solutions of each ionic liquid in a 5-mL volumetric flask. In addition 0.01-
M solutions of each benzalkonium based NSAIDs ILs were also prepared using 
water. Separately, saturated octanol and phosphate buffer pH 7.2 was used for 
the preparation of 0.01 M solutions of M1, M2 and 0.0005 M solution of M3, M4 
ILs (benzalkonium based mixed anion ILs) in a 5-mL volumetric flask. 
Absorbance maxima for benzalkonium based NSAIDs ILs and benzalkonium 
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based mixed anion ILs are provided in Table 3.5. A 4-mL portion of the IL 
solution in saturated octanol was shaken with 4 mL of distilled water/phosphate 
buffer and this was followed by gentle centrifugation (1,000 rpm, Hettich 
zentrifugen LBA centrifuge, 6-hole fixed angle rotor 804SF) to obtain clean 
separation of the two layers. The UV absorbance of the octanol and 
water/phosphate buffer layers was measured and compared with the 
absorbance of the stock solutions. Measurements were repeated three times, 
and the partition coefficients were reported as the average. The percentage of 
ionic liquid in octanol was calculated as the absorbance of the octanol layer 
after extraction divided by the absorbance of ionic liquid in octanol before 
extraction. The water/octanol distribution coefficient was calculated as the 
logarithm of the percentage of IL in octanol divided by the percentage of IL in 
water(Zakrewsky et al. 2014). 
Table 3.4 Absorption maxima for benzalkonium based NSAIDs ILand 
benzalkonium based mixed anion ILs 
S.no Benzalkonium based NSAIDs ILs 
 
Benzalkonium based mixed anion ILs Absorption maxima 
1 [BTEA] [Ibu], [BDMA] [Ibu] - 263 nm - 264 nm 
2 [BTEA] [Diclo], [BDMA] [Diclo] - 286 nm- 287 nm 
3 [BTEA] [Sulfa], [BDMA] [Sulfa] - 257 nm – 258 nm 
4 - M1, M2, M3, M4 296 nm - 297 nm 
 
3.4.7      Ex-vivo skin study 
Rat skin was carefully cleaned under cold running water and stored at -20ºC 
before use. On the day of the experiment, the skin was defrosted, cut into 
square pieces, and mounted with the stratum corneum uppermost in Franz-type 
diffusion apparatus (Hathout and Nasr 2013; Bsieso et al. 2015; Nasr and 
Abdel-Hamid 2016; Abdelgawad et al. 2017; Nasr et al. 2017). The area of the 
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skin was 1.77cm2. The receptor medium was composed of 7.5 ml phosphate 
buffer pH 7.4 containing 0.5% tween 80, which was constantly stirred with a 
magnetic bar, and maintained at 37ºC using a circulating water jacket. An 
amount of 100 mg of the ionic liquid samples were placed in donor 
compartments (n=5). Samples were withdrawn at time intervals (15 min, 30 min, 
1hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 5 hr) from the receptor compartment, and replaced 
with fresh medium. After 5 hours, the skin samples were washed five times with 
distilled water and dried with filter paper to remove any excess formula. Tape 
stripping of the skin was performed with an adhesive tape, in which twenty 
pieces of adhesive tape were firmly pressed on the skin surface and rapidly 
pulled off with fluent strokes. The dermis was separated from the epidermal 
layer in each skin sample using a scalpel, and the tape strips, dermis and 
epidermis were individually placed in beakers containing 10 ml methanol each 
for extraction of the drugs, after placing them in a sonicator for 2 hours. All 
samples were filtered using a membrane filter of pore size 220 nm before 
injection into a HPLC column to be analyzed for the drug contents. The 
amounts of drugs accumulating in the different skin layers and permeated 
through the skin were expressed as a percentage of the total amount of active 
ingredient applied on the skin. 
3.4.8      In-vitro permeation studies 
The in-vitro permeation studies of benzalkonium based mixed anion ILs  and IL 
based ibuprofen hydrogels were carried out using a Franz diffusion cell (Copley 
scientific, vertical diffusion tester) using artificial membrane (Durapore 
membrane filters, Filter type: 0.45 µm HVHP). Six mL phosphate buffer pH 7.2 
was used as receptor chamber and then 200 mg of neat benzalkonium based 
mixed anion ILs/IL based ibuprofen hydrogels was placed evenly on the 
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membrane in a thin layer which is used as donor phase. The donor 
compartment was kept in contact with the receptor chamber and the 
temperature was maintained in the range of 36 °C - 37 °C and the solutions 
were stirred by magnetic bars. 3 mL sample from the receptor compartment 
was taken at appropriate time intervals and replaced by same concentration 
fresh phosphate buffer solution to maintain sink conditions. Then the samples 
were analysed by High Performance Liquid Chromatography (HPLC). 
3.4.9      In-vitro release studies 
Dialysis bags of cellulose membrane were made providing cylindrical 
compartments for hydrogels and which were washed in water previous to use. 
The dialysis bags were filled with 0.5 g of the IL based Ibuprofen hydrogels. The 
exposed surface area of the hydrogel in the dialysis bag was in the range of 3 - 
3.5 cm. Then the bags were immersed in the acceptor compartment containing 
200 mL of the receptor media, which is phosphate buffer pH 7.2. The 
temperature was kept in the range of 36 °C -37 °C and the receptor media was 
constantly stirred with a magnetic bar to maintain sink conditions. At appropriate 
time intervals a 3 mL sample was taken from the receptor media and replaced 
by an equal amount of fresh phosphate buffer pH 7.2 to maintain sink 
conditions. The amount of Ibuprofen diffused into the receptor chamber was 
analysed by High Performance Liquid Chromatography (HPLC). 
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3.4.10      Antibacterial efficacy study 
3.4.10.1 Materials  
Tryptic Soy Agar (TSA , Tryptic Soy Broth (TSB , Mϋller Hinton agar (MHA ; 
Oxoid Microbiology Products, deionized water, Whatman grade AA discs, 6 mm 
diameter (Fisher Scientific) 
3.4.10.2 Bacterial strains used in the study 
Two strains were used: 
Staphylococcus (S.) aureus (NCTC 6571) 
Escherichia (E.) coli (NCCTC 12923) 
3.4.10.3 Culture media and incubation conditions 
Culture media was prepared and treated according to manufacturer’s guidelines 
and sterilised by autoclaving. The strains were routinely grown on TSA agar, 
and incubated at 37 ºC in air for 24 hrs.  
3.4.10.4 Screening for antibacterial activity by disc diffusion tests 
The in vitro antibacterial efficacy of the benzalkonium-sulfacetamide ILs and the 
individual components were tested against both gram-positive and gram-
negative bacteria and in particular against the Staphylococcus (S.) aureus 
(NCTC 6571) and Escherichia (E.) coli (NCCTC 12923) strains using the agar 
diffusion method. Bacterial suspensions were prepared from the TSA culture 
plates by transferring 2-3 colonies in sterile distilled water. The turbidity of the 
bacterial suspensions was adjusted to 0.5 McFarland turbidity standard, that 
corresponds to 1.5x108 colony forming units (CFUs)/ml. This bacterial 
suspension was used to inoculate MHB agar plates evenly using a sterile swab. 
2 mg/ml of each test compound was prepared in distilled water and then diluted 
to the desired concentration range (20, 30, 40, 50 and 100 µg/ml). Then 20 µl of 
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each tested compound was loaded from the working stock solution onto 6 mm 
diameter sterile Whatmann discs (Fischer scientific, UK). The loaded discs were 
placed on the surface of the agar lawns with the help of needle and forceps. 
The plates were incubated at 37 °C for 24 hours. At the end of the incubation, 
the plates were examined and the diameter of each zone of inhibition was 
measured and recorded (in mm). The activity tests were repeated on a separate 
day, using a fresh culture. 
3.4.10.5 MIC determination 
Minimum inhibitory concentration (MIC) is the lowest concentration of 
antimicrobial drug that will inhibit the visible growth of microorganism after 
overnight incubation. Minimum bactericidal concentration (MBC) is the lowest 
concentration of antibacterial agent required to kill the bacteria. Aqueous 
solutions of the benzalkonium-sulfacetamide along with the starting materials 
were prepared to give stock solution of 5000 µg/ml for benzyltriethylammonium 
chloride and benzyltriethylammonium sulfacetamide, 2000 µg/ml for 
benzyldimethylhexadecylammonium chloride, 
benzyldimethylhexadecylammonium sulfacetamide and sodium sulfacetamide, 
which was further diluted to design a set of concentrations from 2500 to 0.30 
µg/ml and 1000 to 0.12 µg/ml in a nutrient broth (TSB). These different 
concentrations were used to investigate the synergistic antibacterial effect of 
benzalkonium ILs by broth dilution method. 200 µl of each sample were placed 
in a single well of three different 96-well plate (first row) – one plate per bacterial 
strain. 100 µl TSB was placed in each subsequent well of the plates; 0.1 ml of 
the sample from first row was transferred to row 2 and mixed thoroughly with 
the TSB by repetitive pipetting and then 0.1 ml of this was transferred in the 
same manner to subsequent rows such that a dilution series was set up. 100 µl 
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of TSB broth containing bacteria was transferred to all wells except the negative 
control column. After overnight growth, the absorbance of the wells was read 
using plate reader set to measure at 570 nm. The percentage bacterial growth 
inhibition was calculated by following formula. 
Percentage growth inhibition = (OD of control/ OD of control – OD of test 
sample) × 100 
 
3.4.11      HPLC Analysis 
The experiments were performed on Waters e2695 separation module with 
Waters 2998 photodiode array (PDA) detector. The chromatographic and the 
integrated data were recorded using Empower 3 software. Chromatographic 
separations were performed on Sunfire C18 5.0 µm (3.0 × 250 mm) column at 
35 ºC using phosphate buffer pH 3.25 (A) and acetonitrile (B) as mobile phase 
with gradient elution at a flow rate of 1.1 mL/min. Gradient programme is shown 
in Table. 3.6. Detection of Ibuprofen and salicylic acid was carried at 191 nm 
and 202 nm respectively with adequate sensitivity. Calibration curve of 
ibuprofen and salicylic acid can be seen in Figure 3.8. 
 
Table 3.5 Gradient programme for HPLC 
 Time (min) Flow (mL/min) % A % B 
1  1.10 80.00 20.00 
2 3.00 1.10 80.00 20.00 
3 16.00 1.10 45.00 55.00 
4 17.00 1.10 25.00 75.00 
5 20.00 1.10 80.00 20.00 
6 25.00 1.10 80.00 20.00 
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Figure 3.8 Calibration curve of ibuprofen and salicylic acid 
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Table 3.7 HPLC parameters for Ex-vivo studies 
 
HPLC analysis : Ex-vivo studies (collaborative work) 
 
Sample HPLC method 
parameters 
Calibration 
equation 
Instrument 
 
[BTEA][Ibu] 
 
 
 
 
 
Mobile phase 
Methanol:water:acetic 
acid 
600:377:23 
Injection volume :10 µl 
Detection wavelength : 
264 nm 
C18 column 
Retention time: 7.85 min 
Column tem: 35ºC 
 
 
Y=844.18x 
R2=0.9998 
 
Waters 2695 
separations 
module (Model 
code SHC) with 
dual wavelength 
absorbance 
detector waters 
2487 
 
[BDMA][Ibu] 
 
[BTEA][Diclo] 
 
 
 
 
 
Mobile phase: 
Methanol:Phosphate 
buffer pH 2.5 
70:30 
Injection volume: 10 ul 
Detection 
wavelength:275nm 
C18 column 
Flow rate: 1ml/min 
Retention time: 5.4 min 
Column temp: 
35ºC 
 
 
Y=22881x 
R2=1 
 
[BDMA][Diclo] 
 
[BTEA][Sulfa] 
 
 
 
 
 
Mobile phase 
methanol:water:acetic 
acid 
10:89:1 
Injection volume: 10 ul 
Detection 
wavelength:254nm 
C18 column 
Flow rate: 1ml/min 
Retention time: 6.6 min 
Column temp: 35ºC 
 
 
 
Y=27372x 
R2=0.9999 
 
[BDMA][Sulfa] 
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Table 3.8 HPLC parameters for in vitro permeation and release studies 
 
HPLC analysis : In vitro permeation and release studies  
 
Sample HPLC method 
parameters 
Calibration 
equation 
Instrument 
 
 
M1 
 
M2 
 
M3 
 
M4 
 
 
 
 
Method: Gradient 
Mobile phase 
Acetonitrile : Phosphate 
buffer pH 3.25 
Injection volume: 50 ul 
Detection wavelength : 
191 nm (Ibuprofen) and 
202 (Salicylic acid) 
C18 column 
Column tem: 35ºC 
Flow rate: 1.10 ml/min 
Retention time: 4.57 min 
(salicylic  acid) and 
18.08 min (Ibuprofen) 
 
 
y = 44978x + 
11174 
R² = 0.9994 
(Ibuprofen) 
 
y = 129650x 
- 122511 
R² = 0.9986 
(Salicylic 
acid) 
 
 
waters e2695 
separation 
module with 
waters 2998 
photodiode array 
(PDA) detector 
 
S1 
 
S2 
 
S3 
 
S4 
 
S5 
 
S6 
 
S7 
 
 
Method: Gradient 
Mobile phase 
Acetonitrile : Phosphate 
buffer pH 3.25 
Injection volume: 50 ul 
Detection wavelength : 
191 nm  
C18 column 
Column tem: 35ºC 
Flow rate: 1.10 ml/min 
Retention time: 
18.08 min 
 
 
 
 
y = 44978x + 
11174 
R² = 0.9994 
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Chapter 4 
Benzalkonium based NSAIDs Ionic liquids (ILs) 
4.1. Introduction 
The focus of this chapter is investigation of the effect of counterions on the 
physicochemical properties and biopharmaceutical performance of 
benzalkonium based NSAIDs ILs for topical treatment. For this, sodium salt of 
Ibuprofen and sodium salt of diclofenac has been selected as a model drug in 
the form of anion and benzalkonium halides as cationic form which was further 
transformed into ILs by metathesis reaction and were characterised by NMR 
and IR spectroscopy. DSC, TGA, electrical conductivity, octanol-water partition 
coefficient measurements and ex-vivo skin deposition behaviour was also 
evaluated. 
As discussed in Chapter 1, topical and transdermal drug delivery offers several 
advantages over oral drug delivery especially in case of non-steroidal anti-
inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac. The most 
prevailing disease in the world is rheumatoid arthritis and its related disease. 
Diclofenac is non-steroidal anti-inflammatory drug (NSAID) which displays poor 
aqueous solubility because of its high melting point and intrinsic hydrophobicity. 
The carboxylic group is the only hydrophilic functional group which is also not 
available to interact with the solvent due to formation of dimer (Cordero et al. 
1997). Stratum corneum is the outermost layer of the skin which functions as 
hydrophobic barrier for absorption of most of the drugs. 
During the 19th century, the antibacterial properties of quaternary ammonium 
compounds were discovered among malachite green, methyl violet and auramin 
(Dunn 1949; Hough-Troutman et al. 2009). The complete potential of 
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quaternary ammonium compounds was acknowledged after the synthesis of 
benzalkonium chloride in 1935, which was found to possess a wide spectrum of 
effectiveness against many bacterial strains after characterization of its anti-
bacterial properties (Domagk 1935). These newly emerged water soluble 
quaternary ammonium compounds display anti-bacterial properties against not 
only gram-positive and gram-negative bacteria, but also against protozoa and 
pathogen species of fungi (Kull et al. 1961). Interestingly, these compounds can 
also act as penetration enhancers for transbuccal and transnasal drug delivery 
systems such as nasal vaccinations (Klinguer et al. 2001). Later these water 
soluble quaternary ammonium compounds have shown potential applications in 
the fields of disinfectants (Lopes 1986), surfactants (Hayakawa and Kwak 
1991), phase transfer catalysis (Makosza 2000) and anti-corrosive agents 
(Hough-Troutman et al. 2009). Certainly a surfactant molecule is useful to 
modify the texture of formulation and also helps to stabilize it. In addition, 
surfactants can alter the transport across biological barriers by directly affecting 
the biological membrane (Khossravi 1997; Savić et al. 2 1  . The antibacterial 
mechanism of action of quaternary ammonium compounds is based on the 
disruption of membrane charge distribution and altering cell membrane 
permeability, leading to leakage of all components from cytoplasm, followed by 
bacterial death (Arias-Moliz et al. 2015).Utilizing API-IL approach not only 
lowers the melting point of the API but also helps to generate room temperature 
IL salts.  
In light of the above, we investigated the feasibility of topical application of 
benzalkonium based NSAIDs ILs and evaluated the impact of counterions on 
the dermal bioavailability and the physicochemical properties. It is worthy to 
note that there is no reported data in the literature on the skin deposition and 
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permeation profiles of these anions (ibuprofen, diclofenac) combined with 
benzalkonium. 
 
4.2. Results and discussions 
4.2.1 Anion exchange reaction of benzalkonium based NSAIDs ILs and 
characterisation 
All synthesized benzalkonium based NSAIDs ILs were in the form of clear 
yellow viscous liquids to colourless viscous liquids at room temperature (Table 
4.1). 
The benzalkonium based NSAIDs ILs were characterized by 1H NMR, 13C NMR 
and FTIR spectroscopy (Figure 4.1 – 4.8). The proton signals for [BTEA] were 
recorded at 1.25- 7.47 ppm and included a signal for 9 protons of its terminal 
methyl groups at 1.25 ppm (t), 6 protons of adjacent methylene groups were 
found at 3.09-3.21ppm (q), 2 protons for the methylene next to phenyl group 
observed at 4.45 ppm (s) while the aromatic protons were found at 7.35-7.47 
(m). The signals obtained for [BTEA] were compared with the signals of 
respective sodium salts of APIs confirming the formation of ILs, indicating good 
stability of active pharmaceutical ingredient during salt formation. This data was 
further supported by the IR spectroscopy. The formation of ILs takes place 
through anion exchange reaction using sodium salt of APIs. Therefore the 
typical C=O stretching vibrations between 1690 cm-1 – 1709 cm-1 exhibited by 
carboxylic group containing APIs were not important to this study. Following the 
metathesis reaction the symmetric and antisymmetric stretching of carboxylic 
anions were found at 1583 cm-1 and 1378 cm-1 [BTEA-Ibu], 1584 cm-1, 1363 cm-
1 [BTEA-Diclo], 1581 cm-1 and 1370 cm-1 [BDMA-Ibu] and 1585 cm-1, 1363 cm-1 
[BDMA-Diclo] respectively. 
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NMR and FTIR characterization data 
Benzyltriethylammonium-ibuprofen [BTEA] [Ibu]: Yield 78%.  
1H NMR (400 MHz, CDCl3)  ppm 0.86 (d, 6 H), 1.25 (t, 9 H), 1.38 (d, 3 H), 1.77 
(m, 1 H), 2.35 (d, 2 H), 3.09 - 3.21 (q, 6 H), 3.52 (q, 1 H), 4.45 (s, 2 H), 6.93 (m, 
2 H), 7.29 (m, 2 H), 7.35 - 7.47 (m, 5 H) 
13C NMR (101 MHz, CDCl3)  ppm 7.93, 18.40, 19.96, 22.34, 30.17, 44.99, 
49.30, 52.37, 57.07, 60.59, 76.93, 77.25, 77.46, 77.57, 127.36, 127.44, 128.40, 
129.22, 130.44, 132.31, 138.19, 143.06, 179.56  
IR (ν max cm
-1):  3086, 2956, 2845, 2346, 1583, 1458, 1378, 1153, 1008, 778, 
713, 617 
 
Benzyltriethylammonium-Diclofenac [BTEA] [Diclo]: Yield 81%.  
1H NMR (400 MHz, CDCl3)  ppm 1.13 - 1.26 (t, 9 H), 3.03 (q, 6 H), 3.64 (s, 2 
H), 4.31 (s, 2 H), 6.36 (dd, 1 H), 6.62 - 6.74 (dt, 1 H), 6.79 - 6.91 (dt, 1 H), 7.14 
(t, 1 H), 7.24 (d, 2 H), 7.28 - 7.39 (m, 5 H), 9.79 (s, 1 H) 
13C NMR (101 MHz, CDCl3)  ppm 7.93, 18.49, 44.66, 52.30, 57.67, 60.47, 
76.79, 77.11, 77.31, 77.43, 116.53, 120.07, 120.15, 122.71, 125.68, 127.20, 
128.75, 129.15, 129.30, 130.37, 130.51, 132.27, 138.67, 143.55, 177.12, 
177.16 
IR (ν max cm
-1): 3208, 2968, 2323, 1606, 1584, 1451, 1363, 1049, 784.4, 703.3, 
643.7 
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Benzyldimethylhexadecylammonium-ibuprofen [BDMA] [Ibu]: Yield 76%.  
1H NMR (400 MHz, CDCl3)  ppm 0.85 (d, 6 H), 0.86 (t, 3 H), 1.20 - 1.32 (m, 26 
H), 1.45 (d, 3 H), 1.54 - 1.67 (m, 2 H), 1.76 (m, 1 H), 2.33 (d, 2 H), 3.05 (s, 6 H), 
3.17 - 3.28 (m, 2 H), 3.53 - 3.65 (q, 1 H), 4.74 (s, 2 H), 6.93 (d, 2 H), 7.30 - 7.42 
(m, 5 H), 7.43 - 7.48 (m, 2 H) 
13C NMR (101 MHz, CDCl3)  ppm 14.12, 19.87, 22.44, 22.69, 22.80, 26.32, 
29.28, 29.37, 29.40, 29.49, 29.61, 29.66, 29.70, 30.23, 31.93, 45.11, 49.52, 
63.20, 67.29, 76.73, 77.05, 77.26, 77.37, 127.52, 127.75, 128.52, 129.05, 
130.39, 133.19, 138.28, 143.19, 179.61 
IR (ν max cm
-1):  3017, 2955, 2921, 1581, 1462, 1370, 1345, 864.8, 782.7, 
734.9, 708.2 
 
Benzyldimethylhexadecylammonium-Diclofenac [BDMA][Diclo]: Yield 76%.  
1H NMR (400 MHz, CDCl3)  ppm 0.81 - 0.93 (t, 3 H), 1.23 - 1.35 (m, 26 H), 
2.93 (s, 6 H), 3.58 - 3.69 (s, 2 H), 4.57 (s, 2 H), 6.41 (dd, 1 H), 6.66 - 6.77 (dt, 1 
H), 6.81 - 6.93 (dt, 1H), 7.18 (dd,1 H), 7.25 (d, 2 H), 7.29 - 7.42 (m, 5 H), 9.63 
(s, 1 H) 
13C NMR (101 MHz, CDCl3)  ppm 14.13, 18.48, 22.70, 22.81, 26.30, 29.27, 
29.37, 29.46, 29.59, 29.64, 29.68, 29.70, 31.93, 49.55, 58.23, 76.72, 77.04, 
77.36, 116.70, 120.22, 122.69, 125.75, 127.55, 128.76, 129.05, 129.21, 129.42, 
130.43, 133.16, 143.53, 177.31 
IR (ν max cm
-1):  3032, 2923, 2853, 1606, 1585, 1452, 1363, 1050, 866.8, 744.2, 
642 
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Figure 4.11H NMR and 13C spectra of [BTEA] [Ibu] 
[BTEA] and [Ibu] protons are represented in red and blue colours 
respectively 
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Figure 4.2 FTIR spectra of [BTEA] [Ibu] 
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Figure 4.3 1H NMR and 13C spectra of [BTEA] [Diclo] 
[BTEA] and [Diclo] protons are represented in red and blue colours 
respectively 
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Figure 4.4 FTIR spectra of [BTEA] [Diclo] 
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Figure 4.5 1H NMR and 13C spectra of [BDMA] [Ibu] 
[BDMA] and [Ibu] protons are represented in red and blue colours 
respectively 
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Figure 4.6 FTIR spectra of [BDMA] [Ibu] 
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Figure 4.71H NMR and 13C spectra of [BDMA] [Diclo] 
[BDMA] and [Diclo] protons are represented in red and blue colours 
respectively 
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Figure 4.8 FTIR spectra [BDMA] [Diclo] 
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4.2.2 Thermal Behaviour 
The effect of counterions on the thermal properties of the benzalkonium based 
NSAIDs ILs was studied using TGA and DSC (Figure 4.9 – 4.12). All the 
benzalkonium based NSAIDs ILs are viscous liquids at room temperature. 
Table.4.1 shows the thermal stability of studied benzalkonium based NSAIDs 
ILs ranging from 147.56 ◦C to 165.60 ◦C. Two step decomposition was observed 
for [BTEA] [Diclo], while the remainder of the studied benzalkonium based 
NSAIDS ILs exhibited one step decomposition process.  
The thermal decomposition temperature of [BTEA] based NSAIDs ILs were 
found in the order of [BTEA] [Ibu] > [BTEA] [Diclo]. The impact of anions can be 
observed by the difference in thermal stability of API-ILs. It could be observed 
from the trend that thermal stability of the [BTEA] based NSAIDs ILs decreases 
with increase in anion size (asymmety), the negative charge is spread over the 
large volume of anion resulting in much weaker interactions between the 
counterions (Leys et al. 2008). The same pattern was observed for [BDMA] 
based NSAIDs ILs, [BDMA] [Ibu] > [BDMA] [Dic]. However, when you compare 
the decomposition temeratures of [BTEA] and [BDMA] based NSAIDs ILs then it 
was observed that [BDMA] based NSAIDs ILs display higher decomposition 
temperatures. The increase in decomposition temperature could be attributed 
due to increase in interparticle forces (Van der Waal forces) which arises with 
increase in alkyl chain length (Canongia Lopes and Padua 2006; Chancelier et 
al. 2016).     
DSC thermograms showed that the glass transition temperature for all the 
synthesized benzalkonium based NSAIDs ILs were in the range of -39.10 to -
37.95 for [BTEA] based NSAIDs ILs and -33.54 to -7.35 for [BDMA] based 
NSAIDs ILs respectively (Table 4.1). The glass transition temperature of [BTEA] 
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based NSAIDs ILs were found in the order of [BTEA] [Diclo] > [BTEA] [Ibu]. The 
observed trend could be correlated to the molecular volume. Higher the 
molecular volume lowers the coulombic force of attraction between ions leading 
to increase in glass transition temperature values. Similar trend was observed 
for [BDMA] based NSAIDs ILs, [BDMA] [Diclo] > [BDMA] [Ibu].Regardless of 
being in liquid phase at room temperature, the [BTEA] and [BDMA] based 
NSAIDs ILs displayed different thermal response, in which [BDMA] based 
NSAIDs ILs exhibited higher glass transition temperature compared to [BTEA] 
based NSAIDs ILs which could be correlated to the increase in molar volumes 
leading to increase in Van der Waals force of attraction (Leys et al. 2008). 
 
 
Table 4.1 Thermal properties of benzalkonium based NSAIDs ILs 
S.no NSAIDs-ILs Tg(
◦
C) Td(
◦
C) Physical state 
1 [BTEA] [Ibu] -39.10 147.56 Colourless Viscous liquid 
2 [BTEA] [Dic] -37.95 141.85 Yellow viscous liquid 
3 [BDMA] [Ibu] -33.54 165.60 Colourless Viscous liquid 
4 [BDMA] [Dic] -7.35 157.02 Yellow viscous liquid 
 
                                          Tg – glass transition temperature ; Td – decopmposition temperature 
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TGA and DSC profiles of benzalkonium based NSAIDs ILs 
 
 
 
 
 
 
 
 
Figure 4.9 TGA and DSC profile of [BTEA] [Ibu] 
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Figure 4.10 TGA and DSC profile of [BTEA] [Diclo] 
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Figure 4.11 TGA and DSC profile of profile of [BDMA] [Ibu] 
 
 
 
 
 
 
108 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 TGA and DSC profile of profile of [BDMA] [Diclo] 
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4.2.3 Electrical Conductivity studies 
The ability of a material to accommodate transport of electric charge is referred 
to as its electrical conductivity. A large conductivity was expected for ILs 
because they are entirely composed of charge carrier ions. The electrical 
conductivity of ILs is different from solutions having dissociated ions or nonpolar 
liquids. This indicated that measurement of electrical conductivity of synthesized 
ILs at different concentrations in water  would be of interest (Widegren et al. 
2005).  
In order to investigate the influence of counterions on the conductivity, the 
electrical conductivity profiles of aqueous solutions of [BTEA] based NSAIDs ILs 
were studied at high concentration range, and the concentration range for all 
[BTEA] based NSAIDs ILs was kept constant. The conductivity of [BTEA] based 
NSAIDs ILs is shown in Figure. 4.13. The room temperature conductivity values 
of [BTEA] [Ibu] were found to be higher compared to [BTEA] [Diclo].  The 
decrease in conductivity values correlated with increasing anion size, which led 
to reduction of effective anion charge density because the negative charge is 
spread over the much large volume.  Therefore, the interaction of these anions 
with benzalkonium cation becomes much weaker (Leys et al. 2008). In addition 
to this, [BTEA] [Ibu], [BTEA] [Diclo] showed different behaviour than that of the 
salt. The dissociation of ILs into free ions transporting electrical charge was 
observed at low molar concentration; up to a certain concentration, the 
conductivity increases with the increasing salt concentration and reaches to a 
maximum then gradually falls with further increase in salt concentration. At high 
concentration ILs possessed low electrical conductivity due to reduced ionic 
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mobility attributed to increased viscosity, polarization effect at interface of 
electrode, large constituent ions of ILs and cation-anion interactions. The ions 
contributing to ILs have different degrees of cation-anion interactions at 
intermediate concentrations (Park and Prausnitz 2015). Two different regions 
exist in the conductivity profiles of ionic solutions. In the first region the 
conductivity increases because ionic charges could be considered as high 
mobility charge carriers while in the second region the conductivity was found to 
be lower as a result of low mobility of charge carrying ions due to increased 
ionic interaction effects (Goindi et al. 2015) 
As described earlier, to investigate the conductivity profiles of [BDMA] based 
NSAIDs ILs, the aqueous solutions were prepared at high concentration. 
[BDMA] [Ibu] drug salt successfully managed to form aqueous solution; but at 
low concentration of the drug salts, while [BDMA] [Diclo] failed to give clear 
solutions due to hydrophobic nature and viscosity. The electrical conductivity 
value for [BDMA] [Ibu] is represented in Figure. 4.13. It can be observed from 
the figure that electrical conductivity data followed the trend of the salt in 
aqueous solution, where the conductivity increases with increase in 
concentration of ILs. Aqueous solution of ILs behaves similar way to 
concentrated salt solutions. The conductivity of ILs aqueous solution increases 
due to the presence of water-rich regions. The dissociation constant of ILs was 
increased with increase in the amount of water (Tshibangu et al. 2011).  
However, comparing the electrical conductivity results of [BTEA] and [BDMA] 
based NSAIDs ILs shows that [BDMA] based NSAIDs ILs displayed a decrease 
in electrical conductivity with increase in the alkyl chain length. Since the 
conductivity of the system is due to mobility of the charge carriers, the increase 
in the volume fraction of the hydrocarbon portion of the cation increases the 
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molecular volume of the organic cation which leads to induce strong Van der 
Waals interactions. These attractive forces induce higher viscosity which results 
in decrease in electrical conductivity (Leys et al. 2008;  apović et al. 2 16 . 
 
          
 
                                    
Figure 4.13 Electrical conductivity of aqueous solutions of [BTEA] and 
[BDMA] based NSAIDs ILs 
 
4.2.4 Octanol-water partition coefficient 
The lipophilicity of a chemical compound is estimated by its octanol/water 
partition coefficient and is a key factor in the formulation of pharmaceuticals. It 
is a significantly important property of the molecule which gives an idea of its 
affinity towards hydrophilic and hydrophobic environments, and has been 
correlated with adsorption and transport properties of drug molecules in the 
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human body as well as sorption to sediments and soils. A number of factors are 
responsible for governing the value of octanol-water partition coefficient 
including concentration, pH, molecular weight, molecular volume (Ingram et al. 
2011).  
The octanol-water partition coefficient of benzalkonium based NSAIDs ILs was 
studied to understand the passive diffusion across biological membranes. The 
results as shown in Table 4.2 indicate that the [BTEA] based NSAIDs ILs are 
more hydrophilic than [BDMA] based NSAIDs ILs. In particular, the octanol-
water partition coefficient (Ko/w) values are higher for [BDMA] based NSAIDs ILs 
than [BTEA] based NSAIDs ILs which could be attributed to increase in 
molecular weight and alkyl chain length on the cation as shown in 
Figure.4.14(Domańska et al. 2  3; Wu et al. 2  3; Crosthwaite et al. 2    . 
 
      
Figure 4.14 Relationship between the number of carbon in the alkyl chain 
length on the cation and Ko/w profiles (Error bars - standard deviation) 
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the following trend: [BTEA] [Diclo] > [BTEA] [Ibu].[BTEA] based NSAIDs ILs Ko/w 
values were found to be less than 1 as they are totally soluble in water. All the 
drug salts are water miscible at room temperature and followed the trend of 
anion hydrophobicity (Leo et al. 1971; Fini et al. 1999; Crosthwaite et al. 2004).  
The same pattern was observed for the [BDMA] based NSAIDs ILs. The Ko/w 
value of [BDMA-Diclo] was found to be high compared to the rest of the studied 
API-ILs because of the hydrophobic nature of the drug and high molecular 
weight of the API-IL.  
 
       
              Figure 4.15 Effect of anions on Ko/w keeping cation constant  
                                       (Error bars - standard deviation) 
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anionic APIs (ibuprofenate, diclofenac) based on [BTEA] cation are displayed in 
Table 4.2 and Figure.4.16.  The [BTEA] [Diclo] content was found in higher 
amount in stratum corneum and epidermis of rat skin, which could be attributed 
to the lipophilisation of diclofenac ion when combined with benzalkonium cation. 
Surprisingly, there was no significant difference observed in the [BTEA] [Diclo] 
and [BTEA] [Ibu] content in dermis. The flux values for [BTEA] [Ibu] was 
expected to be greater than [BTEA] [Diclo] on the basis of molecular volume but 
it seems that the impact of partition coefficient overrules the influence of 
molecular volume (Scheuplein et al. 1969).  
Table 4.2 Skin deposition and permeation amounts ofbenzalkonium based 
NSAIDs ILs 
 
   
Figure 4.16Skin deposition profiles of [BTEA] and [BDMA] based NSAIDs 
ILs (Error bars - standard deviation) 
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NSAIDs-ILs 
 
MW 
 
Ko/w 
Deposited % in 
stratum 
corneum 
Deposited % in 
Epidermis 
Deposited % 
in Dermis 
% Drug 
permeated 
[BTEA] [Ibu] 397.6 0.78 (±0.27) 2.48 (±0.05) 0.72(±0.14) 4.19(±2) 2.02%  (±0.96) 
[BTEA] [Diclo] 487.46 0.99(±0.23) 13.12(±1.28) 6.3(±0.75) 3.08(±0.42) 0.165% (±0.005) 
[BDMA] [Ibu] 565.93 5.93 (±0.35) 23.39(±2.67) 13.87(±2.4) 10.87(±1.7) 0% 
[BDMA] [Diclo] 655.79 6.09(±0.24) 32.61(±4.72) 9.54(±1.7) 8.39(±0.57) 0.037% (±0.007) 
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In the case of [BDMA] based NSAIDs ILs, the skin deposition values of anionic 
APIs (ibuprofenate, diclofenac) are displayed in Table.4.2 and Figure.4.16. The 
[BDMA] [Diclo] content was found in higher amounts in stratum corneum of rat 
skin, which could be attributed to the increase in lipophilicity of the drug salt. 
This increases the solubility of drug salt within lipid domains of the stratum 
corneum and finally improves the membrane permeability (Flynn and Yalkowsky 
1972). The effect of molecular weight on the drug flux seems to be relatively 
negligible compared to the influence of changes in partition coefficient 
(Scheuplein et al. 1969). On the other hand [BDMA] [Diclo] content was found 
to be the lower in epidermis and dermis. The most significant factor for reduced 
permeation across the membrane could be attributed to its hydrophobic nature 
and increase in the molecular volume of diclofenac anion molecule.  
4.2.5.2 Drug permeation study 
In order to compare the skin permeability of anionic APIs (ibuprofen, diclofenac) 
combined with benzalkonium cation,ex vivo permeation experiments were 
carried out through rat skin with the synthesised benzalkonium based NSAIDs 
ILs.  Figure.4.17 shows the comparison of the cumulative permeation profiles of 
[BTEA] and [BDMA] based NSAIDs ILs through rat skin in 5 hrs. The cumulative 
drug permeation trend of [BTEA] based NSAIDs ILs was observed in the order 
of: [BTEA] [Ibu] (2.02%± 0.96) > [BTEA] [Diclo] (0.165%± 0.005). It was 
observed that [BTEA] [Ibu] (2.02%± 0.96) showed 12 fold enhancement in 
cumulative drug permeation in 5 hrs compared to [BTEA] [Diclo] (0.165%± 
0.005). The amount of drug permeated in case of [BDMA] based NSAIDs ILs 
was found in the following order [BDMA] [Diclo] (0.037%±0.007) > [BDMA] [Ibu] 
(0%). However the flux value of [BDMA] based NSAIDs ILs was considerably 
lower than that of [BTEA] based NSAIDs ILs. This may be partly attributed to 
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the difference in thermodynamic activity of anionic APIs due to difference in 
lipophilicity, solubility of anionic drugs and to higher viscosity and higher 
molecular weight. The impact of anions on skin permeation could be understood 
by comparing the octanol-water partition coefficient and molecular weights of 
benzalkonium API-ILs. As can be seen in Figure.4.17, the trend observed for 
[BTEA] based NSAIDs ILs indicates that the increase in molecular weight of 
anion/IL matrix results in decrease in skin permeation. This could be correlated 
to the reduced interactions between the counterions due to increasing 
delocalisation of charge and size of the counterion (Freire et al. 2007; Alves et 
al. 2013). On the other hand the trend observed in case of [BDMA] based 
NSAIDs ILs was quite different, as can be seen in Figure 4.17. 
Comparing the skin permeation of [BTEA] and [BDMA] based NSAIDs ILs, it 
appears that  [BTEA] based drug salts showed enhanced skin permeation 
profiles compared with [BDMA] based drug salts which could be attributed to 
the formation of larger ion pairs or clusters with sufficient hydrophobicity and 
smaller molecular volume.  
 
       
Figure 4.17 Skin permeation profiles of [BTEA] and [BDMA] based NSAIDs 
ILs (Error bars - standard deviation) 
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Most of the results are simply based on the partition coefficient and molecular 
weight measured. It is clear that only [BTEA] [Ibu] could be detected in the 
receptor compartment based on its low molecular weight than 500 and the 
lower Ko/w value which is also reflected on the low percentage drug deposition 
in the different skin layers. On the other side [BTEA] [Diclo] should have similar 
profile but due to the higher molecular weight the permeation was very limited. 
As for both [BDMA] [Ibu]  and [BDMA] [Diclo], their very high partition coefficient 
as well as the large molecular weight enhanced to great extent their lipophilicity 
and partitioning into the different skin layers especially the lipophilic SC layer 
and minimized their permeation to negligible values which makes them very 
suitable for topical applications. 
This study showed the influence of counterions on skin deposition and 
permeation after application of neat benzalkonium based NSAIDs ILs on rat 
skin. The skin deposition and permeation data of studied benzalkonium based 
NSAIDs ILs suggest that these systems show drug retention which may be due 
to a number of reasons. First, ILs are entirely composed of cations and anions 
on equimolar basis. The presence of API in high concentration in IL formulation 
functions as a driving force to enhance the rate of drug delivery via skin. 
Second, benzalkonium has a cationic amino group and the chosen drugs have 
an anionic carboxyl (ibuprofen, diclofenac) group. The interaction between the 
ionic groups of benzalkonium and drugs helps to reduce or neutralize 
electrostatic charges and consequently generate a neutralized complex, which 
might have increased hydrophobicity of drugs. The ILs formed by mixing 
equimolar quantities (1:1) created neutralized IL complexes which influence the 
skin permeation of APIs. The low melting point of benzalkonium based API-ILs 
resulted in increased saturation solubility of drug, which is an important factor 
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governing thermodynamic activity of drug. Third, the flux values of APIs can be 
again attributed to the benzalkonium cation moiety in the synthesised API-ILs, 
which has been reported to have a penetration enhancing effect. Studies have 
reported the use of quaternary ammonium compounds containing quaternised 
nitrogen atom as effective skin penetration enhancers (Ahad et al. 2009) 
(Goindi et al. 2014). In addition to that, quaternary ammonium compounds have 
been used as penetration enhancers for transbuccal and transnasal drug 
delivery systems, such as nasal vaccinations. The ability of these compounds to 
disrupt the lipid bilayer of stratum corneum and penetrate into the skin has been 
widely used in drug delivery systems such as liposomes (Klinguer et al. 2001; 
Hough-Troutman et al. 2009). Fourth, the skin permeability of any molecule 
largely depends on its octanol-water partition coefficient and molecular weight. 
Benzalkonium drug salts exhibited octanol-water partition coefficient ranging 
from  0.78(±0.27) to 6.09 (±0.24) indicating that the value of octanol-water 
partition coefficient was influenced by the counterions. Skin deposition data of 
studied benzalkonium based NSAIDs ILs suggests that these systems display 
drug retention and follows direct relationship between drug deposition and 
molecular weight. On the other hand, permeation data delineated an inverse 
relationship between flux values and molecular weight of the permeant. Some 
other molecular properties for example hydrogen bonding to weak Van der 
Waals forces and drug binding, might be involved and can affect drug delivery 
via the skin. 
However the mechanism behind the skin permeation of APIs through ILs is not 
yet clear, because ILs are formed by equimolar ratios  therefore it is believed 
that both counterions remain together in the skin as clusters or ion pairs instead 
of individual solvated ions. This could be justified by the observed electrical 
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conductivity data. This is also supported by other studies which illustrates that 
ILs do not dissolve to form independent ions but they form a nanostructured 
organization in aqueous solution (Nama et al. 2006; Jiang et al. 2007) and by 
spectroscopic investigations such as NMR techniques (Canongia Lopes et al. 
2006; Canongia Lopes and Padua 2006). The focus of this study has been on 
the application of benzalkonium based NSAIDs ILs to promote the topical drug 
delivery of ibuprofen and diclofenac. 
4.3 Conclusions 
The results of this study suggest that prepared benzalkonium based NSAIDs 
ILs was found to enhance the lipophilicity/hydrophilicity of ibuprofen, diclofenac. 
Benzalkoium cation acted as penetration enhancer and surfactant, forming ILs 
combined with ibuprofen and diclofenac in equimolar ratio (1:1). Skin deposition 
data of studied benzalkonium based NSAIDs ILs suggests that these systems 
show drug retention following direct relationship between drug deposition and 
molecular weight. On the other hand, permeation data followed an inverse 
relationship between flux values and molecular weight of the permeant.  The 
data reported here supports the potential application of IL in topical drug 
delivery. 
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Chapter 5 
Benzalkonium-sulfacetamide Ionic liquids (ILs) 
5.1 Introduction 
Recently, third generation of ILs has been emerged which can be formed simply 
by combining active pharmaceutical ingredients (API) with ILs.  This third 
generation ILs provides enhanced properties such as solubility, drug delivery 
and permeability as compared with corresponding solid pharmaceutical forms 
(Ferraz et al. 2011). The very well-known problem of polymorphism associated 
with crystalline API can be avoided by using active drug in the liquid form which 
dramatically influence drug’s solubility and dosage form (Stoimenovski et al. 
2010b). However toxicity associated with counter ions of ILs delayed their entry 
into biosciences (Cruz-Cabeza 2012). Current communications and reviews talk 
about the toxicity and antimicrobial, antibacterial activity of ILs and their drug 
delivery performance.  Scientists have reported the synthesis and biological 
activity of a series of 1-alkyl-3-methylimidazolium chloride and 1-
alkylquinolinium ionic liquids which have been tested against a panel of 
clinically significant microbial pathogens, including MRSA and found to be 
potent, broad spectrum activity which shows that activity depends on the 
presence of alkyl chain length. According to the authors the long alkyl chain 
containing ILs can broke the microbial biofilm which protect the microorganism 
from antibiotics, disinfectants and antiseptics (Carson et al. 2009; Busetti et al. 
2010). Recently, Cole and co-workers reported the synthesis of ILs with long 
alkyl chain quaternary ammonium and ampicillin anion by using metathesis 
reaction. The prepared ampicillin based ILs were found to possess higher 
antibacterial activity in most of the cases compared to starting materials (Cole et 
al. 2011a). Later on antibacterial and antitumor studies have been carried out 
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with the ILs based on ampicillin as anion while phosphonium, pyrollidinium, 
ammonium, cholinium and few short alkyl chain imidazolium as cation (Ferraz et 
al. 2014a; Ferraz et al. 2015).   
Sulfacetamide is a sulfonamide antibiotic drug which is prescribed in the form of 
sodium salt and finds its applications in ophthalmic (Sridhar et al. 2001) and 
skin (Margolis et al. 2005). Sulfonamide drugs destroy bacteria by blocking the 
synthesis of folic acid in bacteria (Maren 1976). The complete potential of 
quaternary ammonium compounds was acknowledged after the synthesis of 
benzalkonium chloride in 1935, which is found to be possessing wide spectrum 
against many bacterial strains after characterization of its anti-bacterial 
properties (Domagk 1935). These newly emerged water soluble quaternary 
ammonium compounds display anti-bacterial property against not only gram-
positive and gram-negative bacteria, but also against protozoa and pathogen 
species of fungi (Kull et al. 1961). Interestingly these compounds can also act 
as penetration enhancers for transbuccal and transnasal drug delivery systems 
such as nasal vaccinations (Klinguer et al. 2001). Later these water soluble 
quaternary ammonium compounds found potential applications in the fields of 
disinfectants (Lopes 1986), surfactants (Hayakawa and Kwak 1991), phase 
transfer catalysis (Makosza 2000), anti-corrosive agents (Hough-Troutman et al. 
2009). Certainly, surfactant molecule is responsible to modify the texture of 
formulation and also helps to stabilize it. In addition to this, surfactants can alter 
the transport across biological barriers by directly effecting biological membrane 
(Khossravi 1997; Savić et al. 2 1  . The antibacterial mechanism of action of 
quaternary ammonium compounds is based on the disruption of membrane 
charge distribution and altering cell membrane permeability, which leads to 
leakage of all components from cytoplasm which is followed by bacterial death 
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(Arias-Moliz et al. 2015). Thus following the concept of IL to find out the novel 
antimicrobial molecule with new modes of action, the combination of 
antibacterial benzalkonium cations with antibiotic sulphonamide was 
investigated to understand if there is a synergistic biological effect and the effect 
of cationic counterion benzalkonium on the penetration behaviour of 
benzalkonium-sulfacetamide for topical treatment. 
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5.2 Result and discussion 
5.2.1 Characterisation of benzalkonium sulfacetamide IL 
Benzyltiethylammonium sulfacetamide [BTEA] [Sulfa] and 
benzyldimethylhexadecylammonium sulfacetamide [BDMA] [Sulfa] are 
synthesized via metathesis reaction from the corresponding sodium salts of 
sulfacetamide and halide salts of Benzyltiethylammonium and 
benzyldimethylhexadecylammonium. Both of the benzalkonium sulfacetamide 
IL obtained was yellow viscous liquids at room temperature.   
The benzalkonium sulfacetamide IL were characterized by 1H NMR, 13 C NMR 
and IR spectroscopy (Figure 5.1 – 5.4). The proton signals for [BTEA] were 
recorded at 1.37 - 7.74 ppm and included a signal for 9 protons of its terminal 
methyl groups at 1.37 ppm (t), 6 protons of adjacent methylene groups were 
found at 3.27 ppm (q), 2 protons for the methylene next to phenyl group 
observed at 4.53 ppm (s) while the aromatic protons were found at 7.37-7.50 
(m). The signals obtained for [BTEA] were compared with the signals of 
respective sodium salt sulfacetamide confirms the formation of ionic liquids, 
indicating good stability of active pharmaceutical ingredient during salt 
formation. This data was further supported by the IR spectroscopy (IR spectra 
are provided as supplementary Information). Following the metathesis reaction 
the symmetric and antisymmetric stretching of carboxylic anion was found 1592 
cm-1and 1295 cm-1 (for sulfacetamide). 
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NMR and FTIR characterization data 
Benzyltriethylammonium-Sulfacetamide [BTEA] [Sulfa]: Yield 82%.  
1H NMR (400 MHz, CDCl3)  ppm 1.37 (t, 9 H), 1.86 (s, 3 H), 3.27 (q, 6 H), 4.53 
(s, 2 H), 6.51 - 6.57 (d, 2 H), 7.37 - 7.50 (m, 5 H), 7.66 – 7.74 (d, 2 H) 
13C NMR (101 MHz, CDCl3)  ppm 8.20, 18.44, 27.04, 52.76, 58.23, 76.74, 
77.06, 77.26, 77.38, 113.43, 127.19, 128.71, 129.43, 130.68, 132.45  
IR (ν max cm
-1): 3379, 3212, 2982, 2346, 1648, 1592, 1360, 1295, 1128, 1082, 
827.4, 755.6, 683.8, 619.6 
 
Benzyldimethylhexadecylammonium-Sulfacetamide [BDMA] [Sulfa]: Yield 
78 %.  
1H NMR (400 MHz, CDCl3)  ppm 0.81 - 0.93 (t, 3 H), 1.18 - 1.30 (m, 26 H), 
1.85 (s, 3 H), 2.98 (s, 6 H), 4.20 - 4.32 (m, 2 H), 4.57 (s, 2 H), 6.45 - 6.57 (d, 2 
H), 7.32 - 7.50 (m, 5 H), 7.70 (d, 2 H) 
13C NMR (101 MHz, CDCl3)  ppm 14.12, 22.69, 27.07, 29.29, 29.37, 29.44, 
29.51, 29.63, 29.68, 29.71, 31.93, 49.59, 76.72, 77.04, 77.35, 113.70, 128.68, 
129.14, 133.23  
IR (ν max cm
-1): 3339, 2955, 2922, 2853, 1630, 1596, 1362, 1305, 1125, 1084, 
828.1, 681.1 
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Figure 5.11H and 13C NMR spectra of Benzyltriethylammonium-
Sufacetamide [BTEA] [sulfa] 
[BTEA] and [Sulfa] protons are represented in red and blue colours 
respectively 
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Figure 5.2 1H and 13C NMR spectra of Benzyltriethylammonium-
Sufacetamide [BDMA] [sulfa] 
[BDMA] and [Sulfa] protons are represented in red and blue colours 
respectively 
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Figure 5.3 FTIR spectra of Benzyltriethylammonium-Sufacetamide [BTEA] 
[sulfa] 
 
 
Figure 5.4 FTIR spectra of Benzyldimethylhexadecylammonium-
Sulfacetamide [BDMA][Sulfa] 
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5.2.2 Thermal Behaviour 
The effect of cation on the thermal properties of [BTEA] [Sulfa] [BDMA] [Sulfa] 
was studied using DSC and TGA. The synthesized ionic liquids are viscous 
liquids at room temperature. Table.5.1 shows that the thermal stability of [BTEA] 
[Sulfa] and [BDMA] [Sulfa] was found to 161.38, 164.94 respectively. Two step 
decomposition was observed for both [BTEA] [Sulfa] and [BDMA] [Sulfa]. For 
the TGA and DSC profiles of [BTEA] [Sulfa] and [BDMA] [Sulfa] please refer   
(Figure 5.5 and 5.6).The impact of cation can be observed by difference in 
thermal stability of drug salts. When you compare the decomposition temerature 
of [BTEA] [Sulfa] and [BDMA] [Sulfa] then it was observed that [BDMA] [Sulfa] 
display higher decomposition temperature. The increase in decomposition 
temperature could be attributed due to increase in interparticle forces (Van der 
Waal forces) which arises with increase in alkyl chain length (Canongia Lopes 
and Padua 2006; Chancelier et al. 2016).     
However, the DSC thermograms of [BTEA] [Sulfa] and [BDMA] [Sulfa] systems 
display no phase transitions in the temperature range studied, which shows that 
these systems remains amorphous. 
Table 5.1 Physicochemical properties of synthesized benzalkonium 
sulfacetamide ILs 
 
 
 
 
API-ILs 
 
MW 
 
Ko/w 
 
Td(
◦
C) 
% Deposited  
in stratum 
corneum 
% Deposited 
in Epidermis 
%Deposited  
in Dermis 
[BTEA] [Sulfa] 405.5 0.75(±0.18) 161.38 12.37(±4.2) 5.76(±2.84) 11.09(±9.13) 
[BDMA] [Sulfa] 573.8 5.62(±0.57) 164.94 1.42(±0.35) 0.29(±0.14) 0.64(±0.4) 
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TGA and DSC profiles benzalkonium-sulfacetamide ILs 
 
 
      
(a) 
                                      
(b) 
 
        Figure 5.5 TGA profile of (a) [BTEA][Sulfa]  (b) [BDMA][Sulfa] 
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                                                                                                                                      (a)        
                                                                                                                                      (b) 
 
Figure 5.6 DSC profile of (a) [BTEA][Sulfa]  (b) [BDMA][Sulfa] 
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5.2.3 Electrical conductivity studies 
The electrical conductivity profiles of aqueous solutions of [BTEA] [Sulfa] and 
[BDMA] [Sulfa] are studied at high concentration range. The conductivity of 
[BTEA] [Sulfa] and [BDMA] [Sulfa] is shown in Figure 5.7. The room 
temperature conductivity values [BDMA] [Sulfa] was found to be lower than 
[BTEA] [Sulfa], for detailed information please refer back to section 4.2.3.   
 
   
Figure 5.7 Electrical conductivity of aqueous solutions of [BTEA][Sulfa] 
and [BDMA][Sulfa] 
 
 
5.2.4 Octanol-water partition coefficient 
The octanol-water partition coefficient of [BTEA][Sulfa] and [BDMA][Sulfa] was 
investigated to understand the passive diffusion across biological membranes. 
The results as shown in Table.5.1, indicates that the [BDMA][Sulfa]  is more 
lipophilic than [BTEA][Sulfa], which could be attributed due to increase in 
molecular weight and alkyl chain length on the cation as shown in Figure.5.8. 
(Domańska et al. 2  3; Wu et al. 2  3; Crosthwaite et al. 2004). 
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Figure 5.8 Octanol-water partition coefficient of [BTEA][Sulfa] and 
[BDMA][Sulfa] (Error bars - standard deviation) 
 
 
 
5.2.5 Ex-vivo skin studies 
Drug deposition study and permeation studies 
Ex-vivo permeation and deposition studies were performed to determine the 
rate and the extent of benzalkonium API-ILs permeated and deposited in the 
various layers of skin.In order to understand the effect of cation on the skin 
deposition and permeation values, the amount of drug content in stratum 
corneum, epidermis and dermis was evaluated after the ex-vivo skin permeation 
experiment through rat skin. The skin deposition and permeation values can be 
seen in Table.5.1 and Figure.5.9. 
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Figure 5.9 skin deposition profiles and permeation profiles of 
[BTEA][Sulfa], [BDMA][Sulfa] (Error bars - standard deviation) 
 
 
It was observed that permeation and skin deposition values of [BDMA] [Sulfa], 
was found to be lower than [BTEA] [Sulfa] in all the layers of skin. The results 
are based on molecular weight and partition coefficient of the synthesised 
benzalkonium sulfacetaminde ILs. As can be seen from Table.5.1 the molecular 
weight and partition coefficient of [BDMA][Sulfa] is higher compared to 
[BTEA][Sulfa]. The increase in molecular weight influences the diffusion 
coefficient of the [BDMA][Sulfa] with increasing bulky molecule leading to 
decrease in diffusivities (Crank 1975).  Scheuplein et al. suggested that small 
molecule with lower molecular weight cross human skin more faster rate 
compared to large molecule (Scheuplein et al. 1969).  The skin deposition data 
of studied benzalkonium sulfacetamide ILs suggest that these systems show 
drug retention and decrease in skin permeability with increase in molecular 
weight.  As it is clear from results that [BDMA][Sulfa] penetrates much slower 
than [BTEA][Sulfa]. The formulation with desired properties can be generated 
by combining both the studied ILs to tailor the penetration and deposition 
properties of sulfacetamide for topical applications. 
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5.2.6 Antibacterial efficacy studies 
5.2.6.1 Agar diffusion results 
Antibacterial activity of the starting materials and product ILs was determined by 
measuring the diameters of the zones of inhibition surrounding the agar 
diffusion discs saturated with 20 µg, 30 µg, 40 µg, 50 µg and 100 µg/ml of the 
test compounds. Disc diffusion results of the studied ILs and parent compounds 
could be referred in (Figure 5.10). 
The formation of zones of inhibition shows the interaction between the bacteria 
trying to grow on the agar surface and the diffusing test molecule. No 
antibacterial activity is confirmed when the bacterial growth occurs upto the 
edge of the disc.  The results of the diffusion experiment are shown in Table 
5.2. The lack of antibacterial activity was represented by a diameter of “  mm” 
in the table. 
Table 5.2 Disc diffusion results of benzalkonium sulfacetamide IL and 
parent components 
 
 
 
 
 
                                                  Zone diameters are reported in mm 
 
 
Bacterial strain Gram 
[BDMA-Cl] (µg/ml) [BTEA-Cl] (µg/ml) [Sod-Sulfa] (µg/ml) 
20 30 40 50 100 20 30 40 50 100 20 30 40 50 100 
Staphylococcus aureus + 7 10 10.5 11.6 12 0 0 0 0 0 0 0 0 0 0 
Escherichia coli - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Bacterial strain Gram 
[BDMA][Sulfa] (µg/ml) [BTEA][Sulfa] (µg/ml) 
20 30 40 50 100 20 30 40 50 100 
Staphylococcus aureus + 7 10.5 11 12 14 0 0 0 0 0 
Escherichia coli - 0 0 0 0 0 0 0 0 0 0 
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Figure 5.10 Antibacterial activity of benzalkonium sulfacetamide ILs and 
parent components (agar diffusion results) 
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The screening results of agar diffusion test suggest that only two compounds 
[BDMA-Cl] and [BDMA-Sulfa] was found to display antibacterial efficacy against 
staphylococcus aureus at studied concentration. However here was no activity 
with [BTEA-Cl], [Sod-sulfa] and [BTEA-Sulfa]. On the other hand the lack of 
antibacterial efficacy was found against E.coli by all the five tested compounds. 
These parent compounds along with synthesised benzalkonium-sulfacetamide 
ILs were further investigated in minimum inhibitory concentration (MIC) assays 
to quantify their antibacterial efficacy against the studied bacterial strains. 
 
5.2.6.2 MIC determination studies 
The antibacterial activity of [BDMA][Sulfa] and [BTEA][Sulfa] IL along with the 
starting material was studied by minimum inhibitory concentration (MIC) against 
staphylococcus aureus (Gram positive bacteria) and E.coli (Gram negative 
bacteria) to investigate if there is synergistic effect. MIC can be defined as the 
lowest concentration of antibiotic which shows no visible growth. Growth of 
these bacteria in terms of optical density was measured by spectrophotometer 
at 570 nm after 24 hours. Control measurements were performed without the 
addition of test sample and the optical density was found to be 0.497(±0.040) for 
staphylococcus aureus (Table 5.3). The optical density of the test compounds 
was found to be decreased as the concentration was decreased.  The turbidity 
was observed at higher concentration in case of [BDMA][Sulfa] and [BDMA-Cl] 
which is due to the sample itself as no bacterial growth was observed during 
plating. 
Percentage growth inhibition data of product IL and the starting materials 
suggests that inhibition increases with increase in concentration of the test 
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compound. Table 5.3shows the percentage growth inhibition of test results 
against Staphylococcus aureus (Gram-positive bacteria) which indicates that 
100 % growth inhibition was obtained by [BDMA-Cl] and [Sod-Sulfa]  at 0.97 
µg/ml and 125 µg/ml respectively when used alone. The combination of both in 
the form of [BDMA][Sulfa]  IL showed 100 % growth inhibition at 1.95 µg/ml 
concentration. On the other hand, [BTEA-Cl] and [Sod-Sulfa] were found to 
inhibit bacterial growth at 2500 µg/ml and 125 µg/ml respectively, when tested 
alone. In case of [BTEA][Sulfa] IL as combination 100 % growth inhibition was 
observed at 156.25 µg/ml. Based on the plating, the [BDMA][Sulfa] and [BDMA-
Cl] percentage growth inhibition formula cannot be followed due to turbidity of 
the test samples themselves. 
Thus comparing the antibacterial efficacy of synthesised [BDMA][Sulfa] and 
[BTEA][Sulfa] ILs with starting compounds, sodium sulfacetamide, 
benzalkonium halides it was found that the antibacterial activity of products was 
not higher than that of the parent materials. However, comparing the 
antibacterial activity of [BDMA][Sulfa] and [BTEA][Sulfa] IL, the [BDMA][Sulfa] 
was found to be more effective which could be correlated to the presence of 
long alkyl chain length associated to cation (Smiglak et al. 2014). 
Similar trend was observed regarding the antimicrobial efficacy of the 
compouds against E.coli (Gram-negative bacteria). The optical density of the 
control, test samples and percentage inhibition growth is summarised in Table 
5.4.  
However, [BDMA][Sulfa] and [BTEA][Sulfa] IL were found to be more effective  
against staphylococcus aureus (Gram positive bacteria) as compared to  E.coli 
(Gram negative bacteria). This could be attributed to the difference in the 
structure of cell wall of Gram positive and Gram negative bacteria. A very thick 
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layered cell wall composed of peptidoglycan is found in Gram positive bacteria 
while Gram negative bacteria possess very thin cell wall. Gram negative 
bacteria possess an outer membrane which acts as permeability barrier 
whereas Gram positive bacteria lack this outer membrane. The MIC and MBC 
values are shown in Table 5.5 and Table 5.6 respectively. The plating for MBC 
results of studied compounds against staphylococcus aureus and E.coli are 
presented in (Figure 5.11). 
Thus after observing the data of MIC, MBC, optical density and percentage 
growth inhibition of the synthesised ILs and the starting materials it can be said 
that no synergistic effect was observed in case of ILs. This can be explained as 
follows. The antibacterial mechanism of action of sulfonamide drug molecule is 
based on the  blocking of the synthesis of folic acid in bacteria leading to 
bacterial death (Maren 1976). While quaternary ammonium compounds function 
via disruption of membrane charge distribution leading to alter the cell 
membrane permeability. This results to drowning out cytoplasmic components 
and finally bacterial death (Arias-Moliz et al. 2015). In combination, it is likely 
because of the different antibacterial mechanism action of both antibacterial 
agents may compete to access the site of activity within the bacterial cell.   
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Table 5.3 Optical density and % growth inhibition of benzalkonium-sulfacetamide ILs determined at 570 nm 
 
 D:  ptical density         G : Growth inhibition 
Staphylococcus aureus ( Gram-positive bacteria) 
 
Concentration 
(µg/ml) 
 
[BDMA][Sulfa] 
 
[BDMA-Cl] 
 
[Sod-Sulfa] 
 
Concentration 
(µg/ml) 
 
[BTEA][Sulfa] 
 
[BTEA-Cl] 
 
 OD 
 
   G  
 
OD 
 
% GI 
 
OD 
 
% GI 
 
OD 
 
% GI 
 
OD 
 
% GI 
  Control 
1000 
500 
250 
125 
62.5 
31.25 
15.62 
7.81 
3.9 
1.95 
0.97 
0.48 
0.24 
0.12 
 
0.497(±0.04) 
0.409 
0.182 
0.165 
0.06 
-0.005 
-0.02 
-0.024 
-0.018 
-0.018 
-0.011 
0.092 
0.099 
0.275 
0.659 
 
  - 
100 
100 
100 
100 
100.5 
102 
102.4 
101.8 
101.8 
101.1 
90.8 
90.1 
72.5 
34.1 
 
 
0.253 
0.349 
0.253 
0.133 
0.036 
-0.01 
-0.017 
-0.022 
-0.023 
-0.021 
-0.022 
0.056 
0.116 
0.367 
 
- 
100 
100 
100 
100 
100 
101 
101.7 
102.2 
102.3 
102.1 
102.2 
94.4 
88.4 
63.3 
 
 
-0.024 
-0.02 
-0.018 
-0.014 
0.051 
0.323 
0.481 
0.462 
0.461 
0.491 
0.465 
0.475 
0.478 
0.845 
 
- 
102.4 
102 
101.8 
101.4 
94.9 
67.7 
51.9 
53.8 
53.9 
50.9 
53.5 
52.5 
52.2 
15.5 
 
 
2500 
1250 
625 
312.5 
156.25 
78.125 
39.0625 
19.5312 
9.76562 
4.88281 
2.44140 
1.22070 
0.61035 
0.305 
 
 
-0.026 
-0.022 
-0.02 
-0.019 
-0.007 
0.295 
0.433 
0.481 
0.468 
0.455 
0.459 
0.462 
0.462 
0.861 
 
- 
102.6 
102.2 
102 
101.9 
100.7 
70.5 
56.7 
51.9 
53.2 
54.5 
54.1 
53.8 
53.8 
13.9 
 
- 
0.105 
0.251 
0.345 
0.462 
0.517 
0.488 
0.562 
0.55 
0.475 
0.469 
0.365 
0.359 
0.269 
0.894 
 
 
- 
89.5 
74.9 
65.5 
53.8 
48.3 
51.2 
43.8 
45 
52.5 
53.1 
63.5 
64.1 
73.1 
10.6 
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Table 5.4 Optical density and % growth inhibition of benzalkonium-sulfacetamide ILs determined at 570 nm 
 
 D:  ptical density         G : Growth inhibitions
E.coli ( Gram-negative bacteria) 
 
Concentration 
(µg/ml) 
 
[BDMA][Sulfa] 
 
[BDMA-Cl] 
 
[Sod-Sulfa] 
 
Concentration 
(µg/ml) 
 
[BTEA][Sulfa] 
 
[BTEA-Cl] 
 
 OD 
 
   G  
 
OD 
 
% GI 
 
OD 
 
% GI 
 
OD 
 
% GI 
 
OD 
 
% GI 
Control 
1000 
500 
250 
125 
62.5 
31.25 
15.62 
7.81 
3.9 
1.95 
0.97 
0.48 
0.24 
0.12 
 
0.674 (±0473) 
-0.034 
0.32 
0.127 
0.074 
0 
-0.02 
-0.025 
-0.021 
0.635 
0.732 
0.804 
0.646 
0.638 
0.989 
 
- 
103.4 
100 
100 
100 
100 
102 
102.5 
102.1 
36.5 
26.8 
19.6 
35.4 
36.2 
1.1 
 
 
0.252 
0.326 
0.24 
0.138 
0.036 
-0.011 
-0.016 
-0.024 
-0.024 
0.648 
0.696 
0.67 
0.651 
0.788 
 
- 
100 
100 
100 
100 
100 
101.1 
101.6 
102.4 
102.4 
35.2 
30.4 
33 
34.9 
21.2 
 
 
 
 
-0.028 
-0.027 
-0.023 
-0.021 
0.354 
0.503 
0.385 
0.433 
0.685 
0.787 
0.88 
0.71 
0.647 
0.978 
 
- 
102.8 
102.7 
102.3 
102.1 
64.6 
49.7 
61.5 
56.7 
31.5 
21.3 
12 
29 
35.3 
2.2 
 
 
 
 
 
 
 
 
2500 
1250 
625 
312.5 
156.25 
78.125 
39.0625 
19.5312 
9.76562 
4.88281 
2.44140 
1.22070 
0.61035 
0.30517 
 
 
0.055 
-0.022 
-0.021 
0.049 
0.144 
0.371 
0.318 
0.498 
0.665 
0.721 
0.661 
0.703 
0.722 
0.991 
 
- 
94.5 
102.2 
102.1 
95.1 
85.6 
62.9 
68.2 
50.2 
33.5 
27.9 
33.9 
29.7 
27.8 
0.9 
 
 
 
0.466 
0.65 
0.681 
0.719 
0.81 
0.717 
0.734 
0.796 
0.657 
0.678 
0.697 
0.679 
0.681 
0.941 
 
 
 
 
 
53.4 
35 
31.9 
28.1 
19 
28.3 
26.6 
20.4 
34.3 
32.2 
30.3 
32.1 
31.9 
5.9 
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The minimum inhibitory concentration (MIC) (Table 5.5) and minimum 
bactericidal concentration (MBC) values (Table 5.6) were determined for 
[BDMA-Cl], [BTEA-Cl], [Sod-Sulfa], [BDMA][Sulfa] and [BTEA][Sulfa]. 
 
 
      Table 5.5 MIC Valuesa 
 
 
            Strain 
 
 
 
Starting materials 
 
Ionic liquids 
 
[BDMA-
Cl] 
 
 
[BTEA-
Cl] 
 
[Sod-
Sulfa], 
 
[BDMA][Sulfa] 
 
[BTEA][Sulfa] 
 
Staphylococcus 
aureus 
 
 
0.97 
 
>2500 
 
125 
 
1.95 
 
156.25 
 
E.coli 
 
3.9 
 
 
>2500 
 
125 
 
7.81 
 
625 
                           aIn µg/ml 
 
 
         Table 5.6 MBC Valuesa 
 
 
Strain 
 
 
 
Starting materials 
 
Ionic liquids 
 
[BDMA-
Cl] 
 
 
[BTEA-
Cl] 
 
[Sod-
Sulfa], 
 
[BDMA][Sulfa] 
 
[BTEA][Sulfa] 
 
Staphylococcus 
aureus 
 
 
0.97 
 
>2500 
 
~300 
 
1.95 
 
156.25 - 350 
 
 
E.coli 
 
 
7.81 
 
>2500 
 
~300 
 
7.81 
 
625 
                           aIn µg/ml 
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 Staphylococcus aureus 
(Gram +ve) 
 Escherichia coli (Gram –ve) 
 
[BDMA] 
[Sulfa] 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
[BTEA] 
[Sulfa] 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
3.90 µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
1.95µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
0.97µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
7.81µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
78.12µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
1250µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
625µg/ml 
Table 
xxx MIC 
valuesa 
Str in Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 000 125 7.81 625 
aInµg/ml 
 
312.5µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
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Figure 5.11 Antibacterial activity of benzalkonium sulfacetamide ILs and 
parent components (Broth dilution method) 
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Sulfa] 
 
 
 
 
 
 
 
 
 
 
 
 
1.95µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
0.97µg/ml 
Table 
xxx MIC 
valuesa 
Str in Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 000 125 7.81 625 
aInµg/ml 
 
3.905µg/ml 
Table 
xxx 
MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/m
l 
 
7.81µg/ml 
Table 
xxx 
MIC 
valuesa 
Strain Starting material Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/m
l 
 
2500µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
2500µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
250µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
62.5µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
125µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting mater als Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
250µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting materials Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus 
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
 
125µg/ml 
Table 
xxx MIC 
valuesa 
Strain Starting material Ionic liquids 
[BDMA-
Cl] 
[BTEA-
Cl] 
[Sod-
Sulfa], 
[BDMA][Sulfa] [BTEA][Sulfa] 
Staphylococcus
aureus 
0.97 1000 125 1.95 156.25 
E.coli 3.9 1000 125 7.81 625 
aInµg/ml 
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5.3 Conclusions 
The results of this study suggest that prepared benzalkonium sulfacetamide 
ILs were found to enhance the lipophilicity/hydrophilicity. Benzalkoium cation 
acted as penetration enhancer and surfactant, forming ILs combined with 
sulfacetamide in equimolar ratio (1:1). Skin deposition and permeation data 
of studied benzalkonium sulfacetamide ILs suggests that these systems 
show drug retention following an inverse relationship between flux values and 
molecular weight. On the other hand, antimicrobial activity of product ILs 
showed no synergism compared with the starting materials. 
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Chapter 6 
Benzalkonium based mixed anion Ionic liquid (ILs) 
6.1 Introduction 
The objective of this chapter is to understand the permeation behaviour of 
ibuprofen and salicylic acid in different forms (salt and hydrogen bonded 
neutral molecule) that exist in benzalkonium based mixed anion ILs, through 
an artificial membrane. In addition to this the effect of cationic counterion on 
the permeation profiles of ibuprofen and salicylic acid was also assessed. 
The data obtained in chapter 4 indicated that it would be of interest to 
evaluate the effect of hydrogen/ionic bonding on permeation properties of 
three component system. With increasing understanding about the 
biocompatibility and toxicity of Ionic liquids, they have been discussed as a 
formulation concept of active pharmaceutical ingredients (APIs) and enlarged 
into pharmaceutical applications (Hough et al. 2007a).The degree of ionocity 
and molar ratio of counterions are crucial characteristics for pharmaceutical 
companies as these elements are important for governing bioavailability of 
active pharmaceutical ingredients including solubility, absorption, distribution, 
metabolism and finally excretion (Kelley et al. 2013). Studies have been 
reported which demonstrate that not only ionic liquids but deep eutectics, 
oligomeric ionic liquids and ILs with mixed anions also possess wide range of 
degree of ionocity (Bica and Rogers 2010; Bica et al. 2011; Kelley et al. 
2013). 
Macfarlane et al. reported the formation of dimeric and oligomeric ions when 
N-methylpyrolidone reacted with acetic acid and showed that this system 
found to display highest ionocity due to formation of oligomeric anionic 
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species [(AcO)3H2]
- stabilised by hydrogen bonds (Johansson et al. 2008). 
Oligomeric anions can also be found in Lewis acidic ILs which are composed 
of monomeric, dimeric and mixed-valent anions for example AlCl4
-, Al3Cl7
- or 
for halides such as iodides complexed with oligomeric species based on [I3
-],  
[I5
-], and  [I7
-] (Wicelinski et al. 1988; Bica and Rogers 2010). The formation 
of oligomeric cations or anions which are stabilised by hydrogen bond have 
been reported by Rogers et al. by simple mixing of pharmaceutically ionic 
liquid with excess solid or base (Bica and Rogers 2010). Hui Wang et al 
reported the simultaneous transport of ibuprofen and lidocaine as a single 
compound through membrane which are held together by hydrogen bonds or 
partially ionized interactions (Wang et al. 2014).  
Benzalkonium chloride displays anti-bacterial properties against not only 
gram-positive and gram-negative bacteria, but also against protozoa and 
pathogen species of fungi (Kull et al. 1961). As discussed in Chapter 1, 
Ibuprofen is a non-steroidal anti-inflammatory drug which is used to treat pain 
and inflammation in rheumatic disease and other musculoskeletal problems. 
Topical administration of ibuprofen not only allows overcoming the 
drawbacks associated with oral administration but also helps in achieving 
faster pain relief (Tegeder et al. 1999).  Salicylic acid possess broad range of 
properties such as anti-inflammatory, analgesics, antiseptic, preservative and 
key ingredients of skin care products (Wu 2007). Stratum corneum is the 
outermost layer of the skin which forms the barrier for most of the drug 
molecule to be absorbed via skin as only a limited number of drugs display 
the optimal physicochemical characteristic to permeate through skin to exert 
desired therapeutic effect (Wotton et al. 1985). 
147 
 
Ionic liquefied APIs could be formulated in two different ways: (1) combining 
an ionisable drug with a proper counter ion or (2) by combining two 
pharmaceutically active ionisable drugs (Hough and Rogers 2007; 
Stoimenovski et al. 2010a). The formation of hydrogen bonding between 
cation and anion can be easily nullified by utilising the former approach 
therefore  benzalkonium based NSAIDs ILs are prepared via anion exchange 
reaction by mixing benzalkonium chloride and sodium salt of drugs 
(ibuprofen, salicylic acid) in equimolar ratio (1:1). And then benzalkonium 
based mixed anion ILs were prepared by simple mixing of benzalkonium 
based NSAIDs ILs with other acidic active pharmaceutical ingredient. One of 
the key challenges with these benzalkonium based mixed anion ILs moieties 
is to look into whether these moieties are enough bounded/interacting that 
they remain intact and affect membrane transport. Therefore it is interesting 
to look into the permeation profiles of ibuprofen and salicylic acid in different 
form (salt or hydrogen bonded neutral molecule) exist in IL with mixed anions 
through artificial membrane. In addition to this the effect of cationic 
counterion on the permeation profiles of ibuprofen and salicylic acid, thermal, 
octanol-water partition coefficient and conductivity properties was also 
evaluated. 
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6.2 Results and discussion 
6.2.1 Characterisation of benzalkonium based mixed anion ILs 
The benzalkonium based mixed anion ILs were characterized by 1H NMR, 
and 13C NMR (Figure 6.1 - 6.5). The proton signals for 
benzyltriethylammonium cation of M1 were recorded at 1.16 - 7.31 ppm and 
included a signal for 9 protons of its terminal methyl groups at 1.16-1.28 ppm 
(t), 6 protons of adjacent methylene groups were found at 2.99-3.11ppm (q), 
2 protons for the methylene next to phenyl group observed at 4.26 ppm (s) 
while the aromatic protons were found at 7.19-7.31 (m). The signals obtained 
for benzyltriethylammonium cation were compared with the signals of 
ibuprofenate salicylic acid anion confirming the formation of ionic liquid with 
mixed anions and indicating good stability of active pharmaceutical ingredient 
(Table 6.1).  
NMR spectroscopy has the potential to demonstrate the presence of 
hydrogen bonding. The standard temperature range of the Bruker Avance III 
400 spectrometer operating at 400 MHz NMR equipment is 278 K – 333 K. 
These limitations do not allow measurements below 278 K, temperature 
therefore VT (variation temperature) NMR spectroscopy analysis was 
performed on M1 (benzyltriethylamonium-ibuprofenate salicylic acid) in 
deuterated chloroform from 298.15 K to 278.15 K at a decreasing rate of 5 K 
to see the change in the chemical shift of delocalised proton. The result 
shows downfield shift of delocalised acidic proton with decrease in 
temperature. A broad peak at 9.02ppm for M1 was observed which is typical 
short, strong hydrogen bond peak indicating the presence of hydrogen 
bonding between mixed anion in ionic liquid (Figure.6.1) The results obtained 
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in the study could be correlated with the appearance of downfield shift of the 
delocalised proton in aprotic, low polarity solvents (Perrin and Nielson 1997; 
Kumar et al. 1998; Bica and Rogers 2010).  The synthesized benzalkonium 
based mixed anion ILs have the form and appearance of colourless viscous 
liquids to clear yellow viscous liquids at room temperature (Table 6.2). 
A Similar broad peak was observed in all benzalkonium based mixed anion 
ILs. 
 
Table 6.11H NMR data of M1 (Benzyltriethylamonium-ibuprofenate 
salicylic acid) 
 
1H NMR data of M1 in CDCl3  ppm 
(Benzyltriethylamonium-ibuprofenate salicylic acid) 
Benzyltriethylamonium cation ibuprofen salicylic acid anion 
1.16 - 1.28 (t, 9 H), 2.99 - 3.11 (q, 6 H), 4.26 (s, 2 H), 
7.19 - 7.31 (m, 5 H) 
0.88 (d, 6 H), 1.43 (d,  3 H), 1.74 - 1.87  
(m, 1 H) , 2.40 (d, 2 H), 3.69 (q, 1H),  
6.65 – 6.77 (t, 1 H),  6.77 – 6.87 
 (d, 1H),  6.98 – 7.09 (d, 2 H) 7.33 – 7.45  
(d, 2H) 7.80 – 7.91 (dd, 1 H),  9.02 (br. S., 1H) 
 
br – broadened singlet, s-singlet, d- doublet, dd-double doublet,  t- triplet, q-quartet, m-multiples 
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NMR and FTIR characterization data of IL with mixed anions 
 M1 (Benzyltriethylammonium-ibuprofenate salicylic acid) 
1H NMR (400 MHz, CDCl3)    ppm 0.88 (d, 6 H), 1.16 - 1.28 (t, 9 H), 1.43 (d, 
3 H), 1.74 - 1.87 (m, 1 H), 2.40 (d, 2 H), 2.99 - 3.11 (q, 6 H), 3.69 (q, 1 H), 
4.26 (s, 2 H), 6.65 - 6.77 (t, 1 H), 6.77 - 6.87 (d, 1 H), 6.98 - 7.09 (d, 2 H), 
7.19 - 7.31 (m, 5 H), 7.33 - 7.45 (d, 2 H), 7.80 - 7.91 (dd, 1 H), 9.02 (br. s., 1 
H) 
13C NMR (101 MHz, CDCl3)  ppm 7.83, 18.72, 22.40, 30.20, 45.04, 45.41, 
52.57, 60.76, 76.75, 77.06, 77.38, 116.46, 117.77, 126.64, 127.42, 129.11, 
129.52, 130.80, 130.85, 132.14, 132.98, 138.62, 140.11, 161.97 
IR (ν max cm
-1):  2954, 2931, 2848, 1718, 1655, 1625, 1591, 1512, 1456, 
1383, 1214, 754 
M2 (Benzyltriethylammonium-salicylcate ibuprofen) 
1H NMR (400 MHz, CDCl3)  ppm 0.87 (d, 6 H), 1.15 (t, 9 H), 1.41 (d, 3 H), 
1.80 (m, 1 H), 2.38 (d, 2 H),  2.97 (q, 6 H, 3.68 (q, 1 H), 4.18 (s, 2 H), 6.62 - 
6.73 (t, 1 H), 6.78 (d, 1 H), 7.00 (d, 2 H), 7.16 - 7.28 (m, 5 H), 7.31 - 7.44 (d, 
2 H), 7.85 (dd, 1 H), 11.88 - 12.00 (br, 1 H) 
13C NMR (101 MHz, CDCl3)  ppm 7.67, 18.84,  22.36,  22.38, 30.18,  45.02, 
45.62, 52.45,  60.57, 76.76, 77.07, 77.39, 116.34, 117.54, 118.92, 126.65, 
127.43, 129.02, 129.45, 130.74, 132.09, 132.63, 139.01, 139.90, 162.01, 
173.99, 177.83  
IR (ν max cm
-1): 3411, 2954, 2929, 2848, 1708, 1625, 1576, 1456, 1329, 
1214, 856.3  
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M3   (Benzyldimethylhexadecylammonium-ibuprofenate salicylic acid) 
1H NMR (400 MHz, CDCl3)  ppm 0.84 - 0.96 (d, 6 H), 1.20 - 1.33 (m, 26 H), 
1.50 (d, 3 H), 1.60 - 1.72 (m, 2 H), 1.84 (m, 1 H), 2.43 (d, 2 H), 3.02 (s, 6 H), 
3.11 - 3.23 (m, 2 H), 3.70 - 3.79 (q, 1 H), 4.53 (s, 2 H), 6.72 - 6.85 (t, 1 H), 
6.85 - 6.96 (d, 1 H), 7.01 - 7.13 (d, 2 H), 7.23 - 7.35 (d, 2 H), 7.37 - 7.49  
(m, 5 H), 7.95 (dd, 1 H), 9.27 - 9.49 (br, s, 1 H) 
13C NMR (101 MHz, CDCl3)  ppm 14.14, 18.56, 22.40, 22.71, 22.79, 26.20, 
29.16, 29.38, 29.48, 29.62, 29.68, 29.71, 29.73, 29.73, 30.19, 31.94, 45.04, 
45.33, 49.83, 63.97, 68.11, 76.74, 77.05, 77.37, 116.67, 118.12, 126.82, 
127.41, 129.19, 129.34, 130.84, 130.87, 132.83, 133.49, 138.31, 140.28, 
161.91  
IR (ν max cm
-1): 3422, 2954, 2923, 2853, 1715, 1620, 1592, 1484, 1457, 
1252, 778.8 
M4 (Benzyldimethylhexadecylammonium-salicylcate ibuprofen) 
1H NMR (400 MHz, CDCl3)  ppm 0.81 - 0.92 (d, 6 H), 1.10 - 1.26 (m, 26 H),  
1.44 (d, 3 H), 1.51 - 1.63 (m, 2 H), 1.79 (m, 1 H), 2.38 (d, 2 H), 2.92 (s, 6 H), 
3.03 - 3.14 (m, 2 H), 3.71 (q, 1 H), 4.45 (s, 2 H), 6.67 - 6.79 (t, 1 H), 6.84 (d, 
1 H), 6.94 - 7.05 (d, 2 H), 7.19 - 7.28 (d, 2 H), 7.33 - 7.45 (m, 5 H), 7.92 (dd, 
1 H), 12.01- 12.06  (m, 1 H) 
13C NMR (101 MHz, CDCl3)  ppm 14.12, 18.76, 22.39, 22.69, 22.71, 22.73, 
26.20, 29.16, 29.37, 29.39, 29.48, 29.62, 29.67, 29.72, 30.18, 31.93, 45.05, 
45.69, 49.69, 63.72, 67.91, 76.73, 77.05, 77.37, 116.43, 117.63, 119.08, 
127.02, 127.47, 129.06, 129.26, 130.74, 132.68, 132.87, 138.99, 139.94, 
162.09, 174.16, 177.97  
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IR (ν max cm
-1):  3471, 2954, 2924, 2853, 1710, 1624, 1577, 1458, 1216, 
856.7, 702.6  
 
 
 
 
Figure 6.1 1H NMR spectra of [BTEA-Ibu] (bottom) and M1 (top) at 
various temperature 
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Figure 6.2 13C spectra of M1 
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Figure 6.3 1H and 13C NMR spectra of M2 
[BTEA], [Salicylate] and [Ibuprofen] protons are represented in red, blue 
and black colours respectively 
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Figure 6.41H and 13C NMR spectra of M3 
[BDMA], [Salicylate] and [Ibuprofen] protons are represented in red, 
blue and black colours respectively 
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Figure 6.51H and 13C NMR spectra of M4 
[BDMA], [Salicylate] and [Ibuprofen] protons are represented in red, 
blue and black colours respectively 
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6.2.2 Thermal Behaviour 
The thermal properties of the benzalkonium based mixed anion ILs were 
studied using TGA and DSC. Table.6.2 shows the thermal stability of studied 
benzalkonium based mixed anion ILs ranging from 180.33 ◦C to 185.07 ◦C. 
All the benzalkonium based mixed anion ILs are viscous liquids at room 
temperature and thermogravimetric analysis showed a single decomposition 
step for all studied ILs (Figure 6.6 - 6.9). 
The thermal decomposition temperature was found to be in the order of M2 > 
M1. The impact of interactions between counterions can be observed by 
difference in thermal stability of ILs with mixed anions. It could be observed 
from the trend that thermal stability of the ILs with mixed anions decreases 
with increase in anion size of the salt (asymmety), the negative charge is 
spread over the large volume of anion resulting in much weaker interactions 
between the counterions (Leys et al. 2008). The same pattern was observed 
for M4 > M3. However, when the decomposition temeratures of ILs with 
mixed anions were compared on the basis of presence of cation, then order 
of thermal stability would be in the order of M3 > M1 and M4 > M2. The 
increase in decomposition temperature could be attributed due to increase in 
interparticle forces (Van der Waal forces) which arises with increase in alkyl 
chain length (Canongia Lopes and Padua 2006; Chancelier et al. 2016). 
Although little difference in thermal decomposition temperature was observed 
among benzalkonium based mixed anion ILs.  
DSC thermograms show the glass transition temperatures for all of the 
synthesized benzalkonium based mixed anion ILs in the following order -
42.59 (M1), -35.99 (M2), -33.52 (M3) and  
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-48.30 and -30.79 for (M4) (Table 6.2). The presence of glass transition 
temperature provides significant evidence that the material is amorphous. 
The DSC thermogram of M3 (Figure 6.8) shows peaks corresponding melting 
temperature (Tm) of -12.67 °C and crystallization temperature (Tc) which is 
found at -28.82 °C during cooling step, where molecules embrace more 
ordered structure after releasing energy. Please do refer table 3.1 for M1, 
M2, M3 and M4 mixed anion ILs. 
 
TGA and DSC profiles of benzalkonium based mixed anion ILs 
 
 
Figure 6.6 TGA and DSC profiles of M1 
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Figure 6.7 TGA and DSC profile of M2 
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Figure 6.8 TGA and DSC profile of M3 
 
 
 
 
 
 
161 
 
 
 
 
 
 
 
       
 
 
Figure 6.9 TGA and DSC profile of M4 
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6.2.3 Octanol-water partition coefficient 
Lipophilicity of the molecule is the vital element which is described by the 
octanol-water partition coefficient, used to correlate the absorption and 
transport properties of the active pharmaceutical ingredient in the human 
body (Pinto et al. 2013). In this study the lipophilicity of the benzalkonium 
based mixed anion ILs were assessed via experimental determination of 
octanol-water partition coefficient. The results of the study are summarised in 
Table.6.2.  As can be seen, in Figure.6.10 the octanol-water partition 
coefficient for M3 and M4 are higher than those of M2 and M1 ILs with mixed 
anions. The high value obtained for octanol-water partition coefficient can be 
attributed to the increase in the molecular weight and strong Van der Waals 
interactions which increases with increase in the long alkyl chains they have 
(Domańska et al. 2  3; Wu et al. 2  3;  adró et al. 2 14)  From 
experimental results obtained for M1 and M2, the octanol-water partition 
coefficient was found to be higher for M1. This observation could be 
correlated to the hydrophobic nature of ibuprofen anion, due to its bigger size 
to charge ratio as compared to the salicylate anion favouring dispersive 
interactions with organic molecules (Padró et al. 2014). However due to small 
salicylate anion compared with ibuprofen anion exhibits high ionic density 
leading to strong electrostatic interactions between cation and anion (Ingram 
et al. 2011), and which might also allow the formation of hydrogen bonding 
with nearby organic molecule. Same pattern was observed with M3 and M4 
benzalkonium based mixed anion ILs.  
 
 
163 
 
 
            
 
Figure 6.10 Octanol-water coefficient of benzalkonium based mixed 
anion ILs (Error bars - standard deviation) 
 
 
 
Table 6.2 Physicochemical properties of benzalkonium based mixed 
anion ILs 
 
      Tg – glass transition temperature ; Tc – crystallization temperature ;  Tm – melting     point ;   
 Td – decopmposition temperature 
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Molecular weight 
M3
M4
IL with 
mixed 
anions 
Ko/w 
Molecular 
weight 
Tg(
◦
C) Tc(
◦
C) Tm(
◦
C) Td(
◦
C) Physical state 
M1 0.27(±0.019) 565.80 -42.59 - - 180.33 Colourless Viscous liquid 
M2 0.16(±0.012) 565.80 -35.99 - - 183.41 Yellow viscous liquid 
M3 4.79(±1.24) 734.12 -33.52 -28.82 -12.67 183.35 Colourless Viscous liquid 
M4 2.89(±0.38) 734.12 
-48.30, 
-30.79 
- - 185.07 Yellow viscous liquid 
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6.2.4 Electrical conductivity 
Ionic liquids are generally composed of charged carrier ion therefore ILs are 
expected to have large electrical conductivity window. The electrical 
conductivity of ionic liquids is different from solutions having dissociated ions 
or nonpolar liquids. This leads towards interest in measurement of the 
electrical conductivity of synthesized ILs at different concentrations in water 
(Widegren et al. 2005).  
In order to investigate the influence of interactions between counterions on 
the conductivity, the electrical conductivity profiles of aqueous solutions of 
M1, M2, M3, and M4 benzalkonium based mixed anion ILs were studied at 
the highest concentration range. The results of conductivity are shown 
Figure. 6.11. There was no significant difference observed for the room 
temperature conductivity values of M1 and M2 ILs with mixed anions. It can 
be observed from the figure that electrical conductivity data shows the trend 
of salt in aqueous solution where the conductivity increase with increase in 
concentration of ILs. Aqueous solution of ILs behaves similar way to 
concentrated salt solutions. The conductivity of ILs aqueous solution 
increases due to the presence of water-rich regions. The dissociation 
constant of ILs was increased with increase in the amount of water 
(Tshibangu et al. 2011).  
As described earlier, to investigate the conductivity profiles of M3, M4 
benzalkonium based mixed anion ILs the aqueous solutions were prepared 
at highest concentration. But due to hydrophobic nature, increased molecular 
volume and viscosity M3, M4 ILs with mixed anions failed to give clear 
aqueous solutions.  
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Figure 6.11 Electrical conductivity profiles of benzalkonium based 
mixed anion ILs 
 
6.2.5 Permeation studies 
Neat benzalkonium based mixed anion IL was applied on artificial membrane 
and assessment of the drug permeation via artificial membrane was studied. 
The reason behind the direct application of neat IL on the skin excludes the 
need of other excipients which are generally used to solubilize the drug 
molecules. 
6.2.5.1 Evaluation of ibuprofen and salicylic acid permeation through 
membrane in different forms 
Figure.6.12 summarises the permeation rates of ibuprofen and salicylic acid 
in different forms through the membrane over time from M1 and M2 (as neat 
IL).  As can be seen that transport rate of ibuprofen from M1 and M2 via 
hydrophilic membrane is much slower and no significant difference observed 
in the permeation rates of neutral ibuprofen which is hydrogen bonded (M2) 
and ibuprofen in the form of IL salt (M1). The data suggest that ibuprofen 
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transport through the membrane in almost identical manner in both forms.  
Salicylic acid permeates the membrane more rapidly, achieving saturation 
level within 6-7 hour in both forms from M1 and M2. The transport of salicylic 
acid in the form of IL salt (M2) and salicylic acid as neutral molecule which is 
hydrogen bonded (M1) found to permeate at the same rates. Thus it appears, 
salicylic acid and ibuprofen (ionized or hydrogen bonded neutral form) are 
associated strongly via ionic/hydrogen bonding interaction and remain intact 
as single entity which allows the passage of individual API simultaneously 
through membrane.  
On the other hand, permeation of ibuprofen and salicylic acid from M1 and 
M2 through hydrophobic membrane shows different behaviour.  The 
transport rate of ibuprofen in the form of IL salt from M1 was found to be 
higher compared to the hydrogen bonded neutral ibuprofen from M2. The 
results obtained are found to be in accordance with the results reported by 
Sarveiya et al.(2004)where ion-pairing was responsible for achieving better 
permeation rate through a polydimethylsiloxane membrane (Sarveiya et al. 
2004).  While in case of salicylic acid, the permeation rate was found to be 
higher when salicylic acid was in hydrogen bonded neutral form (M1) than in 
the form of IL salt (M2), the results obtained here could be correlated to 
studies performed by Stoimenovski et al where they observed acidic 
molecule transport easily over the IL salt form (Stoimenovski and MacFarlane 
2011). The difference in the permeation rates of ibuprofen and salicylic acid 
from neat IL through hydrophobic membrane could be attributed to the nature 
of membrane, molecular mass and solubility of the IL. 
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Figure 6.12 Permeation of % ibuprofen and salicylic acid from M1 and 
M2 through hydrophilic and hydrophobic membranes  
(Error bars - standard deviation) 
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The ibuprofen and salicylic acid permeation in different forms through the 
membrane over time from M3 and M4 (as neat IL) is shown in Figure.6.13.  
The permeation rate of ibuprofen and salicylic acid in different forms from 
hydrophilic membrane was found to be significantly different from what we 
observe in case of M1 and M2. The permeation rate of ibuprofen in hydrogen 
bonded neutral form (M4) was found to higher compared to ibuprofen in the 
form of IL salt (M3) whereas in case of salicylic acid the permeation profile is 
just reverse and was found to be higher in the form of IL salt (M4) compared 
to salicylic acid in neutral form hydrogen bonded molecule (M3). The results 
obtained could be attributed to the difference in the interactions between 
cation and anions and to their octanol water partition coefficient values. The 
increase in the anion size (keeping cation constant) leads to decrease in 
ionic interactions due to delocalisation of charge (Freire et al. 2007; Leys et 
al. 2008; Alves et al. 2013), and finally transport properties. The increased 
ionic interaction between cation and anion (M4) is responsible to form more 
strong hydrogen bonding with ibuprofen. The increased ionic interaction and 
hydrogen bonding in M4 leading to generate single entity which finally 
increased permeation rate compared to corresponding M3. Similar kind of 
pattern was found for permeation rate of ibuprofen and salicylic acid through 
hydrophobic membrane but in significantly slow rate compared to hydrophilic 
membrane. 
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Figure 6.13 Permeation of % ibuprofen and salicylic acid from M3 and 
M4 through hydrophilic and hydrophobic membranes  
(Error bars - standard deviation) 
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the amount of permeation (Tayar et al. 1991; Pugh et al. 1996). Scheuplein 
et al. also suggested that small molecules display better and faster 
permeation profiles compared to larger molecules (Scheuplein et al. 1969). 
The only promising candidate which appears to have higher permeation 
through hydrophilic membrane with increase in the alkyl chain length on 
cation is salicylic acid (M4). The permeation of salicylic acid in the form of 
salt (M4) with cation having long alkyl chain was found to be dominating over 
other form, which could be attributed to the increase in lipophilicity of the drug 
salt. This increases the solubility of drug salt within lipid domains of the 
stratum corneum and finally improves the membrane permeability (Flynn and 
Yalkowsky 1972). The ibuprofen and salicylic acid permeation profiles 
through membranes can be seen in Figure 6.14.  
6.2.5.3 Effect of cation on permeation of ibuprofen and salicylic acid 
(different form) through membrane 
A similar pattern was observed on permeation of ibuprofen and salicylic acid 
(different form) through membrane (Figure 6.15). 
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Figure 6.14 Effect of cation on permeation of % ibuprofen and salicylic 
acid (same   form) through membrane  
(Error bars - standard deviation 
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Figure 6.15 Effect of cation on permeation of % ibuprofen and salicylic 
acid (different form) through membrane  
(Error bars - standard deviation) 
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6.3 Conclusion 
Benzalkonium based mixed anion ILs were composed of benzalkonium 
chloride, ibuprofen and salicylic acid which are pharmaceutically approved 
molecules. The interactions exist in these ILs not only have huge impact on 
the physicochemical properties but also provides the potential feasibility for 
these neat IL formulation to penetrate through membrane more effectively.  
Although ex-vivo studies are required to support the data generated. Thus, 
benzalkonium based mixed anion ILs are effective and possible promising 
formulation for the topical drug delivery. 
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Chapter 7 
Formulation containing IL hydrogel 
7.1 Introduction 
The objective of this chapter is to investigate the interactions between 
various components of the formulation and to demonstrate in-situ formation 
of ibuprofen IL during formulation for topical treatment. For this purpose, 
Ibuprofen has been selected as a model drug in its acidic form, alkanolamine 
(diisopropanolamine, triisopropanolamine, triethanolamine) as base and 
carbopol 974 was used as gelling agent. The synthesised alkanolamine-
ibuprofen IL was characterised by NMR and IR spectroscopy, DSC and 
TGA.Ibuprofen-IL hydrogels are prepared by incorporating 
diisopropanolamine-ibuprofen (DIPA-Ibu) IL into 1% aqueous carbopol 
dispersion, which was characterised by FTIR spectroscopy. In vitro 
permeation and release studies were also conducted. 
The commonly used Non-Steroidal Anti-inflammatory Drugs (NSAIDs) such 
as ibuprofen, piroxicam and diclofenac are poorly soluble molecules which 
are formulated in the form of topical gels, creams and patches. Though there 
are number of gel compositions reported the most commonly commercially 
used gel formulations contain an acrylic acid polymer as gelling agent. 
Carbopol 974P (Carbopol) is a FDA approved water swellable high molecular 
weight acrylic acid polymer toxicologically more preferred over other 
alternatives of Carbopol polymers (Bonacucina et al. 2004). Carbopol upon 
neutralisation forms a gel with excellent rheological and bioadhesive strength 
properties in less than 2-3 % w/v concentration (MORIMOTO et al. 1985; 
Witschi and Mrsny 1999; Callens et al. 2003; Najafabadi et al. 2004). Low 
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molecular weight amines and alkanolamines such as triethanolamine, 
triisopropanolamine, and diisopropanolamine are commonly used for 
neutralisation of Carbopol. The carboxylic groups of the Carbopol 974P 
molecules would be uncharged at low pH and display weak interactions and 
found to be in coiled state. The carboxylic group of the carbopol 974P is 
converted into carboxylates at nearly neutral and alkaline pH and the 
repulsion between the negatively charged carboxylates is responsible for the 
expansion and finally the formation of hydrogel (Park and Robinson 1985; 
Handbook 1993).  
The   conventional dosage form such as preformed gels do not remain for the 
long time and required frequent dosing.  The in-situ gel system approach 
using carbopol 974P not only combines the advantage of gel formation but in 
addition to that an accurate amount of dose can be applied on to the 
administration site. These formulation remains in solution state before 
application to the administration site and transformed into gel state after 
administration. Moreover these polymers display the ability to tailor the drug 
release from gels (Valenta 2005). The synthesis of ionogels encapsulating IL 
(1-methyl-3-butylimidazolium-ibuprofen) in porous functionalised silica has 
been reported in literature (Viau et al. 2010).  
Recently, there are many reports about design of Active Pharmaceutical 
Ingredient (API) – ILs to improve performance of the API by tailoring 
physicochemical properties such as solubility, lipophilicity, melting point and 
viscosity. API – ILs have also been used to incorporate dual activity for 
example lidocaine-docusate improved efficacy of lidocaine as local 
anaesthetic along with emollient effect of docusate while docusate as a 
176 
 
counter ion was effective in avoiding polymorphic transformation of ranitidine. 
There is growing focus on exploring use of API – ILs to achieve improved 
transport of drugs across the lipophilic barriers. Miwa et al. reported 
significant improvement in the solubility and transdermal permeation of 
etodolac when used as etodolac-lidocaine IL. Wang et al. identified strong 
charge assisted hydrogen bond complex formation between ibuprofen and 
lidocaine. This complex was termed as liquid – cocrystal and the pair is 
transported across the membrane as a complex (Wang et al. 2014). Sarveiya 
et al. also showed association between the two components of the IL. The 
lipophilic drug and counterion neutral aggregates   penetrate the dermal 
layers instead of drug in the ionic form. Though there are advantages and 
encouraging permeation data has been reported, a clinical trial transdermal 
patch (Etoreat) containing etodolac –lidocaine IL has been terminated due to 
failure to show significant pain relief compared to placebo.  As per our 
knowledge there is no FDA approved ionic liquid formulation in the market. 
Ionic liquid based on ibuprofen drug was synthesised in which Ibuprofen was 
chosen in its acidic form to allow proton transfer. Diisopropanolamine, 
triisopropanolamine, triethanolamine (aliphatic amine) were carefully chosen 
as they have been used in cosmetic and pharmaceutical formulations. 
Alkanolamine-ibuprofen IL was prepared by neutralisation reaction and then 
the synthesised IL was used to incorporate into 1% aqueous carbopol 
dispersion to generate hydrogels. These hydrogels were subjected to 
investigate thepotential of In-situ formation of ibuprofen – IL in topical 
ibuprofen gel formulationand the influence of diisopropanolamine (present in 
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diisopropanolamine ibuprofen) on in vitro release and permeation profiles 
was studied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178 
 
7.2 Results and Discussion 
7.2.1 Characterisation of diisopropanolamine-ibuprofen ionic liquid 
For model ILs, we tried for three ILs namely diisopropanolamine-ibuprofen 
(DIPA-Ibu), triisopropanolamine-ibuprofen (TIPA-Ibu) and triethanolamine-
ibuprofen (TEA-Ibu). The first two were prepared by neutralisation reaction 
and characterised by 1H NMR, 13C NMR, FTIR but ibuprofen was found to be 
precipitated in case of triethanolamine-ibuprofen. In order to select best IL 
candidate for incorporation in carbopol dispersion, we performed dissolution 
studies and the data suggest diisopropanolamine-ibuprofen as a promising 
candidate for further studies as its water solubility is far greater than the 
aqueous solubility of triisopropanolamine-ibuprofen (39.71 mg/ml) and 
triethanolamine-ibuprofen (35.51 mg/ml) respectively. The solubility data is 
provided in appendix. Then the ionic liquid   diisopropanolamine-ibuprofenate 
was further carried for next studies and to generate ibuprofen hydrogels 
using 1% aqueous carbopol dispersion. 
1H NMR spectroscopy dataof diisopropanolamine-ibuprofen(DIPA-Ibu) 
showed the peaks at 0.87 ppm and 6.93-7.23 ppm, which is attributed to the 
methyl groups and aromatic ring of ibuprofen, while the peaks observed at 
1.06 ppm and 2.58-2.86 ppm correspond to methyl and methylene groups of 
diisopropanolamine respectively (Figure 7.1).This data was further supported 
by FTIR spectra of diisopropanolamie, ibuprofen and diisopropanolamie-
ibuprofen IL (Figure 7.2). The absorption band of the carboxylic group of 
ibuprofen appeared at 1709 cm-1   while a broad band at 3276 cm-1   appears 
for diisopropanolamine which is attributed due to absorption overlap between 
the amino group and the hydroxyl group of diisopropanolamine. The band 
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that arises near 2955-2960 cm-1   corresponds to the aliphatic groups found in 
both the aliphatic amines and carboxylic compounds. The absorption band of 
the carboxylic group of ibuprofen was shifted to 1560 cm-1   from 1709 cm-1   
in the diisopropanolamine-ibuprofen IL. The absorption band near 1560 cm-1   
was an indication of salt of aliphatic carboxylic acids. The appearance of a 
new band at 1560 cm-1   and disappearance of the band at 3276 cm-1 
confirms the formation of diisopropanolamine-ibuprofen salt in a uniform 
colourless liquid at room temperature. 
Thus the 1H NMR spectroscopy and FTIR absorption spectrum analysis 
confirmed the formation of ionic liquid by the neutralisation reaction between 
diisoropanolamine and ibuprofen. The ionic liquid was composed of 
equimolar ratios (1/1 mol/mol) of the reactants.1H, 13CNMR and FTIR data of 
triisopropanolamine-ibuprofen is provided in appendix. 
 
NMR and FTIR characterization data 
Diisopropanolamine-ibuprofen: 
1H NMR (400 MHz, DMSO-d6)  ppm 0.87 (6 H), 1.06 (6H), 1.27 - 1.39 (3 H), 
1.75 - 1.87 (1 H), 2.40 (2 H), 2.58 - 2.69 (2 H), 2.74 - 2.86 (2 H), 3.40 - 3.53 
(2 H), 3.85 - 3.97 (2 H), 6.93 - 7.05 (2 H), 7.23 (2 H) 
13C NMR (101 MHz, DMSO-d6)  ppm 19.49, 21.01, 21.04, 22.10, 29.66, 
44.39, 47.19, 54.66, 54.85, 62.56, 62.70, 127.06, 128.37, 138.28, 141.21, 
178.77  
IR (ν max cm
-1): 3188, 2957, 2869, 2846, 1560, 1457, 1307, 1255, 1141, 
1064, 1020, 928, 849 
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Figure 7.11H and 13C NMR spectra of Diisopropanolamine-ibuprofen 
[DIPA] and [Ibuprofen] protons are represented in red and blue colours 
respectively 
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Figure 7.2 FTIR spectra of Diisopropanolamine-ibuprofen 
 
7.2.2 Thermal behaviour 
The DSC thermographs of diisopropanolamine-ibuprofen IL, free 
diisopropanolamine and free ibuprofen is provided in (Figure 7.3).  Sharp 
endothermal peaks were observed at melting points: 77.14 ºC and 44.42 ºC 
for free ibuprofen and free diisopropanolamine respectively. These peaks 
were not found in diisopropanolamine-ibuprofen IL, the only thermal transition 
observed was a glass transition temperature at -9.11 ºC. This provides strong 
evidence of the formation of diisopropanolamine-ibuprofen IL, which is a salt 
of diisopropanolamine and ibuprofen, is different from the reacting species, 
and did not result in API degradation. The TGA profile of diisopropanolamine-
ibuprofen IL (Figure 7.4) shows a double decomposition process with 
degradation temperature of 144.27 ºC. 
 
 
 
182 
 
 
 
Figure 7.3 DSC thermograph of Diisopropanolamine-ibuprofen 
 
 
 
Figure 7.4 TGA profile of Diisopropanolamine-ibuprofen 
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7.2.3 Characterisation of IL based ibuprofen hydrogels 
We employed ATR-FTIR in order to evaluate the interactions between the 
three components of the Ibu-DIPA-Carbopol system and to uncover the 
details of the mechanism of an API-IL-polymer complex formation. This 
technique allows to detect the formation of various types of inter- and intra- 
molecular interactions which take place when the aforementioned 
compounds interrelate with one another. As could be seen from Table 3.3 the 
formation of a clear gel starts with the ratio of DIPA-IBU ca. 1.5:1 indicating 
the completion of the gel formation and neutralisation of all the acidic groups 
present in the system by the ionic liquid. This suggests that the excessive 
amount of DIPA is required to neutralise the acidic groups of Carbopol after 
the reaction between Ibu and DIPA is complete. In order to verify this 
assumption we prepared mixtures of 2 components, namely Ibu-DIPA, Ibu-
Carbopol and DIPA-Carbopol, as well as the 3 component mixtures, all with 
varying ratios from 1.8:1 to 0.2:1 for each component to understand which 
kinds of bonds occur as a result of the interactions between them.  
The three component system exhibits a very complicated spectral profile 
(vide infra) as there are possible interactions taking place between DIPA and 
the carboxylic groups belonging to either Carbopol or Ibuprofen. The shift of 
the carbonyl vibrations to the lower wavenumbers is expected regardless the 
molecule it is affiliated with, and nearly identical vibration shift was detected 
for both DIPA-Ibu and DIPA-Carbopol systems. In view of this we initially 
opted for the analysis of the 2-component systems to understand what kind 
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of interaction can be present in these systems, which in turn would help us to 
understand the underlying process of a three-component gel formation.   
 
 
Figure 7.5 FTIR spectra showing diisopropanolamine-ibuprofen 
interaction 
 
Figure 7.5 shows the interactions between DIPA and Ibu. Carbonyl stretching 
vibration of an ibuprofen hydrogen-bonded dimer originally appearing at 1707 
cm-1 is expectedly shifted to lower wavenumbers (of ca. 1560 cm-1) and is 
characteristic of an interaction of the carboxylic anion with an N-H counter-
ion of aliphatic amine DIPA to form a salt (Kubota et al. 2016). Unlike 
reported previously, in our case even at 1:1 ratio we detected only the 
presence of an acid-amine salt and did not observe any co-existence of the 
unreacted components, which was confirmed by the complete disappearance 
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of the 1707 cm-1 vibration of Ibuprofen dimer and its reappearance as a blue-
shifted bonded salt at ca. 1560 cm-1 
 
 
Figure 7.6 FTIR spectra showing diisopropanolamine-carbopol 
interaction 
 
Figure 7.6 in turn, shows the results of interaction between Carbopol and 
DIPA. It is immediately apparent that neutralisation of the carboxylic groups 
happens gradually with the addition of DIPA, with the carbonyl stretching 
vibration being shifted from its original position at 1703 cm-1 to 1550 cm-1 
corresponding to a COO- functional group being ionised by DIPA (Islam et al. 
2004). It can be clearly seen that the carbonyl stretching peak is diminished 
by the ratio of 0.6:1 and completely disappears at the higher ratios 
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suggesting that a virtually complete neutralisation occurs in this range of ionic 
liquid concentrations and thus the formation of the gel structure is achieved. 
As expected, interactions between Carbopol and Ibuprofen are virtually non-
existent (Figure 7.7) where the spectrum of a two-component system Ibu-
Carbopol exhibits mostly peaks of ibuprofen. 
 
 
Figure 7.7 FTIR spectra showing Ibuprofen-Carbopol interaction 
 
Having studied all possible binary combinations of Carbopol, DIPA and 
Ibuprofen, we attempted to evaluate what kind of interactions occur in a 
three-component system and whether the assumption on the suggested 
ratios between the components for complete neutralisation will sustain itself. 
We have therefore tested all the ratios of DIPA-Ibu keeping the amount of 
Carbopol the same for all the mixtures (Table 3.3 in section 3.3.4). 
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Figure 7.8 FTIR spectra showing Ibuprofen-diisopropanolamine-
Carbopol interaction 
 
As mentioned earlier it was not possible to draw meaningful conclusions, as 
the band shift caused by the interaction of DIPA and Carbopol overlaps with 
the one of DIPA and Ibu appearing in the 1550-1560 cm-1 region. This 
prompted us to concentrate on the other types of characteristic vibrations 
(Figure 7.8), for atom assignment see Figure 7.9. 
                            
Figure 7.9 Ibuprofen atom assignments for FTIR 
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The propionic moiety of Ibu with the addition of DIPA becomes distorted 
which can be detected by the multiple changes in the peak positions of the 
corresponding group interactions. Thus, a C-O stretching assigned at 1123  
cm-1 is shifted to higher wavenumbers and when more neutraliser is added a 
new peak appears at 1141 cm-1, whereas the peaks corresponding to a C24-
H25 and CO-H in plane bending at 1321-1330 cm-1 completely disappear, 
along with the peak at 1231 cm-1 corresponding to C-O stretching, A region 
at 1365 cm-1 corresponding to the C24-H25 bending as well as C24-C30-O32 
stretching is shifted to 1360 cm-1. The bond between the aliphatic C24 and 
aromatic C3 carbon atoms, appearing at 1168 cm-1 in Ibuprofen and 
disappearing when the amount of DIPA is enough to neutralise all the 
carboxylic groups (at 1:1 ratio and higher), is also affected by the interaction 
with an ionic liquid. 
All the changes in the vibrational spectra advocate that the distortion of the 
aliphatic part of an Ibu molecule during the interaction with an ionic 
compound can be clearly detected. They also indicate that the interaction 
with DIPA gradually changes the shape of the part of the Ibu molecule while 
forming a salt, whereas Carbopol structure uncoils during neutralisation 
(Kemper et al. 2001) and remains unchanged after all its carboxylic groups 
are charge neutralised, regardless the presence of the excess of DIPA and 
Ibuprofen in the mix. 
Overall, the information extracted from the FTIR spectra allows to theorise 
that the amount if IL in the mixture of DIPA:Ibu with the ratio of 1.6:1 and 
higher is sufficient to neutralise all Ibuprofen as well as the acidic carboxylic 
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groups of Carbopol, but at the same time to still maintain an acceptable 
slightly basic pH level to be delivered transdermally onto the skin with normal 
pH level lying in the broad range of 4.0 to 7.0 (Lambers et al. 2004). 
7.2.4 In-vitro permeation studies 
The in vitro permeation evaluation is useful for understanding drug transport 
across a synthetic membrane. The effect of diisopropanolamine on ibuprofen 
permeation across an artificial membrane was evaluated by using a Franz 
diffusion cell.  Figure 7.10 shows the permeation of ibuprofen across the 
synthetic membrane. The amount of ibuprofen permeated across the artificial 
membrane increased with increase in concentration of diisopropanolamine. 
The amount of Ibuprofen permeated after application of hydrogel S1 is 
significantly lower than that of neat ionic liquid S4 and a hydrogel S7 
containing higher amount of diisopropanolamine. This was observed 
irrespective of the type of membrane.  
The permeation data for ibuprofen in the S1 hydrogel sample reveals less 
ibuprofen permeated because of its unionized free form. The FTIR data gives 
evidence of the presence of carbonyl group of ibuprofen for the S1 hydrogel 
sample, suggesting that ibuprofen is present in its unionized form. On the 
other hand the disappearance of the carbonyl band of ibuprofen for the S4 
and S7 hydrogel samples indicates ibuprofen in ionized form. The increase in 
permeation rate could be attributed to the formation of neutralized ionic liquid 
complex of diisopropanolamine and ibuprofen. Sarveiya et al. suggested that 
ion pairing was responsible for higher transport of amine salts of ibuprofen 
over sodium salt of ibuprofen (Sarveiya et al. 2004).  The permeation of 
Ibuprofen from S7 sample is higher among all the samples which could be 
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correlated to the increased ionic interactions due to formation of oligomer 
ionic liquid (Johansson et al. 2008). Previous literature findings also 
demonstrate the permeation of IL through membranes where the permeation 
was dependent on the nature of components (Miwa et al. 2016).   
 
   
   
 
Figure 7.10 In vitro Ibuprofen permeation profile from IL based 
hydrogels, Refer Table 3.4 for S1-S7 formulations  
(Error bars - standard deviation) 
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7.2.5 In-vitro release studies 
The drug release profiles were evaluated for all the IL based ibuprofen 
hydrogels in buffer solution at pH 7.2. These studies are crucial in analysing 
whether the formulations sustain the ibuprofen release. Difference in the 
release of ibuprofen from IL based ibuprofen hydrogels would be expected as 
the API is in the different forms. It is known that the dissolution of the drug 
can be affected by various factors namely polymorphism, crystallinity, particle 
size, solubility, viscosity (Williams et al. 2013). Therefore it is vital to compare 
the release profiles of ibuprofen, the model NSAID used in this study. The 
cumulative release percentage of ibuprofen from the IL based ibuprofen 
hydrogels is shown in (Figure.7.11) where it was found that the ibuprofen in 
the hydrogel samples S1 and S7 have similar release profiles, and both are 
greater than the release profile for the S4 hydrogel. This may indicate that 
the interaction established between ibuprofen and diisopropanolamine is 
significantly strong in S4 hydrogel, which is not disrupted in aqueous solution. 
About 80% of ibuprofen release was observed for S1 and S7 hydrogels 
which could be attributed to the swelling behaviour of polymer.  This could be 
understood due to an increase in hydration degree leading to the diffusion of 
water into the polymeric network which helps the diffusion of the drug out of 
the polymeric network and into the solution. It is clear from Figure 7.11 that 
the release profile of ibuprofen from the S1 hydrogel sample at pH 7.4 and 
the S7 hydrogel sample at pH 8.7 is quite similar, although ibuprofen is in 
different forms, confirming that the release profile of ibuprofen is related to 
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the swelling behaviour of polymer. The pKa of carbopol 974 polymer is 6.0 
(Agarwal and Mishra 1999) and that of ibuprofen is 4.4 (Velasco et al. 2011). 
The degree of ionization of anionic hydrogels increases when pH is above 
the pKa of the polymer, leading to swelling of hydrogels which finally 
increases the release of the drug (Gupta et al. 2002). 
    
 
Figure 7.11 In vitro release of ibuprofen from IL based ibuprofen 
hydrogel, Refer Table 3.4 for S1-S7 formulations 
 (Error bars - standard deviation) 
 
7.3 Conclusion 
The result of this study suggests the efficacy of combination of 
diisopropanolamine-ibuprofen IL and carbopol 974 results in situ hydrogel 
system for topical application. FTIR data indicate the need for a well-
balanced quantity of ionic liquid and carbopol in order to achieve an effective 
drug-neutraliser-polymer interaction to form a hydrogel structure. The release 
profile of the ibuprofen from IL based ibuprofen hydrogels shows lower 
dissolution in its ionic liquid salt form and permeation data display a direct 
relationship with diisopropanolamine concentration. The efficiency of this 
formulation can be further studied by Ex-vivo experiments. 
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Chapter 8 Global discussion 
Ionic liquids were prepared and characterised in good to excellent yields. 
Benzalkonium cations (benzyltriethylammonium and 
benzyldimethylhexadecylammonium) were combined with four different 
anionic drug (ibuprofen, diclofenac, salicylic acid, sulfacetamide) to generate 
benzalkonium based ILs. Diisopropanolamine was also coupled with 
ibuprofen to yield diisopropanolamine ibuprofenate IL. All these drug salts 
were characterised by 1H, 13C NMR and IR spectroscopy and subjected to 
evaluate their physicochemical properties and biopharmaceutical 
performance. Large numbers of Active Pharmaceutical Ingredient-ionic 
liquids (API-ILs) have been reported in the literature; to date very limited work 
has been conducted on their potential application in the field of topical drug 
delivery.  The main objective of the presented work was to investigate neat 
API-ILs as topical drug delivery systems. To begin, a set of suitable model 
API-ILs were studied to address the gap in the literature. 
It was illustrated in Chapter 4 that benzalkonium based NSAIDs ILs were 
prepared successfully by combining quaternary ammonium cations with 
model APIs such as ibuprofen and diclofenac. All the prepared benzalkonium 
based NSAIDs ILs were found to display glass transition temperature and 
their appearance ranged from a colourless viscous liquid to a yellow viscous 
liquid. The thermal decomposition temperature shows the trend of anion 
asymmetry and decrease in thermal decomposition temperature was 
observed with increase in asymmetry of anion. Interestingly the Van der Waal 
interactions arising due to increase in the hydrocarbon chain attached to 
194 
 
cation led to an increase in the thermal decomposition temperature. The 
conductivity data of aqueous solutions of API-ILs analysed at higher 
concentration suggests that at high concentration, these ILs do not show a 
similar trend as a salt solution. Octanol-water partition coefficient data of 
benzalkoium based NSAIDs ILs shows the trend of anion hydrophobicity 
while an increase in octanol-water partition coefficient was observed with 
increase in molecular weight. The results of skin deposition and permeation 
studies of benzalkonium based NSAIDs ILs was simply based on the partition 
coefficient and molecular weight measured, which suggest that [BETA] [Ibu] 
could be detected in the receptor compartment based on its lower molecular 
weight than 500 and the lower Ko/w value which is also reflected on the 
lower % of drug retained in the different skin layers. On the other hand, while 
[BTEA] [Diclo] would be expected to have a similar profile, due to the higher 
molecular weight the permeation was very limited. Comparatively [BDMA] 
[Ibu] and [BDMA] [Diclo] display very limited permeation because of high 
molecular volume and partition coefficient values which makes them suitable 
candidates for topical applications.  
 The study reported in chapter 5 was intended to investigate if there is a 
synergistic effect by combining sodium sulfacetamide and benzalkonium 
halides (benzyltriethylammoniuim chloride, 
benzyldimethylhexadecylammonium chloride) into benzalkonium 
sulfacetamide. The effect of the cationic counterion; benzalkonium on the 
benzalkonium sulfacetamide ILs physicochemical properties and 
biopharmaceutical performance were examined. Octanol-water partition 
coefficient, skin deposition and permeation data follow the similar trend as 
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observed in Chapter 4. The antimicrobial activity of the synthesised IL 
showed no synergism compared to parent molecules.  
Using the idea established in Chapter 4 the study was extended to examine 
benzalkonium based mixed anion ILs (three component systems) with the 
aim of investigating the effect of ionic interaction/hydrogen bonding on the 
physicochemical properties and penetration behaviour via artificial 
membrane. All the IL with mixed anions was found to display only glass 
transition temperature and was found to be in the form of colourless viscous 
liquid to yellow viscous liquid; the only candidate displaying crystallisation 
temperature, melting point and glass transition temperature was M3 
(benzyldimethylhexadecylammonnium ibuprofen salicylic acid) . The thermal 
decomposition temperature, octanol-water partition coefficient and electrical 
conductivity trend was found to be similar which was observed in the Chapter 
4. The permeation data of ibuprofen and salicylic acid demonstrates inverse 
relationship with the molecular weight of the benzalkonium based mixed 
anion ILs. The permeation data suggest that these IL formulations exist as 
single entity and the penetration properties of ibuprofen and salicylic acid 
depends on the nature of membrane type, octanol-water partition coefficient 
values, molecular weights and type of interactions.  
In the frame of this work ibuprofen hydrogels were developed and prepared 
and in-situ generation of ibuprofen-IL in the hydrogels was investigated. 
Ibuprofen and diisopropanolamine were combined to generate 
diisopropanolamine-ibuprofenate ionic liquid then the prepared IL was 
incorporated in the Carbopol 974 water dispersion to form hydrogels. FTIR 
analysis was performed in order to understand the interaction of ibuprofen-IL 
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hydrogels. In order to improve the appearance, pH, diffusion and permeation 
through artificial membrane the ratio of diisopropanolamine was varied 
keeping the amount of Carbopol 974 and ibuprofen constant. Drug diffusion 
studies were conducted to evaluate the liberation of ibuprofen from the 
vehicle and the diffusion study was performed via synthetic membrane using 
Franz diffusion cell. It could be assessed, that permeation of ibuprofen 
follows direct relationship with the concentration of base which might arise 
due to increase in the ionic interaction between ibuprofen and 
diisopropanolamine.  
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Chapter 9 Conclusions and future 
In summary, this thesis illustrates the tunable strategy of the IL which 
provides a potential tool to tailor the physical, chemical and biological 
properties which allows generating topical drug delivery and improved 
pharmaceutical application. Some positive results for topical application of 
neat ILs have been reported in this dissertation. 
9.1 Conclusion 
1. Four benzalkonium based NSAID ILs were synthesised and 
investigated for their physicochemical and biopharmaceutical 
performance. The results suggest that all the prepared ILs are suitable 
for topical application.   
2.  Benzalkonium-sulfacetamide ILs were evaluated to look into if there is 
any synergistic effect between benzalkonium cation and sulfacetamide 
anion.  The data indicates no synergism between both components. 
3. The transport properties of benzalkonium based mixed anion ILs was 
found to be dependent on the octanol-water partition coefficient, 
nature of the permeant and nature of artificial membrane used to 
study. 
4. Ibuprofen IL hydrogel formulation was investigated to determine the in-
situ formation of ibuprofen IL in ibuprofen topical gel. FTIR-ATR was 
found to be the potential tool to understand the interaction between 
the components of hydrogel formulation. 
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9.2 Suggested Future work 
1. This work looked at only small sub-set of ILs by investigating the 
change of alkyl chain length and the effect of anion on the topical 
applications of NSAIDs. It would be interesting to carry out the same 
analysis to determine the effect of a series of alkyl side chain of 
different cation.  
2. It would be of interest to look into the effect of series of alkyl chain 
length on cation to understand the synergistic effect of benzalkonium 
sulfacetamide ILs. 
3. IL formation dramatically enhances the transport property of drug. The 
overall mechanism depends on the counterion and was not well 
studied; therefore the dissociation behaviour of ion pair aggregates 
before and after penetrating the membrane would be an interesting 
area to look into.  
4. It was shown here that IL modular strategy can be utilised to form 
hydrogels. It would be interesting to look into the rheological properties 
and penetration behaviour of API by using different anionic polymers. 
The effect of different concentration of polymers the diffusion 
properties of API could also be investigated. 
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Appendix 
 
Contents 
1. Figure.S1, S2 1H and 13C NMR, FTIR spectra of triisopropanolamine-
ibuprofen IL 
2. Figure S3 and Solubility determination of Ibuprofen ILs 
 
1. NMR and FTIR characterization data 
Triisopropanolamine-ibuprofen: 
1H NMR (400 MHz, DMSO-d6)  ppm 0.87 (6 H), 0.98 - 1.10 (m, 9 H), 1.36 (3 
H), 1.82 (1 H), 2.35 - 2.44 (2 H), 2.46 - 2.57 (m, 6 H), 3.61 (1 H), 3.70 - 3.83 
(3 H), 6.07 (3 H), 7.00 - 7.12 (2H), 7.14 - 7.27 (2 H) 
13C NMR (101 MHz, DMSO-d6)  ppm 18.61, 20.29, 20.75, 21.07, 22.06, 
29.60, 38.77, 38.98, 39.18, 39.40, 39.61, 44.35, 44.89, 62.82, 63.33, 63.81, 
64.10, 64.54, 64.66, 127.01, 128.70, 138.94, 139.15, 175.95 
IR (ν max cm
-1):  2965.54, 2929.32, 1719.42, 1567.26, 1511.75, 1458.04, 
1216.21, 1140.62, 1059.45, 1004.64, 854.35, 785.92 
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Figure.S1   1H and 13CNMR spectra of triisopropanolamine-ibuprofen 
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Figure.S2   FTIR spectra of triisopropanolamine-ibuprofen 
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2. Solubility determination of ILs 
 
1. Equimolar ratio of diisopropanolamine-ibuprofen, triisopropanolamine-
ibuprofen, triethanolamine-ibuprofen was charged in 10 ml vial and 
stirred at 80 – 90 °C for 30-40 minutes. Then the prepared IL mixture 
was used for solubility studies. 
 
                      Table.1 Solubility determination of ILs 
 
        DIPA-Ibu   - Diisopropanolamine-ibuprofenate  
        TIPA-Ibu    - Triisopropanolamine-ibuprofenate  
        TEA-Ibu     - Triethanolamine-ibuprofenate 
 
 
 IL 
 
DI Water (ml) 
Solubility determination 
  Dipa-ibu  
266 : 412 (mg) 
 Tipa-ibu 
382 : 412 (mg) 
 TEA-ibu 
298 : 412 (mg) 
0.1 Colourless solution Yellowish solution Brownish solution 
0.5 Colourless solution Yellowish solution Brownish solution 
1 Colourless solution Yellowish solution Brownish solution 
2 Colourless solution Yellowish solution Brownish solution 
5 Colourless solution Yellowish solution Brownish solution 
10 Colourless solution Yellowish solution Brownish solution 
20 Colourless solution Turbid solution Turbid solution 
22 Colourless solution Precipitation Precipitation 
200 Colourless solution - - 
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Figure S3 Solubility determination of ILs 
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